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Zusammenfassung 
Abstract 
This present thesis is dedicated to the design and the synthesis of novel biologically active and 
fluorescent heterocycles from common starting materials, such as napthoquinones, furans, 
benzofurans, pyridines and quinoxalines. Based on Palldium(0) catalyzed cross-coupling 
reactions, a series of new ethynylated naphthalenes, ethynylated naphthaleneindoles, 
benzo[b]carbazolediones, indolo[2,3-b]quinoxalines, 5,7-dihydropyrido[3,2-b,5,6-b']diindoles, 
benzofuroindoles and furodiindoles were synthesized with high yield. Synthesized compounds 
show interesting fluorescence properties with high quantum yields (19-78%). The 
benzocarbazolediones were tested for biological activity and are suggested to be used as 
selective inhibitors against nucleotide pyrophosphatase,  
 
Die vorliegende Dissertation widmet sich der Synthese von neuen, biologisch aktiven bzw. 
fluoreszierenden Heterozyklen, ausgehend von leicht zugänglichen Ausgangsstoffen, wie z.B. 
Naphthochinonen, Furanen, Pyridinen und Chinoxalinen. Durch Anwendung von Palladium(0) 
katalysierten Kupplungsreaktionen wurden verschiedene, zum Teil bisher unbekannte, 
alkynylierte Naphthalenindole und Benzocarbazoldione sowie Indolochinoxaline, 
Diindolopyridine und verschiedene Furoindole in vorwiegend guten Ausbeuten hergestellt. Die 
synthetisierten Verbindungen zeigen interessante Fluoreszenzeigenschaften wie z.B. hohe 
Quantenausbeuten (19-78%). Außerdem wurden die hergestellten Benzocarbazoldione 
bezüglich ihrer Aktivität gegen verschiedene Nukleotid Pyrophosphatasen untersucht und 
zeigen zum Teil eine hohe Selektivität gegenüber bestimmten Pyrophosphatasen und 
gleichzeitig eine hohe inhibitorische Wirkung. 
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1. Introduction 
1.1. The importance of organic synthesis for new materials and drug synthesis 
Organic synthesis is involved in most of the industries, in which consumer goods originate from 
oil, coal, and gas and possess a tremendous value in the global economy. The intensive 
development of new synthetic strategies has been noticed to produce new compounds with 
unique properties. They are central to the applications in almost all fields of daily life, such as 
pharmacy, biotechnology, and electronic industry. For example, the drug industry achieved a 
massive development in the 20th century. The discovery of penicillin in the 1930s1 was the 
starting of the golden time for pharmaceutical research. After this eminent discovery, a lot of 
new pharmacological compounds were discovered, developed, improved and manufactured. 
Structural modifications of natural products by organic synthesis was particularly useful to 
improve the pharmacological activity against a chosen target and to reduce side effects.2 For 
instance, morphine is a particular example as an addictive compound, found in opium from the 
unripe seedpods of the Papaver somniferum poppy3 and is used as a pain reliever. At the end of 
19th century, the modification of morphine has been intensively studied with more than 200 
derivatives such as heroin, codeine. By a small modification of functional groups, the 
compound etorphine possesses its opiate agonist potency 1443 times more than morphine.5 
Hence, the organic synthesis is one of the most powerful tools for drug discovery. 
 
 
Figure 1. Examples of commercial drugs 
 
Furthermore, the development of organic electronic technologies is a noticeable achievement 
in the 21st century. The word Organic Light – Emitting Diodes, OLEDs is more and more 
popular and appearing everywhere in human life. The OLED display technologies have been 
globally commercialized in high-end smart watches, mobile devices, laptops, and television. 
Therefore, the new organic light-emitting compounds with a π-conjugated aromatic 
2 
 
heterocyclic systems have been intensively studied to apply in the field of electronic 
technologies.6 For example, pentacene is the particular choice of a highly conjugated organic 
semiconductor generating light under ultra-violet- and visible light. The compound is very 
sensitive to the oxidation and unstable when exposed to air and light. Synthetic modification of 
pentacene by introducing heteroatoms or functional groups resulted in derivatives with 
improved thermal stability, charge mobility, and molecular packing. In particular, new 
pentacene analogs such as 5,12-dimethyl-quinolino[2,3-b]acridine-7,14(5H,12H)-dione 
(DMQA), bis(triisopropylsilylethynyl)pentacenes, perfluoropentacene are potential candidates 
for the development of organic field effect transistors.8 Consequently, organic semiconductors 
such as pentacene derivatives and other polyarylated compounds like 2,5,8,11-tetra-tert-
butylperylene (TBP), rubrene have replaced silicon based diodes in a lot of electronic devices.9 
 
 
Figure 2. Examples of commercial organic semiconducters 
 
Due to the increasing demand of chemicals for drug- and organic electronic materials 
development, many efforts have been made for developing new synthetic approaches. In recent 
years catalysis has emerged as powerful tool of organic chemists, as it opens new avenues for 
new bond formations and reaction outcomes. Moreover it reduces required energy for 
production processes by decreasing the activation barrier of certain processes or avoids the 
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application of stoicometric reagents. The huge impact of catalysis on chemistry and 
consequently on society has been acknowledged by 15 Nobel Prizes from 1901 until 2016 in 
the field of catalysis.10 Catalysis is also important in the environmental technology to solve the 
problem of pollution, energy waste. In the aspect of economy, the catalyst business makes 
approximately $15 billion as the annual turnover. The full value of the products under the 
catalysis processes has a remarkable contribution to the planetary GDP.11  
 
1.2. Cross-coupling reactions as a versatile tool in fine chemical productions 
At the beginning of the 20th century, few commercial drugs such as aspirin, codeine, and insulin 
were manufactured with a high price and limited quantity due to the limitation of the organic 
synthesis. Most of the methodologies for drug synthesis underwent several steps with often 
harsh reaction conditions. For examples, carbazole alkaloid murrayaquinone A have been 
totally synthesized by a 6-step procedure with very low yield (Scheme 1).12 
 
 
Scheme 1. Classical total synthesis of murrayaquinone A 12 
 
Scheme 2. Total synthesis of murrayaquinone A using a Palladium catalyst.13 
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With the development of metal-catalyzed cross-coupling reactions, organic compounds are 
easier synthetically accessible comparing to classical synthesis. For instance, natural product 
murrayaquinone A can be synthesized by a two-step route from aniline with high yield (Scheme 
2), representing an impressive example of the important contribution of metal catalyzed organic 
synthesis in organic chemistry.13 Cross-coupling reactions in the presence of organometallic 
Mg, Li, Zr, Ni, Cu compounds have been used for innumerable organic synthesis.14,15 These 
methodologies are essential tools for the synthesis of complicated natural products, biologically 
relevant compounds, functional materials, pharmaceuticals and agrochemicals. Thus, 
Palladium catalyzed cross-coupling reactions are one of the well-known approaches due to the 
wide-ranging reactivity and high selectivity of Palladium catalysts.17 
Palladium catalyzed cross-coupling reactions are certainly useful in the transformation of aryl 
(pseudo)halides with manifold nucleophiles such as organometallic reacgents (Suzuki-
Miyaura-, Sonogashira-, Stille-, Neghishi-reaction), amines (Buchwald-Hartwig-reaction) or 
alkenes (Heck-reaction), to name just a few.18 Using individually each cross-coupling reaction 
or a combination of two reactions makes the organic synthesis of drugs and functional materials 
convenient and flexible.19 The mechanism in Scheme 3 describes the three-step catalytic cycle 
in which the oxidative addition and reductive elimination is part of all Palladium(0) catalyzed 
cross-coupling reactions. The active Pd(0) complex A undergoes oxidative addition with an 
aryl (pseudo)halide R1X to produce the oxidized Palladium(II) complex B. The strength of 
carbon-halidebond decides about the reactivity of the substrates in the order C-I>C-Br>C-
Cl>C-F. Organofluoride is the least reactive substance. Active bromo and iodo compounds are 
widely used in cross-coupling reactions. After oxidative addition, complex B is electrophilic 
and takes part in the next step with a nucleophilic reactant to produce complex C. The step can 
follow different processes: ligand substitution, transmetalation or migratory insertion, which 
depends on the character of the nucleophiles. In detail, ligand substitution often occurs in 
Buchwald-Hartwig reaction20 while transmetalation takes place for organometallic 
nucleophiles in Suzuki-Miyaura cross-coupling or Sonogashira cross-coupling21 and migratory 
insertion for Heck-type reaction.22 The last step is the reductive elimination of Pd(II) complex 
C to form the desired product with the regeneration of Pd(0) species which can enter a new 
catalytic cycle. 
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Scheme 3. General Mechanism of Palladium(0)-catalyzed cross-coupling reactions. 
 
1.2.1. Suzuki-Miyaura reaction 
One of the most widely used catalytic organometallic methodologies in organic synthesis is the 
Suzuki-Miyaura cross-coupling reaction which was firstly reported in 1981 by Professor Akira 
Suzuki and Professor Norio Miyaura. Their discovery is based on the use of Palladium to 
catalyze the coupling of various organohalides or –pseudohalides with organoboron 
compounds.23,24 For Akira Suzuki’s valuable contributions in organic synthesis, he, Richard F. 
Heck and Ei-ichi Negishi won the Nobel Prize in Chemistry in 2010.11 The reaction has 
expressed its excellent utility to prepare many kinds of organic compounds through a lot of 
applications related to synthetic chemistry.25 In particular, the Suzuki-Miyaura reactions are 
often used to synthesize intermediates for the pharmaceutical industry such as anticancer 
Crizotinib,26a Yuehchukene,26b anti HIV Michellamine B,26c bioactive compound Ribisins A, B 
and D,26d Diazonamide A,26e Vitamin A26f and D159687.26g Furthermore, the antihypertensive 
drug Valsartan for the treatment of heart problems is a commercial example from Novartis, and 
BASF.27 In addition, highly-π conjugated compounds are prepared via Suzuki-Miyaura cross-
coupling in the metric-ton scale by Sigma-Aldrich for organic light-emitting diodes.27 
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Scheme 4. Applications of Suzuki-Miyaura cross-coupling in the synthesis of D159687.26g 
 
The mechanism of Suzuki-Miyaura reaction has been investigated intensively. Similar to the 
mechanism of other cross-coupling reactions,28 the first step is the oxidative addition to form 
complex B (Scheme 5). Then, complex B reacts with the base to form complex C. The second 
step is the transmetalation of the, base activated, organoboron species D to form E. The direct 
formation of complex E from B by the reaction with the tetracoordinated organoboron species 
is discussed in literature as well. The transmetalation involves the transfer of ligands from D to 
C with no change of the oxidation state of Palladium. The final step is the reductive elimination 
of Palladium(II) complex E and the regeneration of the Palladium(0) catalyst A. 
K2CO3, K3PO4, Na2CO3, NaOH, NaHCO3 are common bases for Suzuki-Miyaura cross-
coupling reactions to conduct the reaction well and improve the yield.29 The presence of a base 
increases the rate of the transmetalation step by activating the organoboron reagents and the 
intermideate B. The most common catalysts are Pd(PPh3)4, PdCl2, Pd(OAc)2, Pd2(dba)3 in 
combination with various phosphine ligands.30 Biphasic solvent systems consisting of an 
organic solvent and water are often used because it disperses the organic substances, boron 
compounds, and inorganic salts to increase the selectivity and the yield of the cross-coupling 
reaction.30 
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Scheme 5. Mechanism of the Suzuki-Miyaura reaction. 
 
1.2.2. Sonogashira cross-coupling reaction 
In 1975, Heck and Cassar independently reported a cross-coupling of terminal alkyne and aryl 
halides using Palladium catalysts.35 However, the reaction conditions require high temperatures 
and gave low yield. Later, based on Stephens-Castro reaction, Kenkichi Sonogashira, Yasuo 
Tohda, and Nobue Hagihara developed a milder protocol for the reaction of terminal alkynes 
with aryl halides by adding CuI as a co-catalyst.31 The Sonogashira reaction is a powerful tool 
to synthesize aryl- and vinyl alkynes. Additionally, the reaction is applied in the synthesis of 
pharmaceuticals such as benzylisoquinoline32a or altinicline,32b as well as natural products.33 
The Sonogashira reaction is currently the method of choice for the construction of a Csp-Csp2 
bond. 
 
 
Scheme 6. Application of the Sonogashira cross-coupling in the synthesis of Altinicline. 
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Scheme 7. Mechanism of the Sonogashira reaction  
The Sonogashira reaction consists of two catalytic cycles. The Palladium cycle follows the 
general cross-coupling mechanism for the oxidative addition and reductive elimination steps. 
The organocopper compound is formed in situ by the reaction between the terminal alkyne and 
CuX in the presence of an amine as base. The integration of Pd cycle and Cu cycle is shown in 
Scheme 7.34  
 
1.2.3. Buchwald–Hartwig amination  
Most pharmaceuticals and natural products comprise at least one nitrogen atom. Therefore, the 
C(sp2)-N cross-coupling reaction has gained wide use in synthetic organic chemistry with 
expanded substrate scope. The Buchwald-Hartwig reaction has been noticed for the 
replacement of the conventional amination such as the Goldberg reaction, Mannich reaction, 
reductive amination, etc.37 Buchwald-Hartwig cross-coupling reaction are very useful in the 
synthesis of natural products, bioactive compounds and drugs such as imatinib, a tyrosine 
kinase inhibitor,40a or (-)-epi-Indolactam V.40b 
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Scheme 8. Application of Buchwald-Hartwig amination in the synthesis of (-)-epi-Indolactam. 
 
Scheme 9. Mechanism of the Buchwald-Hartwig amination. 
 
Buchwald–Hartwig amination is to form C(sp2)-N bonds via a Pd-catalyzed process using either 
primary or secondary amines and aryl halides. Stephen L. Buchwald and John F. Hartwig 
developed the methodology independently between 1994 and the late 2000s.36 The mechanism 
undergoes via steps like those known for Palladium catalyzed C-C cross-coupling reactions.38. 
In particular, the Buchwald-Hartwig reaction involves the addition of an amine to form complex 
C, followed by deprotonation to form complex D. The amine addition is named as ligand 
exchange. β-H elimination might occur as a typical side reaction if alkyl- or benzylamines are 
applied. To some extend this side reaction can be surpressed by the application of bidentate 
ligands like Xantphos or BINAP.  
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1.2.4. CH arylation reaction  
C-X/C-H bond activations were firstly mentioned in 1955 to synthesize phenylisoindolin-1-
one.41a (E)-1,2-diphenylethene was prepared in 1969 via oxidative CH activation of benzene 
and styrene with the catalyst system of Pd(OAc)2 and Cu(OAc)2.41b Avoiding the requirement 
of a stoichiometric organometallic coupling partner makes this reaction especially attractive to 
chemists and chemical manufactures due to the reduction of synthetically steps, waste and 
energy production. However, the strong C-H-bond and the typically high number of C-H bonds 
in organic molecules makes these reaction challenging with regard to turn-over and selectivity. 
 
 
Scheme 10. Mechanism of CH-arylation. 
The catalytic cycle proceeds similarly to the general mechanism of Palladium catalyzed cross-
coupling reactions (scheme 10). After an oxidative addition step, a CH-activation step takes 
place, followed by the reductive elimination. Particularly, the mechanism of C-H bond 
activation is shown in Scheme 11. It can undergo via electrophilic substitution pathways.43 
Electrophilic substitution is the electrophilic aromatic substitution SEAr. The interaction of C-
H bond with Palladium undergoes a charge transfer from occupied dπ orbital of Palladium to 
the σ* orbital of the C-H bond. The charge transfer can weaken and break the C-H bond for the 
next steps in the catalytic cycle. 
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Scheme 11. Proposed mechanism of the CH activation. 
 
The interaction of the weak bonds between carbon, hydrogen, the ligands and the metal in the 
intermediate promotes the break of the CH bond of the arene. Studies have supported that the 
acidity of C-H bond of electron-deficient arenes decides the activity of that bond in C-H 
activation reaction. The C-H arylation have been especially noticed for the functionalisation of 
heterocycles such as pyrroles, indoles, carbazoles, quinazolines,44a as well as biologically active 
compounds such as calothrixin A,13 Lithospermic acid,44b kibdelone,44c piperarborenine B and 
D.44d 
 
1.3. Objectives of this thesis 
The possibility of introducing new C–C and C-N bonds via Palladium catalyzed methodologies 
is a highly attractive strategy for drug discovery and advanced materials as discussed above. 
Designing biologically active compounds based on natural products can be handled through 
modifying and combining different Palladium-catalyzed approaches. These methodologies are 
also useful to synthesize new organic materials, aromatic polyheterocyclic compounds. 
Motivated by the importance of aromatic heterocycles and Palladium-catalysis, this thesis is 
focused on the synthesis of important or new aromatic nitrogen-containing heterocycles from 
brominated starting materials of 1,4-naphthoquinone, furan, quinoxaline and pyridine. These 
carbo- and heterocycles have been chosen as they are prominent moieties in various biological 
active compounds which makes the development of new methodologies and the synthesis of 
new derivatives worthwile. Moreover, a special emphasis of this thesis is devoted to the 
construction of -conjugated, polyarylated compounds based on the aforementioned starting 
materials, due to their potential application in organic electronic materials such as organic 
semiconducters or fluorescent dyes.  
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2. Palladium-Catalyzed Synthesis of Multiple Ethynylated Compounds 
2.1. Synthesis of Ethynylated Benzoindoles 
2.1.1. Introduction 
Highly π-conjugated compounds based on nitrogen heterocycles have been attractive targets for 
fluorescent applications such as light-emitting materials, fluorescent labeling and bio-sensors.45 
Particularly, the indole moiety is one of such natural sensitive fluorophores.46 Comparing to the 
indole moiety, the more π conjugated structure of benzoindole, with an additional fused benzene 
ring, possesses a reduced bandgap.47 Benzoindole moieties are considered as electronic donor 
substructures for new fluorescent ladder-type π conjugated compounds.48 Besides, benzoindole 
derivatives show high biological activities such as antibacterial (with higher activity than indole 
compounds e.g. duocarmycin CC-1065),49 antitumor (pyrolo[9,10-b]phenanthrene)50 and 
potent antifouling properties for marine coatings (benzo[g]dipodazine).51 Therefore, various 
new synthetic approaches to benzoindole scaffolds are already available.52 To improve the π 
conjugation, the fluorescent ability as well as the stability, ethynylene moieties are useful to 
design the new structure.53-54  
  
 
Figure 3. Examples of fluorescent and/or bioactive benzoindole derivatives. 
 
In literature, alkylnylated structures are also found in some bioactive compounds so that 
numerous strategies have been developed for the synthesis of these compounds. In fact, most 
of the methodologies are based on alkynylation by the Sonogashira reaction.55 Brachet et. al. 
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reported a mild and general C-H activation for a selective and efficient access to 
regioselectively alkynylated pyrroles, using various bromoalkynes as starting materials.56 An 
efficient, convenient and high yielding procedure for the synthesis of tetra(alkynyl)pyridines 
and pentaalkynylpyridines via multiple Sonogashira reactions of penta- and 
tetrachloropyridines was mentioned in the literature.57 The products are promising light emitting 
organic materials with high quantum yields. The synthesis of alkynylated benzo[e]indoles has 
not been mentioned in literature before, which encouraged me towards the synthesis of novel 
alkynylated benzo[e]indoles. I present here a new strategy to such compounds, applying 
nucleophilic addition of organolithium reagents to bromobenzoquinone followed by tin(II)-
mediated reduction of resulting dioles. The last step is based on a Palladium-catalyzed cascade 
reaction, involving C-N cross-coupling and cyclization via hydroamination. 
 
2.1.2. Results and Discussion 
 
Scheme 12. Synthesis of brominated diarylethynylnaphthalene 2a - f. 
Condition, i, 2.2 equiv. n-BuLi, 2.2 equiv. aryl acetylene, THF, rt; ii, 2 equiv. SnCl2, MeCN, 
H2O, reflux. 
 
The synthetic approach for the bromodiethynylnaphthalenes 2a - f followes a publication of 
Tykwinsky and co-workers.58 The precursors 2a - f were prepared in good yields ranging from 
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64 – 92% yield (Scheme 12). I synthesized ethynylbenzoindoles 3 via a cascade consisting of 
a C-N cross-coupling reaction, followed by a ring-closing step by hydroamination using various 
amines (Table 1). For the first trial, the reaction of 2a with p-toluidine I used 
Pd(OAc)2/Xantphos as the catalytic system in DMF to produce target benzoindole 3a with 38% 
yield. When increasing the reaction time to 48 h, the yield rose to 64% (entry 2, Table 1). 
Furthermore, I examined different reaction conditions by varying Palladium sources and 
ligands. The monodentate ligand SPhos gave 8% higher yield compared to Xantphos (entry 3). 
Unfortunately, the C-N bond formation in the presence of other ligands gave lower yields (see 
Table 1). The use of Pd2(dba)3 resulted in lower yields. To further optimize the procedure, the 
reaction was carried out at different temperatures (60 oC, 90 oC, 110 oC), various bases and with 
toluene instead of DMF. None of them gave improved results. The best reaction condition is 
Pd(OAc)2 (5 mol%), SPhos (10 mol%), Cs2CO3 (0.9 mmol), DMF (10 mL), 90 C,48 h. 
 
Table 1. Optimization of the synthesis of 3a. 
 
 Catalyst Ligand Solvent Base  Temp (°C) Yield (%)a 
1b Pd(OAc)2 Xantphos DMF Cs2CO3 110 38 
2 Pd(OAc)2 Xantphos DMF Cs 2CO3 110 66 
3 Pd(OAc)2 SPhos DMF Cs2CO3 110 74 
4 Pd(OAc)2 BINAP DMF Cs2CO3 110 34 
5 Pd(OAc)2 DPEPhos DMF Cs2CO3 110 24 
6 Pd(OAc)2 PtBu3·HBF4 DMF Cs2CO3 110 33 
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7 Pd(OAc)2 dppf DMF Cs2CO3 110 - 
8 Pd(OAc)2 dppe DMF Cs2CO3 110 26 
9 Pd(OAc)2 PCy3·HBF4 DMF Cs2CO3 110 54 
10 Pd(OAc)2 SPhos DMF K3PO4 110 23 
11 Pd(OAc)2 SPhos Toluene Cs2CO3 110 11 
12 Pd(OAc)2 SPhos DMF NaOtBu 110 32 
13 Pd(OAc)2 SPhos DMF Cs2CO3 90 49 
14 Pd(OAc)2 SPhos DMF Cs2CO3 60 - 
15 Pd2(dba)3 SPhos DMF Cs2CO3 110 17 
16 Pd2(dba)3 RuPhos Toluene Cs2CO3 110 15 
Reaction condition, i, 2a - d (0.3 mmol), 1.0 equiv. amine, Palladium catalyst (5 mol%), 
ligand (10 mol%), 3.0 equiv base, solvent (10 mL), 90 C, 48 h. a Yield of isolated products, 
b24h reaction time. 
 
With optimized condition, the cascade of C-N cross-coupling and cyclizing hydroamination 
gave products 3a - m in good to excellent yields (47-80%) (Table 2). Benzylamines (3d and 
3e) were successfully employed, but gave generally lower yields compared to arylamines. 
Moreover, using an aliphatic amine, 3f was obtained in low 29% yield. The diminished yield 
might be explained by the low reactivity of the 2-phenylethanamine in the hydroamination step. 
Besides, I have isolated a debrominated side-product 4f with 47% yield which has not cyclized 
to the product. However, intermediate 4f hints that the Buchwald-Hartwig reaction might be 
the first step of the developed methodology (Scheme 13). No relationship of the substituent 
pattern of the amine and the yield of products have been detected. The highest yield of 80% 
was obtained when 2a reacted with p-anisidine.  
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Table 2. Synthesis of ethynylbenzoindoles 3a - m. 
 
Compound R1 R2 Yield (%)a 
3a H 4-MeC6H4 74 
3b H 4-FC6H4 64 
3c H 4-MeO-C6H4 80 
3d H 4-F-C6H4-CH2 53 
3e H 3-F3C-C6H4-CH2 47 
3f H Ph-CH2CH2 29 
3g MeO Ph 52 
3h MeO 3-F3C-C6H4 75 
3i MeO 4-MeO-C6H4 65 
3j F Ph 79 
3k F 3-F3C-C6H4 45 
3l F 4-MeO-C6H4 66 
3m F 4- F-C6H4 65 
Reaction condition, i, 2a - d (0.3 mmol), 1.0 equiv. amine, Pd(OAc)2 (5 mol%), SPhos 
(10 mol%), 3.0 equiv. Cs2CO3, DMF (10 mL), 90 C, 48 h. a Yield of isolated products.  
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Scheme 13. The synthesis of 3f and byproduct 4f. 
Reaction condition, i, 2d (0.3 mmol), 1.0 equiv. amine, Pd(OAc)2 (5 mol%), SPhos (10 mol%), 
3.0 equiv. Cs2CO3, DMF (10 mL), 90 C, 48 h. a Yield of isolated products. 
 
 
Scheme 14. Two-fold cascade C-N cross-coupling and hydroamination.  
Reaction condition, i, 2d (0.3 mmol), 2.0 equiv. amine, Pd(OAc)2 (5 mol%), SPhos (10 mol%), 
3.0 equiv. Cs2CO3, DMF (10 mL), 90 C, 48 h. a Yield of isolated products 
 
As a next step, the reactions of symmetrical dibromodiethynylnaphthalenes 2d - e with various 
amines was studied to obtain the pyrrolobenzoindoles 5 (Scheme 14). Unfortunately, previously 
developed conditions produced only one desired product 5a with moderate 35% yield and 3a 
as a major side-product with 47% yield. After optimizing the procedure by testing different 
ligands, solvents, changing reaction time and temperature (Table 3) no improved results were 
obtained for the synthesis of compound 5.  
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Table 3. Optimization for the Synthesis of 5a. 
Entry Pd precursor Ligand Base Solvent Yield (%)a 
1 Pd(OAc)2 Xantphos Cs2CO3 DMF 28 
2 Pd(OAc)2 SPhos Cs2CO3 DMF 35 
3 Pd(OAc)2 Dppe Cs2CO3 DMF - 
4 Pd(OAc)2 Dppf Cs2CO3 DMF - 
5 Pd(OAc)2 BINAP Cs2CO3 DMF 12 
6 Pd(OAc)2 PCy3·HBF4 Cs2CO3 DMF - 
7 Pd(OAc)2 PtBu3·HBF4 Cs2CO3 DMF - 
8 Pd(OAc)2 XPhos Cs2CO3 DMF - 
9 Pd2(dba)3 Xantphos Cs2CO3 DMF - 
10 Pd2(dba)3 SPhos Cs2CO3 DMF - 
11b Pd(OAc)2 Xantphos Cs2CO3 DMF 26 
12 Pd(OAc)2 RuPhos Cs2CO3 DMF - 
13 Pd(OAc)2 - Cs2CO3 DMF - 
14 Pd(OAc)2 SPhos Na2CO3 DMF 28 
15 Pd(OAc)2 SPhos NaOtBu DMF - 
16 Pd(OAc)2 SPhos Cs2CO3 Toluene - 
Reaction condition:2a (0.3 mmol), 2.0 equiv. amine, Pd(OAc)2 (5 mol%), ligand (10 mol%), 
3.0 equiv. base, solvent (10 mL), 90 C, 48 h. a Yield of isolated products. 
 
Although the optimization for the two-fold cascade reaction gave only low yield, the reactions 
of 2d with different amines afforded coupling products 3a, 3d, 3e and 3p in moderate yield 
without corresponding products 5 as side products (Table 4). The starting material 2e with p-
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tolyl groups efficiently gave products 3n - o in good yield (57-62%), which were higher than 
the yields of products from the precursor with phenyl groups. 
 
Table 4. Cascade C-N cross-coupling and hydroamination from dibromodiethynyl compounds. 
 
Compound R1 R2 Yielda (%) 
3a H 4-Me 47 
3d H 4-MeO 58 
3e H 4-F 46 
3n Me 4-Me 57 
3o Me 3-F3C 62 
3p H 3,5-(Me)2 58 
Reaction condition, i, 2d - e (0.3 mmol), 2.0 equiv. amine, Pd(OAc)2 (5 mol%), SPhos 
(10 mol%), 3.0 equiv. Cs2CO3, DMF (10 mL), 90 C, 48 h. a Yield of isolated products. 
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Figure 4. ORTEPs of compound 3m. (The propability of ellipsoids: 45%) 
 
X-ray crystal structure analysis proves the molecular structure of 3p independently. 
Interestingly, the alkynyl moiety is almost in the same plane with the planar benzoindole core 
structure (the phenyl ring is twisted by 7o). The 4-FC6H4 group at the nitrogen atom of the 
benzoindole scaffold is twisted by 71.2o, while the second 4-FC6H4 group at position 2 is rotated 
only by 40.8o. In the solid state, the molecules are ordered parallelly in the crystal lattice with 
different direction between two layers (Figure 4).  
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2.1.3. Absorption and fluorescence properties. 
 
 
Figure 5. Absorption and corrected emission spectra of 3a, 3j and 3m. 
 
Figure 6. Absorption and corrected emission spectrum of 5a compared to 3a. 
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Table 5. Absorption and emission properties of 3, 5. 
cp λabs1  
(nm) 
Log ε (λabs1) 
(l·mol-1·cm-1) 
λabs2  
(nm) 
Log ε (λabs2) 
(l·mol-1·cm-1) 
λem 
(nm) 
Φfluo a 
(%) 
3a 285 4.577 368 4.752 406 77 
3b 276 5.144 365 5.300 404 74 
3c 276 4.524 366 4.638 406 66 
3d 278 5.094 364 5.038 404 78 
3e 281 4.596 365 4.734 403 75 
3f 282 4.579 367 4.714 405 75 
3g 275 4.622 364 4.718 416 77 
3h 285 5.026 370 5.085 414 65 
3i 289 3.629 371 3.652 418 77 
3j 275 4.394 364 4.519 405 71 
3k 277 4.925 364 5.058 403 77 
3l 277 4.525 364 4.598 401 74 
3m 283 4.489 366 4.628 402 74 
3n 286 4.658 369 4.789 408 72 
3o 284 4.838 367 4.950 408 65 
5a 268 4.936 346 4.598 411 70 
ausing quinine hemisulfate monohydrate in 0.05 M H2SO4, as standard for the determination 
of quantum yields (Φ = 51%)59 
 
I characterized each compound of 3 and 5 by UV-VIS absorption and fluorescence spectroscopy 
in acetonitrile at room temperature. Table 5 summarizes the results of these experiments 
(Figures 5 and 6; Table 5). Emission quantum yields were determined using a solution of 
quinine hemisulfate monohydrate in 0.05 M H2SO4 ( = 51%) as a reference standard.59 All 
compounds show strong purple fluorescence upon irradiation under UV light at 365 nm. The 
acquired absorption and emission spectra have a similar shape but the bands differ in intensity 
and position due to the influence of functional groups. 
23 
 
The UV/VIS spectra of all compounds 3 and 5 show strong absorption bands in the range of 
250-300 nm and bands in the range of 300-400 nm (Figure 5-6). Emission spectra of the 
compounds were collected at the excitation wavelength of 360 nm. The emission maxima were 
detected in the range of 397 – 470 nm. The determined quantum yields were mainly high (19-
78%) (Table 5).  
For compounds 3, derivatives substituted with electron donating methoxygroups groups, like 
3g, 3h and 3i show bathochromically shifted emission spectra while ones substituted with 
fluorine as electron accepting functional group (3k, 3l, 3m) are blue shifted. Comparing among 
compounds 3a - f, there is a small effect from the amine substituent on the optical properties 
because the strongly twisted orientation of the substituents relative to the benzoindole 
chromophore is induced by steric constraints. The quantum yields of compounds 3 are only 
slightly affected by the substitution pattern on both the amine and acetylene moiety. Compound 
5, consisting of an additional pyrrol ring show a strongly blue shifted absorption maximum 
relative to compounds 3, while the emission band is not affected compared to 3a. 
 
2.1.4. Electrochemical studies 
To get first insights into the electronic properties of synthesized compounds cyclic 
voltammograms of 3a and 5a were measured (Figure 7). The oxidation event of 3a and 5a are 
ascribed to the oxidation of the indole parts. The earlier oxidation event of 5a at 0.40 V 
comparing with that of 3a at 0.69 V might caused from the additional electron donating pyrrole 
moiety in compound 5a. However, the reduction of compound 3a is more complicated showing 
multiple peaks (Figure 7, 8) due to the complex conjugated -system. Compound 5a gives only 
one reduction event at 3.00 V vs. [Fc+/Fc]. Differential Pulse Voltammetry (DPV) for the 
determination of detailed electronic behaviors are shown in Figures 8, 9 and Table 6. There is 
a small effect of substituents binding to the nitrogen on the oxidation and reduction behaviors. 
Therefore the IP energy (HOMO) and EA energy (LUMO) differ only slightly among 
compounds 3. Compound 3i with a methoxy group binding to the arylethynyl moiety possesses 
a lower oxidation potential, resulting in a higher electrochemical bandgap compared to 
compound 3a. Compound 5a possesses a larger electrochemical bandgap by 0.31 eV, with 
lower oxidation and reduction potentials than compound 3a. The electrochemical bandgaps are 
smaller than the optical bandgap. However, both determined bandgaps are effected likewise by 
the substitution pattern. The difference of these bandgaps can be explained by the interaction 
between the solvent and the substances on the electrode surface.  
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Figure 7. CVs of 3a and 5a in DMF. 
 
Figure 8. DPVs of selected compounds 3 in DMF. 
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Figure 9. DPVs of compounds 3a and 5a in DMF 
Calculations: IP = E1-ox + 4.4 eV (HOMO) ; EA = E2-red + 4.4 eV (LUMO);60 EEC = IP – EA 
(electrochemical band gap)61 aEopt estimated from the 0-0 transition from the intersection of the 
normalized absorption and emission spectra.62  
Table 6. Redox data of selected compounds 3 and 5a in DMF. 
Cp E1-ox 
(V vs. 
Fc+/Fc) 
E1-ox 
(V vs. 
NHE) 
IP 
(eV) 
E2-red 
(V vs. 
Fc+/Fc) 
E2-red 
(V vs. 
NHE) 
EA 
(eV) 
EEC 
(eV) 
EOpta 
(eV) 
3a 0.65 1.38 5.78 -2.42 -1.69 2.71 3.07 3.16 
3c 0.67 1.40 5.80 -2.42 -1.69 2.71 3.09 3.18 
3d 0.63 1.36 5.76 -2.46 -1.73 2.67 3.09 3.16 
3g 0.60 1.33 5.73 -2.50 -1.77 2.63 3.10 3.17 
3j 0.52 1.25 5.65 -2.47 -1.74 2.66 2.99 3.08 
3m 0.68 1.41 5.81 -2.42 -1.69 2.71 3.10 3.20 
5a 0.38 1.11 5.51 -2.89 -2.16 2.24 3.27 3.31 
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2.1.5. Density functional theory (DFT) calculations 
 
Figure 10. Frontier orbital for HOMO (top) and LUMO (bottom) of compound 3a 
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Figure 11. Frontier orbital for HOMO (top) and LUMO (bottom) of compound 5a 
 
For an improved understanding of the electronic structure of compounds 3a and 5a, DFT 
calculations with B3LYP/6-31G(d) basic set was used for HOMO and LUMO calculation and 
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the frontier orbital simulations. The experimental bandgaps and the theoretical bandgaps show 
a small difference of 3.16 eV vs. 3.47 eV for compound 3a and 3.31 eV vs. 3.87 eV for 
compound 5a (Table 7). The frontier orbitals for HOMO and LUMO of both compound 3a and 
5a in Figure 10 and 11 demonstrates that the substituents at the nitrogen atoms give only very 
small contributions to the whole conjugated electronic system.  
 
Table 7. Determined bandgaps of selected compounds 3 and 5a in DMF. 
 
  
cp EEC (eV) EOpta (eV) EDFTb (eV) 
3a 3.07 3.16 3.47 
3c 3.09 3.18 3.48 
3d 3.09 3.16 3.48 
3g 3.10 3.17 3.51 
3j 2.99 3.08 3.45 
3m 3.10 3.20 3.49 
5a 3.27 3.31 3.87 
aEopt estimated from the 0-0 transition from the intersection of the normalized absorption and 
emission spectrum.62b Calculated at B3LYP/6-31G(d) level of theory.63 
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2.2. Multiple Ethynylated Naphthalene 
2.2.1. Introduction 
Naphthalenes are well-known fluorophores and are frequently used as an interesting 
substructure of organic fluorescent materials.64 Changes on the aromatic scaffold, such as 
multiple aryl- or ethynylene motifs have been the recent focus of new highly π conjugated 
compounds for fluorescence applications.65 The planar conformation in the ground and excited 
states, make these derivatives potential candidates for application as nonlinear optical materials. 
Therefore alkynylated naphthalenes are an attractive target to improve the intramolecular 
electron transfer and stability for optical application of this class of compounds.66 
 
 
Figure 12. Examples of alkynylated compounds 
 
The synthesis of the prototypical 1,4-bis(phenylethynyl)naphthalene molecular frameworks and 
closely related materials featuring arylethynyl moieties are available via the Sonogashira cross-
coupling of aryl halides with terminal alkynes in the presence of Palladium and a Copper co-
catalyst.67 Besides, the electrophilic carbonyl center in quinone, naphthoquinone, and 
anthraquinone reacting with alkynyllithium reagents are an alternative and useful methodology 
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for the preparation of simple diarylethynylene derivatives.68 Y.Tobe et al. reported the synthesis 
of 1,2,3,4-tetrakis((isopropylsilyl)ethynyl) naphthalene.69 
The synthesis of polyalkynylated naphthalenes has not been extensively studied so far although 
increasing conjugation length has a strong influence on the molecular electronic system and 
causes red-shifted emission.65 During my studies, I developed a new methodology for the 
synthesis of new tetra(arylethynyl)naphthalenes and 1,4-bis(arylethynyl)-2,3-
bisarylnaphthalenes via Sonogashira cross-coupling and Suzuki–Miyaura cross-coupling of 
dibromodiethynylnaphthalenes 2d - f. Furthermore, I investigated the photophysical properties 
of obtained compounds by steady-state absorption and emission measurements which had not 
been carried out for tetrakis(arylethynyl)naphthalenes before. 
 
2.2.2.Results and Discussion 
2.2.2.1. Synthesis of tetraarylethynylnaphthalenes 6a - l 
 
 
Scheme 15. Synthesis of tetraarylethynylnaphthalene 6a. 
Reaction condition, i, 2d (0.3 mmol), 2.0 equiv. phenylacetylene, PdCl2(CH3CN)2 (5 mol%), 
ligand (10 mol%), CuI (5 mol%), base (1 ml), solvent (5 mL), 80 C, 24 h. 
 
Diethynyl derivatives 2d - f in Scheme 7, section 2.1.2 were employed in the Sonogashira cross-
coupling to synthesize tetraethynylnaphthalenes. To optimize the conditions, the reaction of the 
starting material 2d and phenylacetylene were screened with a catalyst system consisting of 
PdCl2(CH3CN)2 and a variety of phosphine ligands with CuI, solvent, base at different 
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temperatures (see Scheme 15 and Table 8). Up to 79% yield was achieved in the presence of 
the ligand XPhos, HN(iPr)2, dioxane at 80 C. All applied bidentate phosphine ligands (BINAP, 
Xantphos, dppe, and dppf) were not employed successfully in this reaction due to the formation 
of an inseparable mixture of products.  
 
Table 8. Optimization of the synthesis of 6a. 
 Ligand Base Solvent Temp (oC) Yield (%)a 
1 XPhos HN(iPr)2 Dioxane 80 79 
2 XPhos HN(iPr)2 Dioxane 100 55 
3 XPhos HN(iPr)2 Dioxane 60 40 
4 XPhos HN(iPr)2 THF 80 13 
5 SPhos HN(iPr)2 Dioxane 80 54 
6 XPhos Cs2CO3 Dioxane 80 22 
7 SPhos Cs2CO3 Dioxane 80 - 
8 P(tBu)3·HBF4 HN(iPr)2 Dioxane 80 34 
9 Xantphos HN(iPr)2 Dioxane 80 38 
10 RuPhos HN(iPr)2 Dioxane 80 42 
11 Dppf  HN(iPr)2 Dioxane 80 32 
12 Dppe HN(iPr)2 Dioxane 80 12 
13 DavePhos HN(iPr)2 Dioxane 80 17 
14 BINAP HN(iPr)2 Dioxane 80 - 
a Yield of isolated products 
 
The reaction of diethynylnaphthalenes 2d - f, using optimized conditions with several 
acetylenes including those featuring electron-donating and electron-withdrawing substituents, 
afforded the desired products 6a - i (Table 9) with good yield (42-79%). 2e with tolyl group 
gave the products 6e - i with lower yields (42-54%) when comparing to that of the products 
6a - c derived from 2d (61-79%). Unfortunately, 1-hexyne was not successfully employed in 
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this reaction. Acetylenes with strong electron withdrawing groups like p-CN-C6H4 did not take 
part in this reaction. 
 
Table 9. Synthesis of tetraalkynylnaphthalene 6a - l. 
 
Compound R1 R2 Yield (%)a 
6a C6H5 C6H5 79 
6b C6H5 p-FC6H4 71 
6c C6H5 p-MeOC6H4 61 
6d 1-Naphthyl C6H5 63 
6e p-MeC6H4 C6H5 54 
6f p-MeC6H4 p-MeOC6H4 52 
6g p-MeC6H4 p-FC6H4 52 
6h p-MeC6H4 p-tBuC6H4 54 
6i p-MeC6H4 p-MeC6H4 42 
6k p-MeC6H4 C4H9 - 
6l p-MeC6H4 p-CNC6H4 - 
Reaction condition, i, 2d - f (0.3 mmol), 2.0 equiv. alkyne, PdCl2(CH3CN)2 (5 mol%), 
XPhos (10 mol%), CuI (5 mol%), diisopropylamine (1 ml) and dioxane (5 mL), 80 C, 
24 h. a Yield of isolated products 
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2.2.2.2. Synthesis of 2,3-diaryl-1,4-diethynylnaphthalene 7a - k. 
After exploring the scope of the Sonogashira reaction, synthesizing various tetra-alkynyl 
derivatives of naphthalene, I turned the attention to the Suzuki-Miyaura cross-coupling 
reaction. The Suzuki-Miyaura reaction of 2d - f with different arylboronic acids afforded 2,3-
diaryl-1,4-diarylethynylnaphthalenes 7a - k. The reaction using Pd(PPh3)4 and sodium 
carbonate with the solvent system of 1,4-dioxane and water 5:1 gave 7a with 88% yield. Further 
optimizations did not give better results (Table 10). 
 
Scheme 16. Synthesis of 2,3-diaryl-1,4-diethynylnaphthalene 7a. 
Reaction condition, i, 2d (0.3 mmol), 2.0 equiv. arylboronic acid, Palladium catalyst (5 mol%), 
3.0 equiv. base, solvent (10 mL), H2O (2 ml), 100 C, 24 h. 
Table 10. Optimization of the synthesis of 7a. 
 Catalyst Base Solvent Temp (oC) Yield (%) 
1 Pd(PPh3)4 Na2CO3 Dioxane/H2O 100 88 
2 Pd(PPh3)4 Na2CO3 Dioxane/H2O 80 51 
3 Pd(PPh3)4 Na2CO3 Dioxane/H2O 60 - 
4 Pd(PPh3)4 Na2CO3 THF/H2O 100 73 
5 Pd(PPh3)4 NaOH Dioxane/H2O 100 46 
6 Pd(OAc)2 + BINAP Na2CO3 Dioxane/H2O 100 65 
7 Pd(OAc)2 + RuPhos Na2CO3 Dioxane/H2O 100 54 
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With optimized conditions in hand, I examined the scope of the reaction. The Suzuki-Miyaura 
reaction with various arylboronic acids afforded products 7a - l in moderate to excellent yields 
(Table 11). The highest yield of 92% was obtained when employing [1,1'-biphenyl]-4-ylboronic 
acid. Naphthyl derivative 2f gave product 7f in 59% yield. Besides, starting material 2e afforded 
products 7h - k in generally lower yields (58-70%) compared to products 7b - e derived from 
2d (77-92%).  
Table 11. Synthesis of 2,3-diaryl-1,4-diarylethynylnaphthalenes 7a - k. 
 
Compound R1 R2 Yield (%)a 
7a Ph H 88 
7b Ph Me 85 
7c Ph CF3 82 
7d Ph Ph 92 
7e Ph MeO 77 
7f 1-Naphthyl H 59 
7g p-MeC6H4 MeO 66 
7h p-MeC6H4 tBu 58 
7i p-MeC6H4 CF3 67 
7k p-MeC6H4 Ph 70 
Reaction condition, i, 2d - f (0.3 mmol), 2.0 equiv. arylboronic acid (0.6 mmol), 
Pd(PPh3)4 (5 mol%), 3.0 equiv. Na2CO3 (0.9 mmol), 1,4-dioxane (10 mL), H2O (2 ml), 
100 C, 24 h. a Yield of isolated products 
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 Figure 13. ORTEPs of compound 7b. (The propability of ellipsoids: 45%) 
 
The molecular structure of 7b was independently confirmed by X-ray crystal structure analysis 
(Figure 13). In the solid state, the aryl rings at positions 2 and 3 of the naphthalene core are 
twisted by 60.5o while the arylethynyl moieties are twisted only by 24.0o. Molecules of 7b are 
ordered parallelly in the crystal lattice.  
 
2.2.3. Absorption and fluorescence properties. 
All compounds 6 and 7 emit strongly light in the violet region upon irradiation under UV light. 
UV-VIS absorption and fluorescence studies at the excitation wavelength of 360 nm of 
compounds 6 and 7 were carried out in acetonitrile at room temperature (Figure 14-15; Table 
12). Compounds 6 and 7 possess a strong absorption band at 250-300 nm and broad bands with 
a certain fine structure in the range of 300-400 nm. The emission bands of the compounds 
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occupy bands around 397 – 470 nm with the presence of a shoulder in case of all compounds 6 
and a clear second band in case of compounds 7. There is no impact of the functional groups at 
the benzene rings on the absorption and emission bands of each series.  
 
Figure 14. Absorption and corrected emission spectra of 6a, 6b and 6d. 
 
Figure 15. Absorption and corrected emission spectra of 7a, 7c and 7f. 
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Table 12. Absorption and emission properties of 6 and 7. 
Cp λabs1 
(nm) 
Log ε(λabs1) 
(l·mol-1·cm-1) 
λabs2 
(nm) 
Log ε(λabs2) 
(l·mol-1·cm-1) 
λem1 (nm) 
(2nd band) 
Φfluo 
(%)a 
6a 382 4.518 403 4.510 424 (448) 60 
6b 382 4.386 402 4.379 423 (449) 78 
6d 406 4.508 428 4.571 442 (470) 39 
6e 326 4.581 408 4.615 426 (452) 59 
6g 327 4.637 409 4.343 430 (456) 45 
6h 332 5.881 409 5.519 429 (453) 56 
6i 331 4.497 408 4.151 429 (456) 65 
7a 369 3.713 387 4.647 401 (416) 76 
7b 370 4.600 388 4.510 397 (420) 70 
7c 369 5.096 387 5.060 397 (421) 78 
7d 370 4.819 388 4.762 400 (424) 59 
7e 371 4.754 389 4.605 405 (430) 52 
7f 391 4.906 413 4.950 422 (448) 30 
7g 373 4.685 392 4.623 406 (432) 28 
7h 374 4.744 394 4.637 403 (427) 19 
7i 374 4.933 393 4.845 402 (428) 68 
7k 374 4.292 393 4.281 409 (435) 53 
a using quinine hemisulfate monohydrate in 0.05 M H2SO4, as standard for the determination 
of quantum yields (Φ = 51%)59 
 
Emission spectra of compounds 6d and 7g with an extended conjugated π-system show a red-
shift by 22 nm in the emission spectrum comparing to their analog phenylderivatives 6a and 
7a. Ethynyl moieties have a stronger influence on the emission spectra.The emission of 
compounds 6a are more red shifted than compounds 7a with the same substituents due to the 
different numbers of alkynyl moieties. This effect might be explained by the lower conjugated 
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system of compound 7a compared to 6a. The poor conjunction is ascribed from the worse 
orbital overlap of the more sterical phenyl rings to the naphthalene scaffold. 
Compound 6a and 7a, which contain no substituent on the phenyl ring, possess very high 
quantum yields of 60% and 76%, respectively. Noteworthy, the quantum yields of compounds 
containing fluor or trifluoromethyl groups were observed to be even higher 78% (6b, 7c), 68% 
(7k) while electron donating functional groups such as methoxy, methyl, tbutyl groups possess 
lower quantum yields. Compounds with naphthyl or tbutyl moieties have low quantum yields 
(39% (6d), 30% (7g), 19% (7i)). 
 
2.3. Conclusion 
Alkynylated benzoindoles 3 were prepared by a domino reaction consisting of a Buchwald-
Hartwig amination and hydroamination. Tetraalkynylated naphthalenes 6 and diaryl-dialkynyl 
naphthalenes 7 were synthesized by the Sonogashira cross-coupling and Suzuki-Miyaura cross-
coupling, respectively. The absorption and fluorescence properties of all products show 
promising photophysical properties, in particular, high quantum yields. Compounds 3a, 5b, 6a, 
and 7a possess different absorption and emission behaviors what might be explained by the 
charge transfer effect from the ethynyl and pyrrole moieties. The substituents on the amines 
have only a small effect on the absorption and fluorescence properties while incorporation of 
electron donating groups on the arylacetylenes leads to bathochromically shifted UV/Vis and 
fluorescence spectra. CV and DPV measurements of selected compounds 3 and 5 show a small 
impact of substituents on the electrochemical bandgaps of obtained compounds.  
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3. One-Pot Palladium-Catalyzed Synthesis of Benzo[b]carbazolediones 
3.1. Introduction 
Carbazolediones are one popular class of natural products with various excellent biological 
activities, for example, antitumor, antiprotozoal, and antibiotic properies.70-72 Calothrixin 
showes significant cytotoxicity against human Hela cancer cells,73 while Ellipticine quinone 
has antimalarial and cytotoxic properties (Figure 16). 74 Another example, murrayaquinone A 
which is extracted from the root bark of Murrayaeuchrestifolia, was demonstrated as an 
excellent inhibitor against tumor cell SK-MEL-5, Colo-20.75 The carbazolequinone moiety has 
been reported to be a reversible fluorescent “on/off” molecule in a bio-sensor elements to 
determine energy transfer and local redox properties.76  
 
 
Figure 16. Naturally occuring carbazolequinone alkaloids 
 
5H-Benzo[b]carbazoles have been previously approached by a Palladium(II) catalyzed 
oxidative biaryl coupling,77a-e and two-fold Buchwald-Hartwig cross-coupling of 2-bromo-3-
(2-bromophenyl)naphthalene-1,4-dione.77e Besides, the methodologies based on Friedel-Crafts 
acylations,78a,b organolithium coupling,78c direct alkylations at a C-C double bond78d,e are useful 
to synthesize benzocarbazolediones, too. However, the procedures are limited by the number 
of derivatives or are based on multiple step reactions which are time and cost consuming as 
well as waste producing. Therefore, I describe a new one-pot reaction for 
benzo[b]carbazolediones. The first step is a catalyst-free amination of 2,3-
dibromonaphthoquinone in water. The second step is a domino reaction consisting of a Suzuki-
Miyaura cross-coupling reaction and subsequent C–N cross-coupling reaction. Additionally, an 
alternative one-pot synthesis of benzo[b]carbazolediones is reported, which is based on 
Palladium-catalyzed domino reaction of 1,2-dibromobenzenes with secondary anilines. 
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3.3. Results and Discussion 
3.3.1. One-pot synthesis of benzo[b]carbazolediones 
 
 
Scheme 17. The three-step one-pot synthesis of 10b. 
Conditions, i, p-toluidine (0.3 mmol), H2O (1 mL), 60 C; ii, 1.1 equiv. 2-bromophenylboronic 
acid, catalyst (5 mol%), ligand (10 mol%), 3.0 equiv. K3PO4, dioxane (10 mL), 90 C, 24 h.  
 
The developed procedure is described in Scheme 17. The first step followes a previous report.79 
Michael addition of 1b with p-toluidine gave 95% yield of intermediate 8 as a red solid. The 
reaction mixture was added 2-bromophenylboronic acid, the catalyst Pd(PPh3)4, K3PO4, water, 
and dioxane. After 24 h at 90 C, the desired benzo[b]carbazoledione 10b was obtained in 28% 
yield, while intermediate 9b was formed with 47% yield.  
Compound 9b independently underwent intramolecular amination to form 10b in 47% yield. 
The results proved that compound 9b might be the intermediate of the domino reaction and the 
cyclization step from 9 to product 11 might be the limiting step in the domino process. 
To optimize the intramolecular C-N cross-coupling, Pd2(dba)3 was added as a co-catalyst with 
several common ligands (see Table 13).80 The system of Pd(PPh3)4 with Pd2(dba)3 and RuPhos 
(entry 5), improved the isolated yield of 10b to 47% after 24h. However, the reaction, without 
Pd(PPh3)4 (entry 8) achieved only 17% yield. Bidentate phosphine ligands such as BINAP, 
Xantphos, dppe, or dppf were not employed successfully in this reaction. As a next step, the 
impact of temperature and solvents was investigated. The reaction temperature at 90C and 1,4-
dioxane gave the best yield (entries 6-7, 9–11). 
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Table 13. Optimization of the one-pot synthesis of 11b. 
Entry Catalyst Co-catalyst/ligand Yield (%)a 
9b 10b 
1 Pd(PPh3)4 - 47 28 
2 Pd(PPh3)4 Pd2(dba)3 + SPhos 36 35 
3 Pd(PPh3)4 Pd2(dba)3 + Dppe 28 37 
4 Pd(PPh3)4 RuPhos 42 31 
5 Pd(PPh3)4 Pd2(dba)3 + RuPhos 17 47 
6b Pd(PPh3)4 Pd2(dba)3 + RuPhos 52 13 
7c Pd(PPh3)4 Pd2(dba)3 + RuPhos 24 26 
8 - Pd2(dba)3 + RuPhos 31 17 
9d Pd(PPh3)4 Pd2(dba)3 + RuPhos 24 16 
10e Pd(PPh3)4 Pd2(dba)3 + RuPhos 33 39 
11f Pd(PPh3)4 Pd2(dba)3 + XPhos 27 22 
12 Pd(PPh3)4 Pd2(dba)3 + Xantphos - 19 
13 Pd(PPh3)4 Pd2(dba)3 + dppf 19 14 
14 Pd(PPh3)4 Pd2(dba)3 + PtBu3·HBF4 42 29 
15 Pd(PPh3)4 Pd2(dba)3 + PCy3·HBF4 37 27 
16 Pd(PPh3)4 Pd2(dba)3 + BINAP 16 11 
a Yield of isolated products; b 60 C in the second step; c 120 C in the second step; d THF as 
solvent; e DMF as solvent; f toluene as solvent. 
 
With optimized conditions, the desired benzo[b]carbazolediones 10a-g were obtained in 42-
70% yield using aromatic amines (Table 14). Electron donating groups like methyl, methoxy, 
gave moderate yields in the range of 48-49% (10b, 10e and 10g). Compound 10c was isolated 
with improved 60% yield containing an electron withdrawing fluoro substitutent. However 10d 
with a nitro group in 4-position of aniline afforded only 42% yield. 4-aminophenol, m-
(trifluoromethyl)aniline or p-cyanoaniline gave no desired products in the domino process. 
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Aliphatic and benzylic amines were employed successfully under optimized conditions (Table 
14). 2-(3,4-dimethoxyphenyl)ethanamine gave product 10v in the highest obtained yield (70%).  
 
Table 14. One-pot synthesis of Benzo[b]carbazolediones 10a-v. 
 
Compound R Yielda (%) 
10a C6H5 61 
10b 4-CH3C6H4 49 
10c 4-FC6H4 60 
10d 4-(O2N)C6H4 42 
10e 4-(MeO)C6H4 49 
10f 3,5-Me2C6H3 53 
10g 4-t-BuC6H4 48 
10h 3-(F3C)C6H4 0 
10i 4-(NC)C6H4 0 
10j 4-(HO)C6H4 0 
10k n-C4H9 42 
10l n-C5H11 48 
10m n-C6H13 57 
10n n-C7H15 44 
10o n-C8H17 46 
10p C6H5CH2 52 
10q C6H5(CH2)2 55 
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10r C6H5(CH2)3 48 
10s 4-FC6H4CH2 52 
10t 4-(MeO)C6H4CH2 64 
10u 4-(F3C)C6H4CH2 59 
10v 3,4-(MeO)2C6H3(CH2)2 70 
Conditions, i, amine (0.3 mmol), H2O, 60 °C, 6 h; ii, 1.1 equiv. 2-bromophenylboronic acid, 
Pd(PPh3)4 (5 mol%), Pd2(dba)3 (5 mol%), RuPhos (10 mol%), 3.0 equiv. K3PO4, dioxane 
(10 mL), 90 °C, 24 h. a Yield of isolated products 
3.3.2. Domino Synthesis of benzo[b]carbazolediones 
Ackermann and coworkers developed a cyclization of 1,2-dibromobenzenes with secondary 
anilines, based on a domino C-N cross-coupling / CH activation reaction.81 Here, I report in the 
following the application of this methodology to the synthesis of benzo[b]carbazolediones. 
 
 
Scheme 18. The two-step domino synthesis of 10a. 
Reaction conditions, i, 1.1 equiv. diphenylamine, Palladium catalyst (5 mol%), ligand 
(10 mol%), 4.0 equiv. base, toluene (10 mL), 90 C, 24 h. 
 
The reaction of 1b with diphenylamine, using the ligand triphenylphosphine as reported by 
Ackermann,81 afforded benzo[b]carbazoledione 10a, albeit, in only 38% yield (Scheme 18). 
For further optimization, PCy3·HBF4 was used in the reaction instead of triphenylphosphine, 
and the yield increased to 52%. Other ligands (RuPhos, BINAP, SPhos, Xphos, Xantphos, dppe, 
dppf) and Pd(PPh3)4 were not suitable for this reaction. Besides, a change of the solvent (DMF, 
dioxane, THF), base (NaOH, Na2CO3, Cs2CO3) did not result in an improvement of the yield 
(Table 15). Therefore, I continued to extend the scope with these conditions.  
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Table 15. Optimization of the two-step domino synthesis of 10a. 
entry catalyst ligand Base Solvent Temp. oC Yielda (%) 
1 Pd(OAc)2  PPh3 tBuONa Toluene 90 38 
2 Pd(OAc)2  PCy3·HBF4 tBuONa Toluene 90 52 
3 Pd(PPh3)4 - tBuONa Toluene 90 33 
4 Pd(OAc)2  RuPhos tBuONa Toluene 90 - 
5 Pd(OAc)2  BINAP tBuONa Toluene 90 - 
6 Pd(OAc)2  XPhos tBuONa Toluene 90 - 
7 Pd(OAc)2  Xantphos tBuONa Toluene 90 - 
8 Pd(OAc)2  Dppe tBuONa Toluene 90 - 
9 Pd(OAc)2  Dppf tBuONa Toluene 90 - 
10 Pd(OAc)2  SPhos tBuONa Toluene 90 - 
11 Pd(OAc)2  SPhos tBuONa DMF 90 - 
12 Pd(OAc)2  PCy3·HBF4 tBuONa DMF 90 31 
13 Pd(OAc)2  PCy3·HBF4 tBuONa Dioxane 90 24 
14 Pd(OAc)2  PCy3·HBF4 tBuONa THF 90 12 
15 Pd(OAc)2  PCy3·HBF4 NaOH Toluene 90 35 
16 Pd(OAc)2  PCy3·HBF4 Na2CO3 Toluene 90 27 
17 Pd(OAc)2  PCy3·HBF4 Cs2CO3 Toluene 90 19 
18 Pd(OAc)2  PCy3·HBF4 tBuONa Toluene 130 42 
19 Pd(OAc)2  PCy3·HBF4 tBuONa Toluene 110 49 
20 Pd(OAc)2  PCy3·HBF4 tBuONa Toluene 70 - 
Reaction conditions, 1.1 equiv. diphenylamine, Palladium catalyst (5 mol%), ligand 
(10 mol%),4.0 equiv. base, toluene (10 mL), 90 C, 24 h. a Yield of isolated products 
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Table 16. Domino synthesis of benzo[b]carbazolediones (10 and 11).  
 
 
 
 
 
Reaction condition i, 1.1 equiv. amine, Pd(OAc)2 (5 mol%), PCy3·HBF4 (10 mol%), 
4.0 equiv. tBuONa, toluene (10 mL), 90 C, 24 h.  
 
The reaction of 1b with symmetrical diarylamines afforded benzo[b]carbazolediones 10a and 
11b-g in 35-42% yield (Table 16). The employment of unsymmetrical phenyl-(p-tolyl)amine 
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gave an inseparable mixture of regioisomers 10b and 11a, due to the low regioselectivity of the 
C–H activation step. The asymmetrical products 11f and 11g were obtained with higher yields 
(51 and 41%). N-Cyclohexylaniline produces 11h with a low yield of 29%. Other amines 
(11i - j) were not successfully employed in the reaction.  
 
Scheme 19. Application of developed domino reaction with carbazole (A), methylindole (B), 
and indolinone (C). 
Reaction conditions i, 1.2 equiv. N-heterocycle, Pd(OAc)2 (5 mol%), PCy3·HBF4 (10 mol%), 
4.0 equiv. tBuONa, toluene (10 mL), 90 C, 24 h. 
 
The reaction of 1b with carbazole afforded the hexacyclic product 12a, albeit, in only 28% 
isolated yield of the pure product, due to a competing second C–N cross-coupling reaction. The 
side-product 12b was isolated in 32% yield (Scheme 19). 2-Methylindole does not react via CN 
cross-coupling reaction. However, compound 12c was obtained, derived from CH-activation at 
position 3 of the indole. The reaction of 1b with indolinone was also not successful and gave a 
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very complicated and inseparable reaction mixture what might be explained by the lower 
nucleophilicity of the amide. 
 
 
Figure 17. ORTEP of 10c (The propability of ellipsoids: 45%) 
 
 
Figure 18. ORTEP of 11h (The propability of ellipsoids: 45%) 
 
The single crystal XRay diffraction measurement of product 10c and 11h was performed to 
independently confirm the corresponding structures.  
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3.4. Nucleotide Pyrophosphatase Activity  
The enzyme nucleotide pyrophosphatases with seven members (NPP1-7) are attractive targets. 
Human nucleotide pyrophosphatases 1 (NPP-1) controls the bone mineralization. It also takes 
part in the insulin signaling process by controlling the tyrosine kinase activity. Human 
nucleotide pyrophosphatases 3 (NPP-3) is considered as a tumor marker and is associated with 
metastasis of cancer cells and carcinogenesis.82 Although studies of NPP structures and their 
behaviors in the human body were mentioned in the literature for a long time.83 The inhibitors 
against two enzymes NPP-1 and NPP-3 have been limited by the number of them and their 
synthetic approaches. For instances, N6,N6-diethyl-β,γ-dibromomethylene-ATP (ARL67156), 
diadenosine 5′,5″-boranopolyphosphonates, and adenosine 5′-(γ-thio)-α,β-methylene 
triphosphates 83 are some of a small number of NPP1 inhibitors. These inhibitors have limited 
applicability because of their weak metabolic stability. Oxadiazole, biscoumarine derivatives, 
quinazoline-4-piperidine-4-ethylsulfamide derivatives, imidazopyridine- and purine-
substituted thioacetamide derivatives without nucleotides are found to be NPP1 inhibitors.84  
Different derivatives of compounds 10 and 11, were tested for human recombinant NPP1 and 
NPP3. The bio-tests were performed in cooperation with the group of Professor Jamshed Iqbal 
in the Center for Advanced Drug Research, COMSATS Institute of Information Technology, 
Abbottabad, Pakistan. Synthesized compounds show significant inhibition of both enzymes 
when comparing with the previous inhibitors (Table 17).84 The IC50-value indicates how much 
of a drug is required to inhibit 50% of the enzyme activity. That value is considered as the major 
indicator to determine the selectivity and the inhibition of bio-active compounds. 
Compound 10b with a methyl group could be considered as the most potential inhibitor of NPP-
1, which has the highest inhibitory value of IC50 ±SEM = 0.57±0.05 µM. 10c, 10t, 10u were 
more active against NPP-1 than NPP-3. The compound 10a with the phenyl substituent is found 
to be the most active against NPP-3 with the inhibitory value of IC50 ±SEM= 0.16±0.06 µM 
while 10a is less active against NPP-1. The inhibitory value against NPP-1 is IC50 
±SEM = 1.31±0.08 µM.  
The compounds 10e and 11d substituted by a methoxy group are only active with NPP-3 IC50 
±SEM = 0.28±0.03 and 0.27±0.02 µM, respectively. Both of these compounds show no 
inhibition against NPP-1. The compounds 10d, 10v, 11b represent also selective activity 
towards NPP-3 (IC50 ±SEM = 0.30±0.01 µM, 3.72±0.01 µM, and 0.27±0.02 µM, respectively) 
in comparison to NPP-1 i.e, IC50 ±SEM = 2.17±0.09 µM, 0.36±0.06 µM, and 2.39±0.05 µM, 
respectively.  
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The intermediate 9b shows weak inhibition towards both nucleotide pyrophosphatases NPP-1 
and NPP-3. The high inhibitory values of IC50 ±SEM = 1.74±04 µM for NPP-1 and 
1.24±0.01 µM might be caused by the presence of the bromine atom. Hexacyclic compound 
12a displayes no activity against both NPPs. 12a has a highly conjugated and rigid structure 
what could be the reason of the low interaction of 12a with studied NPP enzymes. In summary, 
the carbazoledione moiety may be the primary pharmacophore inhibiting against NPP enzymes. 
Methoxy functional groups may enhance the inhibition of these compounds. 
 
Table 17. Inhibition activity of samples 9b, 10, 11, 12a against NPP-1 and NPP-3.* 
Compound NPP1 
IC50 (µM)±SEM 
NPP3 
IC50 (µM)±SEM 
9b 1.74±04 1.24±0.01 
10a 1.31±0.08 0.16±0.06 
10b 0.57±0.05 1.01±0.08 
10c 0.82±0.04 1.61±0.03 
10d 2.17±0.09 0.30±0.01 
10e -- 0.28±0.03 
10m 2.84±0.07 2.43±0.01 
10o 1.13±0.09 0.86±0.05 
10t 0.59±0.01 1.16±0.04 
10u 0.69±0.02 1.85±0.07 
10v 3.72±0.06 0.36±0.01 
11a 0.77±0.03 0.25±0.01 
11b 2.39±0.05 0.38±0.03 
11d -- 0.27±0.02 
12a -- -- 
Values ± SEM are expressed deviation of three experiments (n = 3). The IC50 is the 
concentration, at which 50% of the enzyme activity is inhibited. *performed by Prof. Iqbal 
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3.5. Conclusion 
Benzo[b]carbazolediones were synthesized successfully by a three-step domino reaction in 
moderate to good yields. In addition, the two-step domino reactions were performed with 
dibromonaphthoquinone and diarylamines to broaden the substrates scope. The yield of 
products from the first methodology are higher than those from the second. The second 
methodology, two-step domino reactions, resulted in the formation of regiosomers when 
asymmetrical diarylamines were used. Obtained benzo[b]carbazolediones show excellent 
inhibition against enzyme nucleotide pyrophosphatases NPP-1 and NPP-3 with high selectivity. 
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4. Palladium-Catalyzed Two-fold Buchwald-Hartwig Amination 
4.1. Synthesis and Optical Properties of Indolo[2,3-b]quinoxalines and 5,7-
dihydropyrido[3,2-b,5,6-b']diindoles 
4.1.1. Introduction 
Highly π-conjugated heteroacenes are, nowadays, commercially used as possible, cheap and 
active elements in organic photovoltaic cells,85a organic light-emitting diodes (OLEDs),85b and 
especially in organic field-effect transistors (OFETs).85c In particular, highly π-conjungated 
poly(hetero)aromatic structures are attractive because of their planar structure and the 
modifiability of their HOMO-LUMO level by substitutions.86 These structures have usually 
strong inter- and intramolecular π-π interactions in the solid state.87 Replacement of carbon 
atoms in π-systems with nitrogen heteroatoms has been considered as an effective strategy to 
modify the electronic structure and to change dipole moments.88-89 
 
 
Figure 19.Selected examples of highly π-conjugated aza-carbazoles compounds 
 
For example, BIQF, BIQTP, BIQMCz with two indoloquinoxaline moieties are known for their 
deep-red light emission (Figure 19).90 Indolo[2,3-b]quinoxalines are, therefore, potential 
candidates for organic light-emitting diodes (OLEDs)91 and excitonic solar cells.91 The 
indolo[2,3-b]quinoxaline moieties are known to increase the thermal stability, and glass 
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transition temperature of these materials and are applied as electron transporting and emitting 
layers.92 Indolo[2,3-b]quinoxalines were firstly synthesized by Marchlewski via the cyclo-
condensation of isatin with o-phenylenediamine derivatives in the presence of AcOH as 
catalyst.93a Indoloquinoxalines can be obtained via the cyclization of o-phenylenediamine with 
1-acetyl-2-bromo-3-indolinone as well.93b 
Because of the importance of quinoxaline in the field of organic materials, I studied a practical 
and efficient two-step synthesis of indolo[2,3-b]quinoxalines. The procedure contains the first 
site-selective Suzuki-Miyaura reaction of 2,3-dibromoquinoxaline with 2-bromophenylboronic 
acid, followed by a two-fold Palladium-catalyzed C–N cross-coupling reaction with a primary 
amine. Additionally, I applied this strategy to 2,3,5,6-tetrabromopyridine for the synthesis of 
unknown pyridodiindoles. In literature, only 5,7-dihydropyrido[3,2-b,5,6-b]diindole has been 
reported.94 
 
4.1.2. Synthesis of Indolo[2,3-b]quinoxalines 
 
Scheme 20. Synthesis of indolo[2,3-b]quinoxalines 15e. 
Conditions, i, 1.2 equiv. 2-bromophenylboronic acid, Pd(PPh3)4 (5 mol%), 3.0 equiv. NaOH, 
THF, H2O, 70 ºC, 4 h. ii, 2.0 equiv. benzylamine, 3.0 equiv. base, Palladium catalyst (5 mol%), 
ligand (10 mol%), solvent, 100 ºC, 6 h. 
 
Indolo[2,3-b]quinoxalines were synthesized by a two-step synthesis. In the first step, the 
Suzuki-Miyaura reaction of 13 with 2-bromophenylboronic acid in the presence of Pd(PPh3)4 
resulted in intermediate 14 in 84% isolated yield, followed by a two-fold C-N cross-coupling 
reaction (Scheme 20). The conditions of the amination of 14 with benzylamine were optimized 
afterwards (Table 18). Both, monodentate- and bidentate phosphine ligands were screened 
during the optimization. The results show that the bidentate ligand DPEPhos gave product 15e 
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in up to 96% yield. Employing Pd(OAc)2 gave lower yield of 15e. Toluene was more 
appropriate than DMF under these conditions. 
 
Table 18. Optimization for the Synthesis of 15e. 
Entry Pd precursor Ligand Base Solvent Yield (%)a 
1* Pd2(dba)3 BINAP tBuONa Toluene 51 
2* Pd(OAc)2 BINAP tBuONa Toluene 23 
3* Pd2(dba)3 Xantphos tBuONa Toluene 63 
4* Pd2(dba)3 DPEPhos tBuONa Toluene 96 
5* Pd2(dba)3 Dppe tBuONa Toluene 14 
6* Pd2(dba)3 Dppf tBuONa Toluene 73 
7* Pd2(dba)3 PCy3·HBF4 tBuONa Toluene - 
8* Pd2(dba)3 PtBu3·HBF4 tBuONa Toluene 15 
9 Pd2(dba)3 XPhos tBuONa Toluene 61 
10 Pd2(dba)3 XPhos·tBu2 tBuONa Toluene 59 
11 Pd2(dba)3 SPhos tBuONa Toluene 25 
12 Pd2(dba)3 DavePhos tBuONa Toluene 34 
13 Pd2(dba)3 RuPhos tBuONa Toluene 39 
14 Pd(OAc)2 DPEPhos tBuONa Toluene 12 
15 Pd2(dba)3 DPEPhos Cs2CO3 Toluene 32 
16 Pd2(dba)3 DPEPhos tBuONa DMF 56 
* In the cooperation with Dr. Tran Quang Hung (50% of the optimisation reactions were 
optained by myself).  
 
54 
 
The application of these conditions allowed the synthesis of products 15a - f, derived from 
aliphatic amines, allylamine, and benzylamines, with excellent yields (Table 19). The amination 
of allylamine underwent an isomerization of the double bond to form 15d due to the presence 
of the strong base tBuONa (Scheme 21).  
 
Table 19. Synthesis of 15a-f. 
 
Compound R Yield (%)a 
15a n-C3H7 96 
15b n-C5H11 93 
15c n-C7H15 85 
15d Allyl 73 b 
15e Bn 94 
15f 4-(MeO)C6H4CH2 92 
Conditions: i, 2.0 equiv. amine, 3.0 equiv. NaOtBu, Pd2(dba)3 (5 mol%), DPEPhos (10 mol%), 
toluene, 100 ºC, 6 h. aYields of isolated products; bthe product 6-(prop-1-en-1-yl)-6H-
indolo[2,3-b]quinoxaline 15d was formed by isomerization of the allylic double bond (see 
Scheme 21). 
 
 
Scheme 21. Synthesis of indolo[2,3-b]quinoxalines 15d.  
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4.1.3. Synthesis of 5,7-dihydropyrido[3,2-b,5,6-b']diindoles 
2,3,5,6-Tetrabromopyridine 16 was synthesized according to a literature procedure established 
by Flowers.95  
 
 
Scheme 22. Synthesis of 2,3,5,6-Tetrabromopyridine 17  
Condition, i, Br2, AcOH, 0 oC. ii, HBr 48%, NaNO2, H2O, -3 oC → rt. 
 
In the first step (Scheme 23), compound 18 was prepared by Suzuki–Miyaura reaction with 2-
bromophenylboronic acid. The amination of 18 with allyl amine was optimized with various 
ligands, precatalysts and solvents at different reaction temperatures. The best yield of product 
18d (84%) was obtained when DPEPhos was used as the ligand in the presence of Pd2(dba)3 
(i.e. see Table 20).  
 
 
Scheme 23. Synthesis of 5,7-dihydropyrido[3,2-b,5,6-b']diindoles 19d. 
Conditions, i, 2.2 equiv. 2-bromophenylboronic acid, Pd(PPh3)4 (5 mol%), 3.0 equiv. NaOH, 
THF, H2O, 70 ºC, 4 h. ii, 3.0 equiv. amine, 6.0 equiv. base, Pd2(dba)3 (5 mol%), ligand 
(10 mol%), solvent, 100 ºC, 7 h. 
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Table 20. Optimization for the Synthesis of 19d. 
Entry Ligand Solvent Base Temp. (oC) Yield (%)a 
1* BINAP Toluene tBuONa 100 11 
2* Xantphos Toluene tBuONa 100 17 
3* DPEPhos Toluene tBuONa 100 74 
4* Dppe Toluene tBuONa 100 58 
5* Dppf Toluene tBuONa 100 41 
6* PCy3·HBF4 Toluene tBuONa 100 - 
7* PtBu3·HBF4 Toluene tBuONa 100 6 
8* XPhos Toluene tBuONa 100 4 
9 RuPhos Toluene tBuONa 100 7 
10 SPhos Toluene tBuONa 100 8 
11 DavePhos Toluene tBuONa 100 7 
12 Dppe  Toluene Cs2CO3 100 37 
13 Dppe 1,4-Dioxane tBuONa 100 28 
14 Dppe THF tBuONa 100 - 
15 Dppe Toluene tBuONa 80 42 
16 Dppe Toluene tBuONa 110 53 
* In the co-operation with Dr. Tran Quang Hung (50% of the optimisation reactions was 
optained by myself) 
 
Under optimized conditions, the reaction of compounds 18 with aliphatic amines afforded 
desired 5,7-dihydropyrido[3,2-b,5,6-b]diindoles 19a – c in good to excellent yields (Table 21). 
Allyl substituted 19d gave the highest yield (84%). Benzylamines and its derivatives gave good 
yields, too (products 19e 60%, 19f 70%).  
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Table 21. Synthesis of 19a - f. 
 
Compound R Yield (%)a 
19a n-C7H15 80 
19b n-C3H7 86 
19c n-C12H25 71 
19d Allyl 84 
19e Bn 70 
19f 4-(MeO)C6H4CH2 60 
Conditions, i, 3.0 equiv. amine, 6.0 equiv. tBuONa, Pd2(dba)3 (5 mol%), DPEPhos 
(10 mol%), toluene, 100 ºC, 7 h. a Yield of isolated products; 
 
4.1.4. Absorption and Fluorescence Properties. 
The fluorescence spectra were recorded at the excitation wavelength of 350 nm for compounds 
15 and 360 nm for compounds 19 (Figure 20, 21). Absorption maxima and fluorescent data are 
listed in Table 22. The UV/VIS spectra of selected compounds 19 show strong absorption bands 
in a range of 290-310 nm and weak absorption bands at about 380 nm. Compounds 15a, 15c 
and 15e have two strong absorption bands around 270 and 350 nm and a very weak band 
between 350-400 nm. In each series, there are small differences in the shape and the position 
of maxima in the absorption- and emission bands due to different substituents. The emission 
spectra of 19 display a narrow emission band with 3 maxima around 383, 393 and 403 nm. 
While compounds 15 possess a broad emission band with a band at about 480 nm. The Stokes 
shifts of compounds 19 are about 1700 cm-1 while ones of compounds 15 are larger, in the range 
of 7600 cm-1. All measured compounds of 19 give similar quantum yields of about 33%. 
Derivatives 19 show very low quantum yields (~5%). 
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Figure 20. Absorption and emission spectra of selected compounds 15. 
 
Figure 21. Absorption and emission spectra of selected compounds 19. 
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Table 22. Absorption and emission spectroscopic data of 15 and 19. 
Cp 
λabs1 
(nm) 
Log 
ε(λabs1)a 
λabs2 
(nm) 
Log 
ε(λabs2)a 
λabs3 
(nm) 
Log 
ε(λabs3)a 
λem (nm) 
(shoulders) 
Eoptb
(eV) 
Φ fluoc 
15a 336 3.626 352 3.728 394 3.043 475 3.25 5 
15c 336 4.834 352 4.939 394 4.240 483 3.28 6 
15e 334 4.822 351 4.934 395 4.238 477 3.22 5 
19b 364 4.274 375 4.348 382 4.471 406 (392, 381) 3.44 33 
19c 364 4.249 375 4.329 382 4.413 406 (392, 382) 3.48 31 
19d 362 4.149 371 4.233 380 4.488 404 (393, 380) 3.36 35 
19f 360 4.090 370 4.135 381 4.184 404 (392, 381) 3.34 34 
a(l·mol-1·cm-1); bEopt estimated from the absorption edge wavelength62; cusing quinine 
hemisulfate monohydrate in 0.05 M H2SO4 (Φ = 51%)59 
 
4.1.5. Electrochemical properties 
The corresponding redox peaks in cyclic voltammograms for selected compounds of 15 and 19 were 
overlapped by the background current and the signal from the solvent. Therefore, the DPV method was 
employed using DMF as solvent at room temperature and under argon atmosphere for electrochemical 
investigations. In voltammograms (Figure 23, 24), the oxidation and the reduction processes of 
compounds 15 and 19 show clear and symmetrical redox peaks. These symmetrical peaks could suggest 
that the oxidation and the reduction processes are reversible. The reduction and oxidation of compounds 
19 occurred at considerably lower potential than that of compounds 15.  
The values for the electronic properties IP (HOMO) and EA (LUMO) of selected compounds 15 and 19 
are shown in Table 23. Band gaps EEC of compounds 19 are larger than that of compounds 15. Comparing 
HOMO and LUMO values among compounds 19, substrates 19e with a benzyl group had the highest 
HOMO level and the lowest LUMO level resulting in the smallest band gap (3.47 eV). The same trend 
was observed for 15e containing a benzyl substituent when comparing among compounds 15. 
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Figure 22. Differential Pulse Voltammetry Plot of 15. 
 
Figure 23. Differential Pulse Voltammetry Plot of 19. 
 
The optical band gaps are lower than the electrochemical band gaps. The optical bandgap is 
determined by the excitation of electron from HOMO to LUMO. Meanwhile, the 
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electrochemical bandgap is determined by the reduction potential and oxidation potential of the 
substances on the electrode surface in a solvent. Therefore, the effect of solvation and the 
limitation of the interface between the substances and electrodes can attribute to the redox 
behaviors. 
 
Table 23. Electrochemical properties of selected compounds of 15 and 18. 
Cp E1-ox (V vs Fc/Fc+) E2-red (V vs Fc/Fc+) IP (eV)a EA (eV)a EEC (eV)a 
15a 1.819 -1.496 6.22 2.90 3.32 
15c 1.813 -1.508 6.21 2.89 3.32 
15d 1.787 -1.545 6.19 2.86 3.33 
15e 1.874 -1.512 6.27 2.89 3.38 
19a 1.263 -2.268 5.64 2.13 3.51 
19c 1.265 -2.35 5.67 2.05 3.62 
19d 1.312 -2.197 5.71 2.20 3.52 
19e 1.457 -2.003 5.87 2.40 3.47 
19f 1.312 -2.256 5.71 2.14 3.57 
aCalculations: IP = E1-ox + 4.4 eV (HOMO) ; EA = E2-red + 4.4 eV (LUMO); EEC = IP – EA 
(electrochemical band gap)60,61 
 
4.1.6. Conclusion 
The 2-step procedure: Suzuki-Miyaura cross-coupling reactions, followed by Pd-catalyzed 
double amination is a useful strategy to synthesize indolo[2,3-b]quinoxalines 15 and 5,7-
dihydropyrido[3,2-b,5,6-b']diindoles 19 in excellent yields. Selected compounds 15 and 19 
show fluorescence properties with low quantum yields (about 5% for compounds 15 and about 
30% for compound 19). The substituents have a small effect on the electrochemical and 
fluorescence properties. Compounds 19 possess larger bandgaps than compounds 15.  
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4.2. Palladium-Catalyzed Synthesis and Nucleotide Pyrophosphatase Activity of 
Benzo[4,5]-furo[3,2-b]indoles and Furo[3,2-b,4,5-b']diindoles 
4.2.1. Introduction 
The poly(hetero)aromatic compounds consisting of thiophenes and pyrroles have been well-
known motifs for light-emitting applications due to their advancements for conducting 
properties and stability.96 Recently, organic semiconductors containing furan moieties instead 
of thiophenes became attractive due to their isoelectronic properties.97 With the presence of the 
furan and pyrrole moieties, benzofuroindoles have been mentioned as highly efficient light-
emitting components in optical devices98 Moreover, 10H-benzo[4,5]-furo[3,2-b]indole, was 
reported with remarkable activity in the treatment of sexual steroid hormone receptor mediated 
diseases.99a 10H-benzo[4,5]-furo[3,2-b]indole-1-carboxylic acid can control the potassium 
channel in the human body for the treatment of smooth muscle dysfunctional contraction.99b 
 
 
Figure 24. Selected examples of furoindole derivatives 
 
Benzofuro[2,3-b]indoles can be prepared via classic Fischer-indole cyclization100 with 
phenylhydrazine under acidic conditions. Besides, the Palladium catalyzed cross-coupling with 
indole derivatives is a noticeable strategy to obtain these compounds.101 Based on previous 
work related to Pd-catalyzed Suzuki-Miyaura reactions of 2-bromophenylboronic acid with 
2,3,5,6-tetrabromopyridine, 2,3-dibromoquinoxaline, tetrabromothiophene,80a and 2,3-
dibromo-1-methyl-1H-indole in my research group,80b I studied the synthesis of various 
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benzofuro[2,3-b]indolo derivatives by this approach. At the same time, Truong et al. have, 
mentioned the double Buchwald-Hartwig amination resulting the same products via iodine-
mediated electrophilic cyclization for the starting material synthesis.101c In comparison, I 
propose a convenient two-step procedure: regioselective Suzuki-Miyaura reaction of 2,3-
dibromobenzofuran and subsequent cyclization by double Buchwald-Hartwig reaction. In 
addition, I applied this strategy, for the first time, to tetrabromofuran as starting material. This 
interesting and highly symmetrical substrate has only been scarcely used so far in Palladium 
catalyzed reactions. These reactions lead to furodiindoles – a highly symmetrical heterocyclic 
core structure which has, to the best of my knowledge, not been reported so far. 
 
4.2.2. Synthesis of benzo[4,5]-furo[3,2-b]indoles 
2,3,-dibromobenzofuran (21) was synthesized according to a literature procedure.102 
Intermediate 22 (84% yield) was prepared by a Suzuki-Miyaura cross-coupling of 21 and 2-
bromophenylboronic acid using Pd(PPh3)4 as catalyst.  
 
 
Scheme 24. Synthesis of 2,3-Dibromobenzofuran 21 
Condition, i, Br2, AcOK, CH2Cl2, 4 h, reflux. 
 
 
Scheme 25. Synthesis of benzo[4,5]-furo[3,2-b]indoles 23a-j. 
Conditions, i, 1.1 equiv. 2-bromophenylboronic acid, Pd(PPh3)4 (2.5 mol%), 3.0 equiv. K3PO4, 
1,4-dioxane, H2O, 100 ºC, 8 h.80 ii, 1.1 equiv. amine, 3.0 equiv. tBuONa, Palladium catalyst 
(5 mol%), ligand, solvent (10 mol%), 110 ºC, 12 h. 
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To develop a more efficient procedure for the synthesis of benzo[4,5]-furo[3,2-b]indoles 23, 
the conditions of the double CN cross-coupling of 22 were optimized using p-toluidine (Scheme 
25, Table 24).  
 
Table 24. Optimization for the synthesis of 21b. 
 
Entry Pd precursor Ligand Solvent Yield (%)a 
1 Pd2(dba)3 Dppf Toluene 57 
2 Pd2(dba)3 Xantphos Toluene 44 
3 Pd2(dba)3 Dppe Toluene 62 
4 Pd2(dba)3 BINAP Toluene 75 
5 Pd2(dba)3 PtBu3·HBF4 Toluene 41 
6 Pd2(dba)3 XPhos Toluene 36 
7 Pd2(dba)3 SPhos Toluene 54 
8 Pd2(dba)3 DavePhos Toluene 35 
9 Pd2(dba)3 RuPhos Toluene 45 
10 Pd(OAc)2 BINAP Toluene 52 
11 Pd2(dba)3 BINAP Dioxane 61 
12 Pd2(dba)3 BINAP DMF 14 
Condition, i, 1.1 equiv. amine, 3.0 equiv. tBuONa, Pd2(dba)3 (5 mol%), ligand (10 mol%), 
toluene, 110 ºC, 12 h. aYield calculated by 1H-NMR of the crude product using 1,4-dioxane 
as an internal standard. 
 
According to my observation, monodentate phosphine ligands were not suitable for this reaction 
while bidentate phosphine ligands gave compound 23b in better yields. Compound 23b was 
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obtained with the highest yield (75%) when BINAP, Pd2(dba)3 as the catalyst system in toluene 
was used for this reaction. The reaction afforded 52% yield with Pd(OAc)2 as the catalyst 
precursor. 
 
Table 25. Optimization for the synthesis of 23h. 
 
Entry Ligand Yield (%)a 
1 Dppf 23 
2 Xantphos 47 
3 Dppe 34 
4 BINAP 57 
5 PtBu3·HBF4 43 
6 XPhos 32 
7 SPhos 44 
8 DavePhos 67 
9 RuPhos 52 
Condition, i, 1.1 equiv. amine, 3.0 equiv. tBuONa, Pd2(dba)3 (5 mol%), ligand (10 mol%), 
toluene, 110 ºC, 12 h. aYield calculated by 1H-NMR of the crude product using 1,4-dioxane 
as an internal standard 
 
Using optimized conditions, different anilines were used for the double amination to afford 
products 23a - g with good to excellent yields. The substituents of aniline derivatives have no 
effect on the yield. However, the conditions were not suitable for the double amination using 
alkyl- or benzyl amines. Therefore, an additional screening of ligands was performed for the 
reaction with benzylamine (Table 25). The best yield of the product 23h was 67% in the 
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presence of Pd2(dba)3 and DavePhos. Aliphatic amines like n-heptyl and cyclohexylamine gave 
the final products 23i - j with moderate yields (53 and 57%, respectively) (Table 26).  
 
Table 26. Synthesis of 23a-j. 
 
 
  
Compound R Yield (%)a 
23a Ph 63b 
23b 4-MeC6H4 75b 
23c 4-FC6H4 79b 
23d 3-(CF3)C6H4 81b 
23e 4-(MeO)C6H4 65b 
23f 3,4-(MeO)2C6H3 51b 
23g 4-tBuC6H4 84b 
23h Bn 67c 
23i n-C7H15 53c 
23j Cyclohexyl 57c 
Condition, i, 1.1 equiv. amine, 3.0 equiv. tBuONa, Pd2(dba)3 (5 mol%), ligand (10 mol%), 
toluene, 110 ºC, 12 h. aYield calculated by 1H-NMR of the crude product using 1,4-dioxane as 
an internal standard. aIsolated yields; ligand,b BINAP;c DavePhos 
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4.2.3. Synthesis of furo[3,2-b,4,5-b']diindole 
2,3,4,5-Tetrabromofuran 25 was prepared following a literature procedure (Scheme 26).103  
 
Scheme 26. Synthesis of 2,3,4,5-Tetrabromofuran 25. 
Condition, i, Br2, KOH, H2O; ii, KOH, MeOH, reflux. 
 
The precursor 3,4-dibromo-2,5-bis(2-bromophenyl)furan 26 (78% isolated yield) was obtained 
via the Suzuki-Miyaura reaction of tetrabromofuran 25 with 2-bromophenylboronic acid. 
Various amines were employed to afford the desired furo[3,2-b,4,5-b']diindoles 27 by twofold 
double Buchwald-Hartwig amination (Scheme 27).  
 
 
Scheme 27. Synthesis of furo[3,2-b,4,5-b']diindole 27b. 
Conditions, i, 2.2 equiv. 2-bromophenylboronic acid, Pd(PPh3)4 (2.5 mol%), 5.0 equiv. K3PO4, 
dioxane (10 ml), H2O, 90 ºC, 8 h. ii, 3.0 equiv. amine, 5.0 equiv. tBuONa, Palladium catalyst 
(5 mol%), ligand (10 mol%), solvent, 110 ºC, 6 h. 
 
However, previously optimized conditions for compound 23 could not be applied to synthesize 
compounds 27 due to the occurance of an inseparable mixture of products. The ligands, 
Palladium precursor, reaction temperature and solvents were screened in an additional 
optimization for compound 27b (Scheme 27, Table 27). The reaction with Pd2(dba)3 and dppf 
gave compound 27b in the best yield (65%).  
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Table 27. Optimization for the synthesis of 27b. 
Entry Pd precursor Ligand Solvent Yield (%)a 
1 Pd2(dba)3 Dppf Toluene 65 
2 Pd2(dba)3 Xantphos Toluene 44 
3 Pd2(dba)3 Dppe Toluene 48 
4 Pd2(dba)3 BINAP Toluene 55 
5 Pd2(dba)3 PtBu3·HBF4 Toluene 41 
6 Pd2(dba)3 XPhos Toluene 29 
7 Pd2(dba)3 SPhos Toluene 33 
8 Pd2(dba)3 DavePhos Toluene 22 
9 Pd2(dba)3 RuPhos Toluene 25 
10 Pd(OAc)2 Dppf Toluene 52 
11 Pd2(dba)3 Dppf Dioxane 61 
12 Pd2(dba)3 PCy3·HBF4 DMF 22 
13 Pd2(dba)3 DPEPhos DMF 23 
14 Pd2(dba)3 Dppf THF 8 
15 Pd(OAc)2 Dppf THF 18 
16 Pd(OAc)2 BINAP Toluene  38 
17 Pd2(dba)3 Dppf DMF 14 
aYield calculated by 1H-NMR using 1,4-dioxane as an internal standard 
 
The newly developed conditions allowed to extend the scope of reaction with various anilines 
and aliphatic amines. The products 27 were obtained in moderate to good yields. The product 
27f substituted with 4-tBuC6H4 was synthesized with the best yield (86%). The amination with 
benzylamine and n-heptylamine gave the product 27h and 27g in the yield of 37% and 22%, 
respectively. Using dppe instead of dppf gave the products 27h and 27g in improved yields 
(53% and 46%). There is no relation between the electron donor or acceptor ability of 
substituents and the yields of reaction products. 
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Table 28. Synthesis of 27a-h. 
 
Compound R Yield (%)a 
27a Ph 51 
27b 4-MeC6H4 65 
27c 4-FC6H4 59 
27d 3-(CF3)C6H4 66 
27e 4-(MeO)C6H4 53 
27f 4-tBuC6H4 86 
27g Bn 37 (53)b 
27h n-C7H15 22 (46)b 
Conditions, i, 2.2 equiv. 2-bromophenylboronic acid, Pd(PPh3)4 (2.5 mol%), 5 equiv. K3PO4, 
dioxane, H2O, 90 ºC, 8 h. ii, 3.0 equiv. amine, 5 equiv. NaOtBu, Pd2(dba)3 (5 mol%), dppf (10 
mol%), toluene, 110 ºC, 6 h. a Isolated yields; b dppe was used as ligand 
 
X-ray crystal structure analysis was performed to independently prove the structures of 23c and 
27d (Figures 25, 26). The compound 23c was crystallized in the monoclinic form in which the 
molecules are packed into layers. The 4-fluorophenyl substituent is twisted by 49.4o compared 
to the planar furoindole core structure. The molecules of 27d are ordered into layers to form 
monoclinic system (needles form). The two substituents at the Nitrogen atom are not parallel 
and twisted by 43.6o and 51.0o compared to the planar furodiindole scaffold.  
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Figure 25. ORTEPs of 23c (The propability of ellipsoids: 45%). 
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Figure 26. ORTEPs of 27d (The propability of ellipsoids: 45%). 
72 
 
4.2.4. Absorption and fluorescence properties.  
 
Figure 27. Absorption and emission spectra of selected compounds 23. 
 
Figure 28. Absorption and emission spectra of selected compounds 27. 
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Steady-state UV-VIS absorption and emission spectra of selected compounds 23 and 27 were 
measured in acetonitrile at 25 oC and are displayed in Figure 27 and 28. The determined 
absorption-, emission maxima and quantum yields are listed in Table 29. 
 
Table 29. Absorption and emission properties of 23 and 27. 
Cp λabs1 
[nm] 
Log 
ε(λabs1)a 
λabs2 
[nm] 
Log 
ε(λabs2)a 
λabs3 
[nm] 
Log 
ε(λabs3)a 
λem1 
[nm] 
λem2 
[nm] 
Eoptb
[eV] 
Φfluoc 
23b 253 5,169 318 5,137 - - 366  3.70 72 
23c 253 5,072 318 5,048 - - 365  3.70 48 
23e 254 4,468 318 4,395 - - 369  3.72 59 
23h 252 4,615 318 4,581 - - 370  3.73 64 
23j 252 4,387 318 4,369 - - 363  3.75 82 
27b 256 4,514 335 4,542 353 4,582 359 378 3.41 87 
27c 252 4,319 334 4,321 349 4,405 357 377 3.44 57 
27e 257 4,551 336 4,572 353 4,602 358 375 3.38 69 
27g 256 4,415 338 4,429 355 4,489 361 379 3.39 52 
a(l·mol-1·cm-1), bEopt estimated from the absorption edge wavelength.62 cusing quinine 
hemisulfate monohydrate in 0.05 M H2SO4, (Φ = 51%)59 
 
The strong absorption bands at about 250 nm and around 300-370 nm were recorded for all 
compounds 23 and 27. For each kind of compounds 23 and compounds 27, the spectra possess 
the same shape with small differences in intensity and the position of the absorption maxima. 
Such small differences indicate that substituents at the Nitrogen atoms have only small impact 
on the optical properties and the furoindol scaffold is the main chromophore. Compounds 27 
gave a moderate red-shift about 20 nm when comparing with compounds 23 due to the 
extension of the π-system by the second pyrrole ring in compounds 27. Based on the absorption 
maxima, the measurements of fluorescence spectra were performed with an excitation 
wavelength of 300 nm. The emission maxima of compounds 23 were in a range from 363 to 
370 nm, while compounds 27 emit at 360 nm with no real difference in shape and position of 
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the emission maxima (Table 29). The emission spectra of 23 show a single asymmetrical band 
while these of 27 consist of two emission bands. The Stokes shift values of compounds 23 and 
27 were about 3000 cm-1 and 500 cm-1, respectively. All measured compounds 23 and 27, 
possess remarkably high quantum yields (48-87%). Compound 27b gave the highest quantum 
yield (87%). Substituents had a weak effect on the absorption behaviors, but a strong effect on 
the emission quantum yields is observed. The substances with methyl groups (compounds 23b, 
27b; quantum yield: 72% and 87%) possess higher quantum yields than these with electron 
withdrawning fluoro groups (compounds 23c, 17c; with quantum yields: 48% and 57%). The 
presence of oxygen in compounds 23e and 27e accompanies with a decrease of the quantum 
yields to 59 % and 69% compared to compounds 23b, 27b, respectively.  
 
4.2.5. Electrochemical studies 
 
Figure 29. Cyclic Voltammetry plot of 23b and 27b in DMF. 
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Figure 30. Differential Pulse Voltammetry plot of selected compounds 23. 
 
Figure 31. Differential Pulse Voltammetry plot of selected compounds 27. 
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23b and 27b possess non-reversible oxidation and reduction events, shown in the cyclic 
voltammograms (Figure 29). There is no difference of the reduction events of compounds 23b 
and 27d which is ascribed for the furan moiety. The oxidation event of compound 27b is by 
0.236 V earlier than that of compound 23b due to the electron donating input of the second 
indole moiety in compound 27b. Furthermore, Differential Pulse Voltammography (DPV) was 
performed to evaluate the HOMO and LUMO energies, described in Figure 30, 31 and Table 
30. 
 
Table 30. Redox data of 23 and 27 in DMF. 
Cp E1-ox (V vs Fc/Fc+) E2-red (V vs Fc/Fc+) IP (eV)a EA (eV)a EEC (eV)a 
23b -2.270 1.327 -5.727 -2.130 3.597 
23c -2.225 1.388 -5.788 -2.175 3.613 
23e -2.255 1.327 -5.727 -2.145 3.582 
23h -2.300 1.282 -5.682 -2.100 3.582 
23j -2.235 1.362 -5.762 -2.165 3.597 
27b -2.230 1.091 -5.491 -2.170 3.321 
27c -2.114 1.176 -5.576 -2.286 3.290 
27e -2.305 1.005 -5.405 -2.095 3.310 
27g -2.270 1.101 -5.501 -2.130 3.371 
aCalculations: IP = E1-ox + 4.4 eV (HOMO) ; EA = E2-red + 4.4 eV (LUMO); EEC = IP – EA 
(electrochemical band gap)60, 61 
 
An influence of substituents cannot be recognized for compounds 23. All derivatives possess 
similar electronic behaviors despite various substituents. Only a small difference can be 
detected for the oxidation peaks. Therefore, they possess very similar LUMO and HOMO 
energy levels. The redox events of compounds 27 are more complicated with high dependency 
on the substituents. However, their electrochemical band gaps are not much different with the 
77 
 
value of 3.6 eV for compounds 23b, 23c, 23e, 23h and 23j and 3.3 eV for compounds 27b, 27c, 
27e and 27g. The electrochemical band gaps are slightly lower than the optical band gaps.  
 
4.2.6. Nucleotide Pyrophosphatase Activity. 
Derivatives of compounds 23 and 27 were tested for human recombinant NPPs, i.e. NPP1-3. 
These compounds show significant inhibition of both enzymes of NPP-1 and NPP-3 (Table 31). 
 
Table 31. Biological activity of 23 and 27. 
Compound NPP-1 
IC50 (µM)±SEM 
NPP-3 
IC50(µM)±SEM 
23a -- 1.38±0.03 
23b 2.84±0.06 0.59±0.02 
23c 1.29±0.07 3.14±0.09 
23d 3.57±0.03 0.49±0.04 
23e -- 
0.26±0.01 
23h 2.62±0.03 0.27±0.06 
23i 3.27±0.08 2.55±0.07 
23j 6.14±0.09 2.39±0.05 
27b 0.11±0.06 0.61±0.09 
27c -- 0.13±0.06 
27d -- 0.28±0.04 
27e 1.38±0.09 0.18±0.01 
27g 0.53±0.09 0.21±0.04 
27h -- 0.24±0.02 
Values ± SEM are expressed as deviation of three experiments (n = 3). The IC50 is the 
concentration, at which 50% of the enzyme activity is inhibited. *performed by Prof. Iqbal 
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Compound 23a with phenyl group and 23e with 4-MeOC6H4 group, respectively, show high 
selectivity against the nucleotide pyrophosphatase enzyme NPP-3. Compound 23c is more 
sensitive against NPP1 than NPP3 with an inhibitory value of NPP-1, 
IC50±SEM = 1.29±0.07 µM, while compounds 23b, 23d, 23h were more sensitive against NPP3 
than NPP1. Aliphatic substituted compounds 23j, 23i show no selectivity against both enzymes.  
Interestingly, compounds 27 could be potential inhibitors against nucleotide pyrophosphatases 
NPP-3. Compound 27b is highly active against both NPP-3 and NPP-1 
(IC50±SEM = 0.11±0.06 µM). In contrast, compounds 27e and 27g are more active against 
NPP-3 than NPP-1. Compounds 27c, 27d and 27h are only selective to NPP-3 
(IC50±SEM = 0.13±0.06, 0.28±0.04 and 0.24±0.02 µM, respectively). With high inhibitory 
value of IC50 ±SEM = 0.13±0.06 µM , compound 27c may be considered as the most potential 
candidate applied for the inhibition of NPP-3. Furo[3,2-b,4,5-b']diindoles 27 exhibit an even 
stronger activity to both enzymes than indole derivatives 23. 
  
4.2.7. Conclusion. 
Benzo[4,5]-furo[3,2-b]indoles 23 and furo[3,2-b:4,5-b']diindoles 27 were successfully 
prepared via a 2-step procedure using a Suzuki-Miyaura cross-coupling reaction in the first 
step, followed by Pd-catalyzed double N-arylation. The electrochemical and fluorescence 
studies demonstrated that both compounds 23 and 27 are promising candidates for optical 
application with high quantum yields. Compound 27 with two indole moieties have a smaller 
bandgap (3.3 eV for the electrochemical bandgap and 3.4 eV for the optical bandgap) 
comparing with compound 23 with one indole moiety (3.6 eV for the electrochemical bandgap 
and 3.7 eV for the optical bandgap). Effects on the optical and electrochemical properties of 
obtained compounds induced by the N-substituents are very small but allow to verify the 
electron affinity and the ionization potential. In addition, compounds 23 and 27 show high 
inhibition against nucleotide pyrophosphatase NPP-1 and NPP-3. The biological activities of 
these compounds are dependent on the substituents on the Nitrogen atom.  
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5. Summary 
I have prepared highly-conjugated systems from cheap and commercial available precursors. 
In detail, introducing one or two bromine atoms into positions 2 and 3, corresponding 
brominated naphthoquinones are attractive building blocks for further structural modification. 
Thus in this thesis I have shown that various, highly functionalized naphthalene- and quinone 
derivatives are easily accessible from these simple starting materials by application of 
Palladium catalyzed cross-coupling reactions.  
  
Scheme 28. The modification of naphthoquinone structure 
Moreover, polyhalogenated quinoxalines, furans and pyridines have been used as easily 
available starting materials for the synthesis of heterocyclic ladder-type tetracene and pentacene 
analogs, using a two-step procedure consisting of a Suzuki-Miyaura reaction of the halogenated 
heterocycle with 2-bromophenylboronic acid followed by a double Buchwald-Hartwig 
reaction. Preliminary optical and electrochemical studies of selected compounds have been 
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undertaken to get first insights into the structure-property relationship of newly synthesized 
compounds.  
 
 
Scheme 29. The combination of Suzuki-Miyaura and Buchwald-Hartwig cross-coupling 
reactions. 
 
An addition selected compounds, namely benzocarbazolediones and furoindoles have been 
studied regarding their inhibition activity related to human nucleotide pyrophosphatase and 
show to some extent high activity and selectivity to these enzymes 
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7. Appendix 
7.1 Gerneral information 
All used chemicals, if not otherwise stated, are commercially available and used without further 
purification. All reactions were carried out in dried glass pressure tubes under an argon 
atmosphere. Analytical TLC on Merck silica gel 60 F254 plates was visualized by fluorescence 
quenching. Column chromatography was performed on Merck Geduran Si 60 (0.063-0.200 
mm). 1H NMR and 13C NMR spectra were carried out on a Bruker Advance DRX-500 MHz, 
300 MHz or 250 MHz. Chemical shifts in ppm were corrected by residual solvent. 
Multiplicities: s = singlet, d = doublet, dd = doublet of doublets, t = triplet, td = triplet of 
doublets, tt = triplet of triplets, m = multiplet, q = quartet. Nicolet 550 FT – IR spectrometer 
was used with ATR sampling technique for solids and liquids. Signal characterization: 
w = weak, m = medium, s = strong. Gas chromatography - mass analysis was performed on an 
Agilent HP-5890 instrument with an Agilent HP-5973 Mass Selective Detector (EI) and HP-5 
capillary column using helium carrier gas. Agilent 1969A TOF mass spectrometer was used for 
ESI HR-MS measurements. High Resolution MS (HRMS) was performed on a Finnigan MAT 
95 XP. Single crystal X-Ray structure determination was carried out on a Bruker X8Apex 
diffractometer with CCD camera (Mo K radiation and graphite monochromator, a = 0.071073 
Å). Melting points were determined on a Micro-Hot-Stage GalenTM III Cambridge 
Instruments. The melting points are not corrected.  
 
Electrochemical protocols 
All electrochemical studies were performed with an Autolab (PGSTAT 302N, Metrohm) at 
22 oC in dried dimethylformamide under an Argon atmosphere. 0.1 M tetrabutylammonium 
hexafluorophosphate (Fluka) was used as conducting support. The working electrode was a 
glassy carbon disk electrode (d = 2 mm), a Pt-electrode as the counter electrode, an Ag/AgCl/ 
LiCl sat. in EtOH-system as the reference electrode (all electrodes: Metrohm) and the 
ferrocenium/ferrocene as internal reference system (potential of Fc+/Fc: 0.51 V [vs. 
Ag/AgCl/LiCl sat. in EtOH]. The CV scans were repeated three times at a scan rate of 
40 mV.s−1. The DPV measurements in oxidative and anodic directions were performed with a 
step potential of 5 mV, modulation amplitude of 0.025 V, modulation time of 0.05 s and an 
interval time of 0.5 s 
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Biological protocols  
Cell Transfection with Human NPPs. COS-7 cells were transfected with plasmids expressing 
human NPPs ((NPP-1)1 or (NPP-3)2) in 10-cm plates, by using Lipofectamine. The confluent 
cells were incubated for 5 hr at 37 °C in DMEM/F-12 in the absence of fetal bovine serum and 
with 6 µg of plasmid DNA and 24 µL of Lipofectamine reagent. Subsequently, the same volume 
of DMEM/F-12 containing 20% FBS was added to stop the transfection and cells were 
harvested 48–72 h later.  
 
Preparation of membrane fractions. The transfected cells were washed three times with Tris–
saline buffer at 4 °C and then the cells were collected by scraping in the harvesting buffer 
(95 mM NaCl, 0.1 mM PMSF, and 45 mM Tris buffer, pH 7.5). Afterwards, the cells were 
washed twice by centrifugation at 300×g for 5 min at 4 °C.3 These cells were resuspended in 
the harvesting buffer containing 10 µg/mL aprotinin and then sonicated. Cellular and nuclear 
debris were discarded by 10 min centrifugation (300×g at 4 °C). Glycerol (final concentration 
of 7.5%) was added to the resulting supernatant and all the samples were kept at -80 °C until 
used. Bradford microplate assay4 was used for the estimation of protein concentration. Bovine 
serum albumin was used as a reference standard.  
 
Protocol of Nucleotide pyrophosphatase (NPP-1 & NPP-3) activity. The conditions for the 
assay were optimized with slight modifications in previously used spectrophotometric method.5 
The reaction was carried out in the assay buffer which contained 5 mM MgCl2, 0.1 mM ZnCl2, 
25% glycerol and 50 mM tris-hydrochloride (pH: 9.5). Initial screening was performed at a 
concentration of 0.1 mM of the tested compounds. The total volume of 100 µL contained 70 µL 
of the assay buffer, 10 µL of tested compound (0.1 mM with final DMSO 1% (v/v)) and 10 µL 
of NPP-1 (27 ng of protein from COS cell lysate in assay buffer) or 10 µL of h-NPP-3 (25 ng 
of protein from COS cell lysate in assay buffer). The mixture was pre-incubated for 10 minutes 
at 37 ˚C and absorbance was measured at 405 nm as pre-read using microplate reader (BioTek 
FLx800, Instruments, Inc. USA). The reaction was then initiated by the addition of 10 µL of p-
Nph-5-TMP substrate at a final concentration of 0.5 mM and the reaction mixture was incubated 
for 30 more min at 37 °C. The change in the absorbance was measured as after-read. The 
activity of each compound was compared with the reaction in absence of tested 
compounds/inhibitors. The compounds which exhibited over 50% inhibition of either the NPP-
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1 activity or NPP-3 activity were further evaluated for determination of IC50 values. For this 
purpose their dose response curves were obtained by assaying each inhibitor concentration 
against both NPPs using the above mentioned reaction conditions. All experiments were 
repeated three times in triplicate. The IC50 values, determined by the non-linear curve fitting 
program PRISM 5.0 (GraphPad, San Diego, California, USA). 
 
7.2. Supplement for optical spectra of compounds 3, 6, 7 
 
 
Figure S1. Absorption and corrected emission spectra of 3 
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Figure S2. Absorption and fluorescence spectra of compounds 6. 
 
 
Figure S3. Absorption and fluorescence spectra of compounds 7. 
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6.3. Supplement for Chapter 2 
 
Scheme S1. Synthesis of diarylethynylnaphthalenes 2a-f. 
 
Procedure for the starting compounds 2: The solution of 1,4-naphthoquinones in THF was 
dropped into the mixture of n-Buli and arylacetylenes. The reaction was stirred for 10 minutes 
at room temperature, then, was heated to 60 oC for 30 minutes. After cooling down, a saturated 
solution of ammonium chloride was added. The mixture was extracted with ethyl acetate, dried 
for the next step. The obtained brown solid was dissolved in MeCN (20 ml) and water (1 ml), 
then SnCl2 was added. The reaction was refluxed for 6h. After cooling down to room 
temperature, the mixture was diluted with water and extracted with ethyl acetate. The combined 
organic layers were dried over sodium sulfate and concentrated under vacuum. The crude 
material was purified by flash column chromatography (silica gel, heptane/ethylacetate). 
 
 
Scheme S2. Synthesis of ethynylbenzoindole 3. 
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Procedure for ethynylbenzoindole 3 (amination), An argon purged pressure tube was 
charged with brominated 1,4-diethynylnaphthalene(0.3 mmol) and the amine (0.3 mmol), 
Pd(OAc)2 (5 mol%), SPhos (10 mol%), base (0.9 mmol) and DMF (10 mL). The reaction was 
set up at 90 C for 48 h. Afterwards the mixture was allowed to reach room temperature, was 
diluted with water and extracted with ethyl acetate. The combined organic layers were dried 
over sodium sulfate and concentrated under vacuum. The crude material was purified by flash 
column chromatography (silica gel, heptane/ethylacetate). 
 
Scheme S3. Synthesis of tetraarylethynylnaphthalene 6. 
 
Procedure for tetraarylethynylnaphthalene 6a (Sonogashira reaction), An argon purged 
pressure tube was charged with 2,3-dibromo-1,4-diethynylnaphthalene 1 (0.3 mmol) and 
PdCl2(CH3CN)2 (5 mol%), SPhos (or XPhos) (10 mol%), CuI (5 mol%),diisopropylamine 
(1 ml) and dioxane (5 mL), then the arylacetylene (0.3 mmol) was added. The reaction was set 
up at 80 C for 24 h. Afterwards the mixture was allowed to reach room temperature, was 
diluted with water and extracted with ethyl acetate. The combined organic layers were dried 
over sodium sulfate and concentrated under vacuum. The crude material was purified by flash 
column chromatography (silica gel, heptane/ethylacetate). 
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Scheme S4. Synthesis of 2,3-diaryl-1,4-diethynylnaphthalene 7. 
 
Procedure for 2,3-diaryl-1,4-diethynylnaphthalene 7 (Suzuki-Miyaura reaction), An argon 
purged pressure tube was charged with 2,3-dibromo-1,4-diethynylnaphthalene(0.3 mmol) and 
arylboronic acid (0.3 mmol), Pd(PPh3)4 (5 mol%), Na2CO3 (0.9 mmol) and dioxane(10 mL). 
The reaction was set up at 100 C for 24 h. Afterwards the mixture was allowed to reach room 
temperature, was diluted with water and extracted with ethyl acetate. The combined organic 
layers were dried over sodium sulfate and concentrated under vacuum. The crude material was 
purified by flash column chromatography (silica gel, heptane/ethylacetate). 
 
2-Phenyl-5-(phenylethynyl)-3-(p-tolyl)-3H-benzo[e]indole (3a) 
Following the general procedure, 3a was obtained as a yellow 
solid (96 mg, 74 %), mp = 166 – 168 C. 1H NMR (250 MHz, 
CDCl3) δ 8.55 (dd, 3J = 8.1 Hz, 4J = 0.9 Hz, 1H, CHAr), 8.38 – 8.31 
(m, 1H, CHAr), 7.71 (s, 1H, CHAr), 7.68 – 7.62 (m, 3H, CHAr), 
7.60 – 7.55 (m, 1H, CHAr), 7.44 – 7.19 (m, 13H, CHAr), 2.45 (s, 
3H, CH3). 13C NMR (63 MHz, CDCl3) δ 140.7, 137.9, 135.5, 
135.0, 132.5 (CAr), 131.6, 130.3 (2CHAr), 129.6 (CAr), 129.0, 
128.5, 128.4 (2CHAr), 128.1 (CHAr), 128.0 (2CHAr), 127.8 (CAr), 
127.4, 127.1, 126.5, 124.6 (CHAr), 124.4, 124.0 (CAr), 123.5, 117.0 (CHAr), 115.2 (CAr), 103.0 
(CHAr), 93.2, 89.3 (C≡C), 21.4 (CH3). IR (ATR, cm-1), ṽ = 1585 (m), 1475 (s), 1363 (s), 1282 
(m), 1257 (m), 1228 (m), 750 (s), 705 (m), 692 (s), 684 (s), 665 (s), 657 (s), 646 (s). MS (EI, 
97 
 
70 eV), m/z (%) = 435 (6), 434 (33), 433 (M+, 100), 417 (4), 340 (3), 315 (6), 208 (6), 77 (5). 
HRMS (EI), calcd for C33H23N (M+), 433.18250, found, 435.18283. 
 
3-(4-Fluorophenyl)-2-phenyl-5-(phenylethynyl)-3H-benzo[e]indole (3b) 
Following the general procedure, 3b was obtained as a yellow solid 
(64 %), mp = 208 – 209 C. 1H NMR (300 MHz, CDCl3) 
δ 8.53 – 8.46 (m, 1H, CHAr), 8.32 – 8.26 (m, 1H, CHAr), 7.66 – 7.48 
(m, 5H, CHAr), 7.39 – 7.22 (m, 11H, CHAr), 7.19 – 7.07 (m, 2H, 
CHAr). 19F NMR (282 MHz, CDCl3) δ -113.20. 13C NMR (75 MHz, 
CDCl3) δ 161.8 (d, 1J = 248.3 Hz, CF), 140.6, 134.8 (CAr), 134.0 
(d, 4J = 3.2 Hz, CAr), 132.0 (CAr), 131.5 (2CHAr), 129.9 (d, 
3J = 8.6 Hz, 2CHAr), 129.5 (CAr), 128.9 (2CHAr), 128.4 (4CHAr), 
128.1 (CHAr), 127.6 (CAr), 127.5, 127.0, 126.5, 124.6 (CHAr), 124.3, 123.7 (CAr), 123.3 (CHAr), 
116.5 (d, 2J = 22.9 Hz, 2CHAr), 116.4 (CHAr), 115.4 (CAr), 103.2 (CHAr), 93.2, 88.9 (C≡C). 
IR (ATR, cm-1), ṽ = 3070 (w), 1598 (m), 1508 (s), 1477.28 (s), 1390 (m), 1220 (s), 1068 (m), 
1029 (m), 1014 (m), 948 (m), 862 (m), 840 (s). MS (EI, 70 eV), m/z (%) = 438 (31), 437 (M+, 
100), 413 (1), 333 (6), 313 (7), 219 (19), 218 (25), 179 (12). HR-MS (EI), Calcd for C32H20FN 
(M+) = 437.15743, found 437.15706. 
3-(4-Methoxyphenyl)-2-phenyl-5-(phenylethynyl)-3H-benzo[e]indole (3c) 
Following the general procedure C, 3c was obtained as a yellow 
solid (80 %), mp = 201 – 202 C. 1H NMR (250 MHz, CDCl3) 
δ 8.58 – 8.51 (m, 1H, CHAr), 8.38 – 8.30 (m, 1H, CHAr), 
7.68 – 7.57 (m, 5H, 5CHAr), 7.43 – 7.27 (m, 10H, CHAr), 7.24 
(s, 1H, CHAr), 7.04 – 6.97 (m, 2H, CHAr), 3.88 (s, 3H, OCH3). 
13C NMR (63 MHz, CDCl3) δ 159.1, 140.8, 135.25, 132.4 (CAr), 
131.6 (2 CHAr), 130.9, 129.6 (CAr), 129.4, 129.0, 128.5, 128.4 
(2CHAr), 128.1 (CHAr), 127.8 (CAr), 127.5, 127.1, 126.5, 124.6 
(CHAr), 124.3, 123.9 (CAr), 123.5, 117.0 (CHAr), 115.1 (CAr), 114.8 (2 CHAr), 102.7 (CHAr), 
93.2, 89.2 (C≡C), 55.7 (OCH3). IR (ATR, cm-1), ṽ = 3099 (w), 3056 (w), 3029 (w), 3002 (w), 
2956 (w), 2919 (w), 2848 (w), 2200 (w), 1724 (w), 1596 (w), 1587 (m), 1510 (s), 1492 (m), 
1475 (m), 1465 (m), 1454 (m). MS (EI, 70 eV), m/z (%) = 452 (30), 451 (84), 450 (71), 449 
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(M+, 100), 362 (12), 184 (4), 155 (6), 91 (4), 44 (14). HR-MS (EI), Calcd for C33H23NO2 
(M+), 449.17741, found 449.17690. 
 
3-(4-Fluorobenzyl)-2-phenyl-5-(phenylethynyl)-3H-benzo[e]indole (3d) 
Following the general procedure C, 3d was obtained as a yellow solid (52 %), 
mp = 171 – 173 C 
1H NMR (300 MHz, CDCl3) δ 8.65 – 8.60 (m, 1H, CHAr), 8.40 – 8.35 
(m, 1H, CHAr), 7.79 – 7.63 (m, 5H, CHAr), 7.55 – 7.40 (m, 8H, CHAr), 
7.26 (s, 1H, CHAr), 7.11 – 6.93 (m, 4H, CHAr), 5.50 (s, 2H, CH2). 19F 
NMR (282 MHz, CDCl3) δ - 115.0. 13C NMR (75 MHz, CDCl3) δ 162.1 
(d, 1J = 245.8 Hz, CF), 141.5 (CAr), 133.6 (d, 4J = 3.2 Hz, CAr), 133.5, 
132.3 (CAr), 131.6 (2CHAr), 129.3 (CAr), 129.2, 128.7, 128.5 (2CHAr), 
128.2 (d, 3J = 9.3 Hz, 2CHAr), 127.8 (CAr), 127.5, 127.4, 127.1, 126.5 
(CHAr), 124.6 (CAr), 124.5 (CHAr), 123.8 (CAr), 123.3 (CHAr), 116.1 (d, 
2J = 23.1 Hz, 2CHAr), 115.7 (CHAr), 115.0 (CAr), 102.4 (CHAr), 93.2, 89.1 (C≡C), 47.2 (CH2). 
IR (ATR, cm-1), ṽ = 3049 (w), 3029 (w), 2993 (w), 2906 (w), 2858 (w), 2200 (w), 1602 (m), 
1585 (m), 1567 (w), 1519 (w), 1508 (s), 1492 (m), 1477 (s), 1459 (m), 1438 (m), 1417 (w). MS 
(EI, 70 eV), m/z (%) = 453.18 (7), 452 (25), 451 (M+, 84), 342 (100), 313 (7), 265 (4), 237 (3), 
109 (5). HR-MS (EI), Calcd for C33H22NF (M+), 451.17308 found 451.17264. 
 
2-Phenyl-5-(phenylethynyl)-3-(3-(trifluoromethyl)benzyl)-3H-benzo[e]indole (3e) 
Following the general procedure C, 3e was obtained as a yellow 
solid (47 %), mp = 179 – 180 C. 1H NMR (250 MHz, CDCl3) 
δ 8.62 - 8.49 (m, 1H), 8.38 – 8.26 (m, 1H, CHAr), 7.71 – 7.28 (m, 
16H, CHAr), 7.22 (s, 1H, CHAr), 7.09 (d, 3J = 7.8 Hz, 1H, CHAr), 
5.54 (s, 2H, CH2). 19F NMR (235 MHz, CDCl3) δ -62.64. 
13C NMR (63 MHz, CDCl3) δ 141.4, 139.0, 133.4, 132.2 (CAr), 
131.5 (2CHAr), 131.2 (q, 2J = 33.0 Hz, CCF3), 129.6 (CHAr), 129.3 
(CAr), 129.1 (3CHAr), 128.8, 128.4 (2CHAr), 128.4, 128.1 (CHAr), 
127.8 (CAr), 127.0, 126.5 (CHAr), 124.6 (CAr), 124.5 (CHAr), 124.4 (q, 3J = 3.8 Hz, CHAr), 123.8 
(q, 1J = 272.7 Hz, CF3), 123.6 (CAr), 123.3 (CHAr), 122.8 (q, 3J = 3.8 Hz, CH), 115.9 (CHAr), 
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115.2 (CAr), 102.6 (CHAr), 93.2, 88.9 (C≡C), 47.4 (CH2). IR (ATR, cm-1), ṽ = 3052 (w), 2919 
(w), 2198 (w), 1614 (w), 1598 (w), 1585 (m), 1567 (w), 1537 (w), 1519 (w), 1490 (m). MS (EI, 
70 eV), m/z (%) = 503 (22), 502 (73), 501 (M+, 100), 424 (6), 342 (94), 315 (15), 265 (5). 178 
(3), 109 (1). HR-MS (EI), Calcd for C34H22NF3 (M+), 501.16989, found 501.16999. 
 
3-Phenethyl-2-phenyl-5-(phenylethynyl)-3H-benzo[e]indole (3f) 
Following the general procedure C, 3f was obtained as a yellow 
solid (19 %), mp = 154 – 155 C. 1H NMR (250 MHz, CDCl3) δ 
8.63 – 8.50 (m, 1H, CHAr), 8.35 – 8.21 (m, 1H, CHAr), 7.91 (s, 1H, 
CHAr), 7.76 – 7.67 (m, 2H, CHAr), 7.66 – 7.51 (m, 2H, CHAr), 
7.48 – 7.33 (m, 8H, CHAr), 7.19 (dd, 3J = 6.6 Hz, 4J = 3.7 Hz, 3H, 
CHAr), 7.04 (s, 1H, CHAr), 6.97 – 6.85 (m, 2H, CHAr), 4.67 – 4.37 
(m, 2H, CH2), 3.20 – 2.91 (m, 2H, CH2). 13C NMR (63 MHz, 
CDCl3) δ 141.4, 138.0, 132.9, 132.8 (CAr), 131.7, 131.7 (CHAr), 
129.6 (2CHPh), 129.2 (CAr), 128.8, 128.7, 128.6, 128.6, 128.2 (2CHPh), 128.0 (CAr), 127.1, 
126.8, 126.4 (CHAr), 124.6 (CAr), 124.4 (CHAr), 124.0 (CAr), 123.4, 116.3 (CHAr), 114.6 (CAr), 
102.2 (CHAr), 93.1, 89.4 (C≡C), 45.9, 37.0 (CH2). IR (ATR, cm-1), ṽ = 3027 (w), 2850 (w), 
1585 (m), 1452 (m), 1357 (s), 1230 (m), 1178 (m), 1072 (m), 981 (m), 968 (m), 946 (m), 842 
(m). MS (EI, 70 eV), m/z (%) = 448 (44), 447 (100), 358 (9), 357 (33), 356 (99), 355 (20), 354 
(21). HR-MS (EI), Calcd for C34H25N (M+), 447.19815, found 447.19765. 
 
2-(4-Methoxyphenyl)-5-((4-methoxyphenyl)ethynyl)-3-phenyl -3H-benzo[e]indole (3g) 
Following the general procedure C, 3g was obtained as a yellow solid 
(42 %), mp = 185 – 186 C. 1H NMR (250 MHz, CDCl3) δ 8.66 – 8.49 
(m, 1H, CHAr), 8.37 – 832 (m, 1H, CHAr), 7.74 – 7.23 (m, 13H, CHAr), 
6.98 – 6.79 (m, 4H, CHAr), 3.86 (s, 3H, OCH3), 3.82 (s, 3H, OCH3). 
13C NMR (63 MHz, CDCl3) δ 159.5, 159.0, 140.3, 138.1, 134.5 (CAr), 
132.9, 130.1 (2 CHAr), 129.0 (CAr), 129.5, 128.3 (2 CHAr), 127.7 
(CHAr), 127.6 (CAr), 127.0, 126.2 (CHAr), 124.8 (CAr), 124.3 (CHAr), 
124.2 (CAr), 123.3, 116.4 (CHAr), 116.0, 115.1 (CAr), 114.0, 113.8 
(2CHAr), 102.2 (CHAr), 92.9, 87.7 (C≡C), 55.3, 55.2 (OCH3). IR 
(ATR, cm-1), ṽ = 3047 (w), 2921 (w), 2850 (w), 1737 (w), 1731 (w), 
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1614 (w), 1596 (m), 1562 (w), 1529 (w), 1506 (s), 1498 (s), 1484 (s), 1456 (m), 1446 (m), 1430 
(w), 1411 (w). MS (EI, 70 eV), m/z (%) = 481 (19), 480 (56), 479 (M+, 100), 464 (43), 392 
(11), 240 (12), 218 (8), 196 (12), 130 (1). HR-MS (EI), Calcd for C34H25NO2 (M+), 479.18798, 
found 479.18701. 
 
2-(4-methoxyphenyl)-5-((4-methoxyphenyl)ethynyl)-3-(3-(trifluoromethyl)phenyl)-3H-
benzo[e]indole (3h) 
Following the general procedure C, 3h was obtained as a yellow 
solid (75 %), mp = 216 – 2178 C. 1H NMR (250 MHz, CDCl3) 
δ 8.59 – 8.49 (m, 1H, CHAr), 8.35 – 8.25 (m, 1H, CHAr), 7.72 – 7.43 
(m, 9H, CHAr), 7.28 – 7.12 (m, 3H, CHAr), 6.92 – 6.77 (m, 4H, 
CHAr), 3.82 (s, 3H, OCH3), 3.77 (s, 3H, OCH3). 19F NMR 
(235 MHz, CDCl3) δ -62.55. 13C NMR (63 MHz, CDCl3) δ 159.6, 
159.2, 140.3, 138.8, 134.3 (CAr), 133.0 (2CHAr), 132.0 (q, 
2J = 33.0 Hz, CCF3), 131.6 (CHAr), 130.2 (2CHAr), 130.1 (CHAr), 
129.6, 127.6 (CAr), 127.1, 126.5 (CHAr), 125.1 (q, 3J = 3.7 Hz, 
CHAr), 124.6 (CHAr), 124.5 (CAr), 124.4 (q, 3J = 3.8 Hz, CHAr), 
124.2 (CAr), 123.5 (q, 1J = 275.36 Hz, CF3), 123.4 (CHAr), 115.8, 115.8 (CAr), 115.6 (CHAr), 
114.1, 114.0 (2 CHAr), 103.0 (CHAr), 93.4, 87.5 (C≡C), 55.3, 55.2 (OCH3). IR (ATR, cm-1), 
ṽ = 3070 (w), 3037 (w), 2996 (w), 2952 (w), 2935 (w), 2908 (w), 2836 (w), 1604 (m), 1583 
(m), 1565 (m), 1510 (s), 1486 (s), 1457 (s), 1438 (s), 1415 (w). MS (EI, 70 eV), m/z (%) = 549 
(10), 548 (18), 547 (M+, 50), 532 (14), 499 (18), 497 (100), 483 (10), 482 (28). HRMS (ESI-
TOF), Calcd for C35H24F3NO2 (M+), 547.17587, found 547.17591. 
 
2,3-Bis(4-methoxyphenyl)-5-((4-methoxyphenyl)ethynyl)-3H-benzo[e]indole (3i) 
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Following the general procedure C, 3i was obtained as a yellow solid (65 %), 
mp = 222 – 223 C. 1H NMR (300 MHz, CDCl3) δ 8.43 (dd, 
3J = 8.1 Hz, 4J = 0.8 Hz, 1H, CHAr), 8.22 (dd, 3J = 8.0 Hz, 
4J = 0.8 Hz, 1H, CHAr), 7.57 – 7.40 (m, 5H, CHAr), 7.22 – 7.10 
(m, 5H, CHAr), 6.91 – 6.69 (m, 6H, CHAr), 3.77 (s, 3H, OCH3), 
3.74 (s, 3H, OCH3), 3.69 (s, 3H, OCH3). 13C NMR (75 MHz, 
CDCl3) δ 159.6 (CAr), 159.1 (2CAr), 140.6, 135.0 (CAr), 133.0 
(2CHAr), 131.0 (CAr), 130.2 (2CHAr), 129.6 (CAr), 129.5 (2CHAr), 
127.7 (CAr), 127.2 (CHAr), 126.3 (CAr), 125.0 (CHAr), 124.4 (CAr), 
124.1, 123.4, 116.6 (CHAr), 116.1, 115.1 (CAr), 114.8, 114.2, 
113.9 (2CHAr), 101.9 (CHAr), 93.0, 87.9 (C≡C), 55.6, 55.4, 55.3 
(OCH3). IR (ATR, cm-1), ṽ = 3000 (w), 2954 (m), 2923 (s), 2852 (m), 2202 (w), 1724 (m), 1650 
(w), 1600 (m), 1567 (m), 1556 (m), 1508 (s), 1456 (s), 1438 (m). MS (EI, 70 eV), m/z (%) = 511 
(14), 510 (34), 509 (M+, 100), 494 (25), 479 (5), 255 (7), 189 (9), 44 (4), HR-MS (EI), Calcd 
for C35H27NO3 (M+), 509.19855, found 509.19782. 
 
2-(4-Fluorophenyl)-5-((4-fluorophenyl)ethynyl)-3-phenyl-3H-benzo[e]indole (3j) 
Following the general procedure C, 3j was obtained as a yellow solid (74 %), 
mp = 236 – 238 C.  
1H NMR (300 MHz, CDCl3) δ 8.49 (dd, 3J = 8.2 Hz, 4J = 0.8 Hz, 1H, 
CHAr), 8.35 – 8.29 (m, 1H, CHAr), 7.70 – 7.43 (m, 8H, CHAr), 
7.35 – 7.27 (m, 5H, CHAr), 7.12 – 6.93 (m, 4H, CHAr). 19F NMR 
(235 MHz, CDCl3) δ -111.27, -114.06. 13C NMR (63 MHz, CDCl3) δ 
163.4 (d, 1J = 249.2 Hz, CF), 161.4 (d, 1J = 247.6 Hz, CF), 139.7, 
137.9, 134.8 (CAr), 133.5 (d, 3J = 8.3 Hz, 2CHAr), 130.7 (d, 3J = 8.1 Hz, 
2CHAr), 129.7 (2CHAr), 129.6 (CAr), 128.5 (d, 4J = 3.4 Hz, CAr), 128.3 
(2CHAr), 128.1 (CHAr), 127.8 (CAr), 127.1, 126.6, 124.7 (CHAr), 124.5 
(CAr), 123.5 (CHAr), 120.0 (d, 4J = 3.5 Hz, CAr), 116.8 (CHAr), 115.8 
(d, 2J = 21.2 Hz, 2CHAr), 115.5 (d, 2J = 22.8 Hz, 2CHAr), 115.3 (CAr), 
103.1 (CHAr), 92.2, 88.8 (C≡C). IR (ATR, cm-1), ṽ = 3050 (w), 2921 (w), 2852 (w), 1596 (m), 
1562 (w), 1529 (w), 1506 (s), 1498 (s), 1484 (s), 1456 (m), 1446 (m), 1430 (m). MS (EI, 70 eV), 
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m/z (%) = 456 (43), 455 (M+, 100), 407 (2), 281 (10), 217 (35), 166 (11), 73 (8), 44 (3). HRMS 
(ESI-TOF), calcd for C32H19NF2 (M+H+), 456.15583, found, 456.15445. 
 
2-(4-Fluorophenyl)-5-((4-fluorophenyl)ethynyl)-3-(4-(trifluoromethyl)phenyl)-3H-
benzo[e]indole (3k) 
Following the general procedure C, 3k was obtained as a yellow 
solid (45 %), mp = 243 – 244 C. 1H NMR (300 MHz, DMSO) δ 
8.50 (d, 3J = 7.5 Hz, 1H, CHAr), 8.46 (d, 3J = 7.6 Hz, 1H, CHAr), 
7.92 – 7.61 (m, 10H, CHAr), 7.41 – 7.19 (m, 6H, CHAr). 19F NMR 
(235 MHz, DMSO) δ -61.42, -111.04, -113.72. 13C NMR 
(63 MHz, DMSO) δ 162.1 (d, 1J = 247.8 Hz, CF), 161.9 (d, 
1J = 246.5 Hz, CF), 139.9, 138.2, 134.3 (CAr), 133.5 (d, 3J = 8.5 Hz, 
2CHAr), 132.2, 132.2 (CHAr), 131.8 (q, 2J = 34.2 Hz, CCF3), 131.0 
(CHAr), 130.9 (d, 3J = 8.3 Hz, 2CHAr), 129.0 (CAr), 128.0 (d, 
4J = 3.3 Hz, CAr), 127.4 (CAr), 126.5 (d, 2J = 24.0 Hz, 2CHAr), 
125.0 (q, 3J = 3.7 Hz, CHAr), 124.9 (q, 3J = 3.9 Hz, CHAr), 124.4 (CAr), 123.6 (CHAr), 119.3 (d, 
4J = 3.4 Hz, CAr), 119.0 (q, 1J = 276.4 Hz, CF3), 115.9 (CHAr), 115.8 (d, 2J = 22.5 Hz, 2CHAr), 
115.4, 115.1 (CHAr), 114.7 (CAr), 104.0 (CHAr), 92.3, 88.4 (C≡C). IR (ATR, cm-1), ṽ = 3070 
(w), 2921 (w), 2852 (w), 2202 (w), 1612 (w), 1598 (m), 1583 (w), 1562 (w), 1506 (s), 1484 (s), 
1459 (m), 1440 (m). MS (EI, 70 eV) = m/z (%) = 525 (9), 524 (53), 523 (M+, 100), 453 (2), 
377(2), 262 (7), 227 (2), 144 (1). HR-MS (EI), Calcd for C33H18NF5 (M+), 523.13539, found 
523.13481. 
 
2-(4-Fluorophenyl)-5-((4-fluorophenyl)ethynyl)-3-(4-methoxyphenyl)-3H-benzo[e]indole 
(3l) 
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Following the general procedure C, 3l was obtained as a yellow 
solid (66 %), mp = 197 – 198 C. 1H NMR (250 MHz, CDCl3) 
δ 8.50 (dd, 3J = 8.1 Hz, 4J = 1.0 Hz, 1H, CHAr), 8.35 – 8.29 (m, 
1H, CHAr), 7.72 – 7.51 (m, 5H, CHAr), 7.34 – 7.20 (m, 5H, 
CHAr), 7.14 – 6.91 (m, 6H, CHAr), 3.88 (s, 3H, OCH3). 19F NMR 
(235 MHz, CDCl3) δ -111.33, -114.19. 13C NMR (63 MHz, 
CDCl3) δ 162.5 (d, 1J = 249.2 Hz, CF), 162.3 (d, 1J = 247.8 Hz, 
CF), 159.3, 139.8, 135.1 (CAr), 133.5 (d, 3J = 8.3 Hz, 2CHAr), 
130.6 (d, 3J = 8.0 Hz, 2CHAr), 130.6, 129.5 (CAr), 129.4 (2CHAr), 
128.6 (d, 4J = 3.4 Hz, CAr), 127.8 (CAr), 127.1, 126.6, 124.6 
(CHAr), 124.3 (CAr), 123.5 (CHAr), 120.0 (d, 4J = 3.5 Hz, CAr), 116.9 (CHAr), 115.8 
(d, 2J = 22.1 Hz, 2CHAr), 115.5 (d, 2J = 21.6 Hz, 2CHAr), 115.1 (CAr), 114.9 (2CHAr), 102.6 
(CHAr), 92.1, 88.8 (C≡C), 55.7 (OCH3). IR (ATR, cm-1), ṽ = 3049 (w), 2956 (w), 2923 (w), 
2850 (w), 1612 (w), 1600 (w), 1583 (w), 1506 (s), 1483 (s), 1452 (m), 1440 (m). MS (EI, 
70 eV), m/z (%) = 487 (13), 486 (40), 485 (M+, 100), 470 (7), 440 (10), 346 (6), 320 (6), 210 
(9), 173 (4), 110 (6), 71 (4), 44 (36). HR-MS (EI), Calcd for C33H21NOF2 (M+), 485.15857, 
found 485.15792. 
2,3-Bis(4-fluorophenyl)-5-((4-fluorophenyl)ethynyl)-3H-benzo[e]indole (3m) 
Following the general procedure C, 3m was obtained as a yellow 
solid (65 %), mp = 234 – 235 C. 1H NMR (250 MHz, DMSO) δ 
8.09 – 7.98 (m, 2H, CHAr), 7.33 – 7.16 (m, 4H, CHAr), 7.12 (d, 
3J = 3.4 Hz, 2H, CHAr), 7.07 – 6.89 (m, 6H, CHAr), 6.83 - 6.67 (m, 
4H, CHAr). 19F NMR (235 MHz, DMSO) δ -111.09, -113.11, -
113.93. 13C NMR (63 MHz, DMSO) δ 161.5 (d, 1J = 247.83 Hz, 
CF), 161.3 (d, 1J = 247.26 Hz, CF), 161.0 (d, 1J = 247.07 Hz, CF), 
139.4, 134.1 (CAr), 133.1 (d, 4J = 3.1 Hz, CAr), 132.9 (d, 3J = 8.5 Hz, 
2CHAr), 130.2 (d, 3J = 8.3 Hz, 2CHAr), 129.8 (d, 3J = 8.9 Hz, 
2CHAr), 128.3 (CAr), 127.6 (d, 4J = 3.4 Hz, CAr), 126.9 (CAr), 126.0, 125.7 (CHAr), 124.2 (CAr), 
123.6 (CAr), 123.0 (CHAr), 118.8 (d, 4J = 3.5 Hz, CAr), 115.9 (d, 2J = 23.0 Hz, 2CHAr), 115.6 
(CHAr), 115.2 (d, 2J = 22.2 Hz, 2CHAr), 114.6 (d, 2J = 21.8 Hz, 2CHAr), 113.9, 102.7 (CHAr), 
91.6, 87.9 (C≡C). IR (ATR, cm-1), ṽ = 3064 (m), 2921 (m), 2850 (m), 1598 (m), 1506 (s), 1486 
(s), 1432 (m), 1417 (m). MS (EI, 70 eV), m/z (%) = 475 (9), 474 (35), 473 (M+, 100), 429 (8), 
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351 (14), 281 (9), 221 (10), 147 (8), 73 (14), 44 (12). HR-MS (EI), Calcd for C32H18NF3 
(M+), 473.13859, found 473.13801. 
2,3-Di-p-tolyl-5-(p-tolylethynyl)-3H-benzo[e]indole (3n) 
Following the general procedure C, 3n was obtained as a yellow 
solid (57 %), mp = 182 – 183 C. 1H NMR (250 MHz, CDCl3) 
δ 8.56 – 8.49 (m, 1H, CHAr), 8.36 – 8.28 (m, 1H, CHAr), 
7.69 – 7.49 (m, 5H, CHAr), 7.33 – 7.26 (m, 3H, CHAr), 7.25 – 7.16 
(m, 6H, CHAr), 7.09 (d, 3J = 8.0 Hz, 2H, CHAr), 2.45 (s, 3H, CH3), 
2.39 (s, 3H, CH3), 2.34 (s, 3H, CH3). 13C NMR (63 MHz, CDCl3) 
δ 140.8, 138.2, 137.8, 137.3, 135.6, 135.0 (CAr), 131.5, 130.2 
(2CHAr), 129.6 (2CAr), 129.3, 129.2, 128.8, 128.1 (2CHAr), 127.8 
(CAr), 127.2, 126.4, 124.5 (CHAr), 124.3 (CAr), 123.4 (CHAr), 
120.9 (CAr), 116.8 (CHAr), 115.2 (CAr), 102.6 (CHAr), 93.3, 88.6 
(C≡C), 21.7 (CH3), 21.4 (2CH3). IR (ATR, cm-1), ṽ = 3029 (w), 2919 (w), 2850 (w), 1704 (w), 
1699 (w), 1693 (w), 1683 (w), 1673 (w), 1668 (w), 1658 (w), 1650 (w), 1608 (w), 1587 (w), 
1558 (w), 1510 (s). MS (EI, 70 eV), m/z (%) = 464 (14), 464 (48), 462 (44), 461 (M+, 100), 
445 (4), 360 (8), 329 (12). HR-MS (EI), Calcd for C35H27N (M+), 461.21380, found 461.21295. 
 
2-(p-Tolyl)-5-(p-tolylethynyl)-3-(3-(trifluoromethyl)benzyl)-3H-benzo[e]indole (3o) 
Following the general procedure C, 3o was obtained as a yellow solid (60 %), 
mp = 1181 – 182 C. 1H NMR (250 MHz, CDCl3) δ 8.53 (dd, 
3J = 8.1 Hz, 4J = 1.0 Hz, 1H, CHAr), 8.30 (dd, 3J = 7.9 Hz, 
4J = 1.0 Hz, 1H, CHAr), 7.69 – 7.45 (m, 6H, CHAr), 7.43 – 7.28 
(m, 4H, CHAr), 7.20 (m, 5H, CHAr), 7.08 (d, 3J = 7.8 Hz, 1H, 
CHAr), 5.53 (s, 2H, CH2), 2.41 (s, 3H, CH3), 2.39 (s, 3H, CH3). 
19F NMR (235 MHz, CDCl3) δ -62.65. 13C NMR (63 MHz, 
CDCl3) δ 141.4, 139.1, 138.3, 138.2, 133.3 (CAr), 131.8 (q, 
2J = 32.6 Hz, CCF3), 131.4 (2CHAr), 129.5 (CHAr), 129.5 (2CHAr), 
129.3, 129.6 (CAr), 129.2 (CHAr), 129.2, 129.1 (2CHAr), 127.8 
(CAr), 127.1, 126.4 (CHAr), 124.5 (CAr), 124.4 (CHAr), 124.3 (q, 
3J = 3.8 Hz, CHAr), 124.1 (q, 1J = 276.0 Hz, CF3), 123.2 (CHAr), 122.8 (q, 3J = 3.8 Hz, CHAr), 
120.6 (CAr), 115.8 (CHAr), 115.2 (CAr), 102.3 (CHAr), 93.3, 88.3 (C≡C), 47.3 (CH2), 21.5, 21.2 
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(CH3).IR (ATR, cm-1), ṽ = 3060 (w), 3027 (w), 2995 (w), 2956 (w), 2921 (w), 2863 (w), 1616 
(w), 1589 (w), 1564 (w), 1510 (m), 1488 (m), 1444 (m), 1430 (w). MS (EI, 70 eV), m/z 
(%) = 531 (8), 530 (41), 529 (M+, 100), 370 (48), 159 (10). HR-MS (ESI-TOF/MS), Calcd for 
C36H26NF3 (M+H)+, 530.20901, found 530.20797. 
 
3-(3,5-Dimethylphenyl)-2-phenyl-5-(phenylethynyl)-3H-benzo[e]indole (3p) 
Following the general procedure, 3b was obtained as a yellow solid 
(96 mg, 74 %), mp = 176 – 178 C. 1H NMR (250 MHz, CDCl3) 
δ 8.55 – 8.43 (m, 1H, CHAr), 8.29 – 8.21 (m, 1H, CHAr), 7.65 – 7.61 
(m, 1H, CHAr), 7.59 – 7.44 (m, 4H, CHAr), 7.35 – 7.10 (m, 9H, 
CHAr), 6.97 (s, 1H, CHAr), 6.86 (s, 2H, CHAr), 2.25 (s, 6H, 2CH3). 
13C NMR (63 MHz, CDCl3) δ 140.6 (CAr), 139.3 (2CAr), 138.0, 
135.1, 132.5(CAr), 131.6 (2CHAr), 129.8 (CHAr), 129.6 (CAr), 128.8, 
128.5, 128.3 (2CHAr), 128.1 (CHAr ), 127.8 (CAr), 127.4, 127.1, 
126.4 (CHAr), 126.0 (2CHAr), 124.5 (CHAr), 124.4, 123.9 (CAr), 123.5, 117.1 (CHAr), 115.0 
(CAr), 102.9 (CHAr), 93.2, 89.4 (C≡C), 21.4 (2CH3). IR (ATR, cm-1), ṽ = 3060 (w), 2918 (w), 
1644 (m), 1589 (s), 1505 (s), 1218 (s), 1155 (m), 1090 (m). MS (EI, 70 eV), m/z (%) = 449 
(17), 448 (60), 447 (M+, 100), 431 (4), 315 (6), 324 (5). HR-MS (EI), Calcd for C34H25N 
(M+), 447.19815, found 447.19765. 
 
2,9-Diphenyl-1,10-di-p-tolyl-1,10-dihydrobenzo[e]pyrrolo[3,2-g]indole (5a) 
Following the general procedure C, 5a was obtained as a yellow solid (35 %), 
mp = 166 – 168 C.  
1H NMR (300 MHz, CDCl3) δ 8.36 – 8.26 (m, 2H, CHAr), 
7.56 – 7.50 (m, 2H, CHAr), 7.24 (s, 2H, CHAr), 7.20 – 7.08 (m, 
6H, CHAr), 7.07 – 6.94 (m, 4H, CHAr), 6.65 (d, 3J = 8.0 Hz, 4H, 
CHAr), 6.41 (m, 4H, CHAr), 2.23 (s, 6H, 2CH3). 13C NMR 
(75 MHz, CDCl3) δ 140.8, 138.2, 136.5, 134.0 (2CAr), 130.6, 
129.2, 128.1, 128.1 (4CHAr), 127.5 (2CHAr), 125.9, 125.8 (2CAr), 
124.5, 123.7 (2CHAr), 123.7 (2CAr), 105.8 (2CHAr), 21.7 (2CH3).  
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IR (ATR, cm-1), ṽ = 2915 (w), 2850 (w), 2740 (w), 1899 (w), 1666 (w), 1656 (w), 1596 (m), 
1585 (m), 1573 (w), 1548 (w), 1510 (s), 1479 (m), 1444 (m). HR-MS (ESI-TOF/MS), Calcd 
for C40H30N2 (M+), 538.24021, found 538.24021. 
 
1,2,3,4-tetrakis(phenylethynyl)naphthalene (6a) 
Following the general procedure, 6a was obtained as a yellow solid (79 %), mp = 166 – 168 C.  
1H NMR (300 MHz, CDCl3) δ 8.49 - 8.41 (m, 2H, CHAr), 7.77 – 7.60 
(m, 10H, CHAr), 7.47 – 7.31 (m, 12H, CHAr). 13C NMR (75 MHz, 
CDCl3) δ 132.1 (2CAr), 131.8, 131.8 (4CHPh), 128.8, 128.7 (2CHAr), 
128.5, 128.5 (4CHPh), 128.2, 126.9 (2CHAr), 125.7, 124.1, 123.5, 
123.2 (2CAr), 100.6, 98.1, 88.1, 86.7 (2C≡C). IR (ATR, cm-1), 
ṽ = 2206 (m), 1943 (w), 1899 (w), 1886 (w), 1828 (w), 1801 (w), 
1754 (w), 1673 (w), 1594 (m), 1569 (m), 1533 (m), 1513 (w), 1488 
(s), 1454 (m), 1440 (m). MS (EI, 70 eV), m/z (%) = 530 (20), 529 
(43), 528 ([M]+, 100), 527 (10), 524 (12), 450 ( 16), 224 (10), 155 
(7). HR-MS (EI), Calcd for C42H24 (M+), 528.18725, found 528.18713. 
 
2,3-bis((4-fluorophenyl)ethynyl)-1,4-bis(phenylethynyl)naphthalene (6b) 
Following the general procedure, 6b was obtained as a white solid 
(71 %), mp = 208 – 209 C.1 H NMR (300 MHz, CDCl3) δ 
8.38 – 8.28 (m, 2H, CHAr), 7.65 – 7.47 (m, 10H, CHAr), 
7.37 – 7.29 (m, 6H, CHAr), 7.02 – 6.93 (m, 4H, CHAr). 19F NMR 
(282 MHz, CDCl3) δ 110.10 13C NMR (75 MHz, CDCl3) δ 162.9 
(d, 1J = 250.4 Hz, 2CF), 133.8 (d, 3J = 8.4 Hz, 4CHAr), 132.2 
(2CAr), 131.9 (4CHAr), 129.1 (2CHAr), 128.7 (4CHAr), 128.3, 
127.0 (2CHAr), 125.5, 124.3, 123.3 (2CAr), 119.7 (d, 4J = 3.5 Hz, 
2CAr), 116.0 (d, 2J = 22.1 Hz, 4CHAr), 100.8, 97.0, 88.0, 86.8 
(2C≡C). IR (ATR, cm-1), ṽ = 3058 (m), 3022 (w), 2962 (w), 1596 (m), 1538 (w), 1510 (s), 1490 
(s). MS (EI, 70 eV), m/z (%) = 466 (14), 565 (41), 564 ([M]+, 100), 486 (11), 66 (18), 44 (22). 
HR-MS (EI), Calcd for C42H22F2 (M+), 564.16841, found 564.16689. 
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2,3-bis((4-methoxyphenyl)ethynyl)-1,4-bis(phenylethynyl)naphthalene (6c) 
Following the general procedure, 6c was obtained as a yellow 
solid (61 %), mp = 198 – 200 C. 1 H NMR (250 MHz, CDCl3) 
δ 8.48 – 8.37 (m, 2H, CHAr), 7.71 (m, 4H, CHAr), 7.65 – 7.56 
(m, 6H, CHAr), 7.47 – 7.36 (m, 6H, CHAr), 6.96 – 6.85 (m, 
4H, CHAr), 3.85 (s, 6H, 2OCH3). 13C NMR (63 MHz, CDCl3) 
δ 160.1 (2CAr), 133.5 (4CHAr), 132.1 (2CAr), 131.9 (4CHAr), 
128.9 (2CHAr), 128.6 (4CHAr), 128.0, 127.0 (2CHAr), 126.1, 
123.8, 123.5, 115.8 (2CAr), 114.3 (4CHAr), 100.5, 98.4, 87.3, 
87.0 (2C≡C), 55.5 (2OCH3). IR (ATR, cm-1), ṽ = 3074 (w), 
3058 (w), 2991. (w), 2958 (w), 2933 (w), 2910 (w), 2833 (w), 2194 (m), 1604 (m), 1569 (w), 
1533 (m). MS (EI, 70 eV), m/z (%) = 590 (10), 589 (26), 588 ([M]+, 59), 545 (4), 424 (4), 249 
(10), 97 (4), 66 (17), 44 (100). HR-MS (EI), Calcd for C44H28O2 (M+), 588.20838, found 
588.20702. 
 
1,1'-((2,3-bis(phenylethynyl)naphthalene-1,4-diyl)bis(ethyne-2,1-diyl))dinaphthalene 
(6d) 
Following the general procedure, 6d was obtained as a yellow solid 
(63 %), mp = 266 – 268 C. 1 H NMR (300 MHz, CDCl3) δ 8.73 (d, 
3J = 8.2 Hz, 2H, 2CHAr), 8.67 – 8.60 (m, 2H, CHAr), 8.01 (dd, 
3J = 7.2 Hz, 3J = 1.1 Hz, 2H, CHAr), 7.91 (t, 3J = 8.2 Hz, 4H, CHAr), 
7.77 – 7.71 (m, 2H, CHAr), 7.68 – 7.64 (m, 4H, CHAr), 7.57 – 7.47 
(m, 4H, CHAr), 7.39 – 7.27 (m, 8H, CHAr). 13C NMR (75 MHz, 
CDCl3) δ 133.4 (4CAr), 133.4 (2CAr), 132.4 (4CHAr), 131.2, 129.6, 
128.8 (2CHAr), 128.5 (6CHAr), 128.4, 127.4, 127.2, 126.8, 126.7 
(2CHAr), 125.9 (2CAr), 125.5 (2CHAr), 124.3, 123.4, 121.0 (2CAr), 
99.2, 98.5, 91.6, 88.6 (2C≡C).  
IR (ATR, cm-1), ṽ = 2956 (m), 2923 (m), 2210 (m), 2198 (m), 1934 (m), 1918 (w), 1822 (w), 
1803 (m), 1702 (w), 1598 (m), 1585 (m), 1575 (m), 1538 (m), 1504 (m), 1488 (m). MS (EI, 
70 eV), m/z (%) = 628 ([M]+,5), 429 (2), 281 (6), 267 (4), 207 (13), 57 (29), 44 (100). HR-MS 
(EI), Calcd for C50H28 (M+), 628.21855, found 628.21810. 
 
108 
 
2,3-bis(phenylethynyl)-1,4-bis(p-tolylethynyl)naphthalene (6e) 
Following the general procedure, 6e was obtained as a yellow solid (54 %), mp = 196 – 197 C.  
1 H NMR (300 MHz, CDCl3) δ 8.50 – 8.37 (m, 2H, CHAr), 7.77 – 7.52 
(m, 10H, CHAr), 7.44 – 7.34 (m, 6H, CHAr), 7.22 (d, 3J = 7.9 Hz, 4H, 
CHAr), 2.42 (s, 6H, 2CH3). 13C NMR (75 MHz, CDCl3) δ 139.2, 
132.2 (2CAr), 132.0, 131.8, 129.4 (4CHAr), 128.7 (2CHAr), 128.6 
(4CHAr), 128.2, 127.1 (2CHAr), 125.6, 124.3, 123.7, 120.3 (2CAr), 
101.0, 98.0, 88.4, 86.3 (2C≡C), 21.8 (2CH3). IR (ATR, cm-1), 
ṽ = 3056 (w), 3041 (w), 3029 (w), 2917 (w), 2852 (w), 2200 (w), 
1731 (w), 1724 (w), 1594 (w), 1569 (w), 1533 (w), 1508 (m), 1488 
(m), 1463 (w), 1440 (m), 1405 (w). MS (EI, 70 eV), m/z (%) = 557 
(6), 556 ([M]+,12), 57 (7). 464 (1), 262 (1), 169 (1), 154 (2), 104 (1) 
43 (100), . HR-MS (EI), Calcd for C44H28 (M+), 556.21855, found 
556.21681. 
 
2,3-bis((4-methoxyphenyl)ethynyl)-1,4-bis(p-tolylethynyl)naphthalene (6f)  
Following the general procedure, 6f was obtained as a yellow 
solid (51 %), mp = 224 – 225 C. 1 H NMR (300 MHz, CDCl3) 
δ 8.53 – 8.34 (m, 2H, CHAr), 7.68 – 7.55 (m, 10H, CHAr), 
7.33 – 7.16 (m, 4H, CHAr), 6.98 – 6.80 (m, 4H, CHAr), 3.86 (s, 
6H, 2OCH3), 2.42 (s, 6H, 2CH3). 13C NMR (63 MHz, CDCl3) 
δ 159.9, 139.0 (2CAr), 133.3 (4CHAr), 132.0 (2CAr), 131.7, 
129.3 (4CHAr), 127.8, 126.8 (2CHAr), 125.8, 123.7, 120.3, 
115.8 (2CAr), 114.1 (4CHAr), 100.6, 98.0, 87.2, 86.3 (2C≡C), 
55.3 (2OCH3), 21.6 (2CH3). IR (ATR, cm-1), ṽ = 3056 (w), 
3031 (w), 2989 (w), 2915 (w), 2208 (w), 1606 (w), 1573 (w), 
1564 (w), 1513 (m), 1481 (m), 1461 (w), 1450 (m), 1434 (s). 
MS (EI, 70 eV), m/z (%) = 617 (14), 616 ([M]+,30), 57 (5), 43 (100), 42 (39), 41 (61). HR-MS 
(EI), Calcd for C46H32O2 (M+), 616.23968, found 616.23954. 
 
1,4-bis(p-tolylethynyl)-2,3-bis((4-(trifluoromethyl)phenyl)ethynyl)naphthalene (6g)  
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Following the general procedure, 6g was obtained as a yellow 
solid (52 %), mp = 242 – 243 C. 1 H NMR (300 MHz, CDCl3) 
δ 8.43 – 8.33 (m, 2H, CHAr), 7.72 – 7.49 (m, 14H, CHAr), 7.21 
(d, 3J = 7.9 Hz, 4H, CHAr), 2.43 (s, 6H, 2CH3). 19F NMR 
(282 MHz, CDCl3) δ -62.8. 13C NMR (63 MHz, CDCl3) δ 
139.6, 132.3 (2CAr), 132.0, 131.8 (4CHAr), 130.4 (q, 
2J = 33.7 Hz, 2CCF3), 129.5 (4CHAr), 128.6 (2CHAr), 127.4 
(2CAr), 127.2 (2CHAr), 125.6 (q, 3J = 3.8 Hz, 4CHAr), 125.0, 
124.6 (2CAr), 123.3 (q, 1J = 243.8 Hz, 2CF3), 120.1 (2CAr), 
101.5, 96.2, 90.5, 86.0 (2C≡C), 21.8 (2CH3). IR (ATR, cm-1), 
ṽ = 2919 (w), 2861 (w), 2200 (w), 1610 (m), 1537 (w), 1510 
(m), 1488 (m), 1463 (w), 1440 (m), 1405 (w).. MS (EI, 70 eV), m/z (%) = 693 (17), 692 
([M]+,38), 673 (1), 532 (1), 461 (1), 57 (7), 43 (100). HR-MS (EI), Calcd for C46H26F6 
(M+), 692.68906, found 692.68742. 
 
2,3-bis((4-(tert-butyl)phenyl)ethynyl)-1,4-bis(p-tolylethynyl)naphthalene (6h) 
Following the general procedure, 6h was obtained as a yellow 
solid (54 %), mp = 230 – 231 C. 1 H NMR (300 MHz, CDCl3) 
δ 8.47 – 8.41 (m, 2H, CHAr), 7.66 – 7.58 (m, 10H, CHAr), 7.40 
(d, 3J = 8.4 Hz, 4H, CHAr), 7.23 (d, 3J = 7.9 Hz, 4H, CHAr), 2.42 
(s, 6H), 2CH3), 1.37 (s, 18H, 6CH3). 13C NMR (63 MHz, CDCl3) 
δ 152.0, 139.1, 132.2 (2CAr), 131.8, 131.7, 129.4 (4CHAr), 128.0, 
127.0 (2CHAr), 125.8 (2CAr), 125.5 (4CHAr), 124.1, 120.8, 120.5 
(2CAr), 100.8, 98.3, 87.9, 86.5 (2C≡C), 35.0 (2C(CH3)3), 31.4 
(6CH3), 21.8. (2CH3). IR (ATR, cm-1), ṽ = 3076 (w), 3058 (w), 
3029 (w), 2960 (m), 2902 (m), 2863 (m), 2204 (w), 1658 (w), 
1650 (w), 1606 (w), 1537 (m), 1508 (m). MS (EI, 70 eV), m/z 
(%) = 669 (7), 668 ([M]+,13), 44 (17), 43 (100), 42 (40), 41 (67). HR-MS (EI), Calcd for C52H44 
(M+), 668.34375, found 668.34478. 
 
1,2,3,4-tetrakis(p-tolylethynyl)naphthalene (6i) 
Following the general procedure, 6i was obtained as a yellow solid(42 %), mp = 226 – 227 C.  
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1 H NMR (300 MHz, CDCl3) δ 8.48 – 8.39 (m, 2H, CHAr), 
7.69 – 7.52 (m, 10H, CHAr), 7.25 – 7.10 (m, 8H, CHAr), 2.41 (s, 
12H, 4CH3). 13C NMR (63 MHz, CDCl3) δ 139.0, 138.8, 132.0 
(2CAr), 131.7, 131.7, 129.3, 129.2 (4CHAr), 127.9, 126.9 
(2CHAr), 125.7, 123.9, 120.5, 120.3 (2CAr), 100.7, 98.2, 87.7, 
86.3 (2C≡C), 21.6, 21.6 (2CH3). IR (ATR, cm-1), ṽ = 3079 (w), 
3060 (w), 3031 (w), 2935 (w), 2915 (w), 2198 (w), 2171 (w), 
1901 (w), 1789 (w), 1778 (w), 1693 (w), 1681 (w), 1673 (w), 
1666 (w), 1633 (w), 1604 (w), 1581 (w), 1564 (w). MS (EI, 
70 eV), m/z (%) = 586 (8), 585 (28), 584 ([M]+,67), 44 (15), 43 
(100), 42 (38), 41 (60). HR-MS (EI), Calcd for C46H32 
(M+), 584.24985, found 584.25013. 
 
2,3-diphenyl-1,4-bis(phenylethynyl)naphthalene (7a) 
Following the general procedure, 7a was obtained as a yellow solid 
(88 %), mp = 212 – 213 C. 1 H NMR (250 MHz, CDCl3) δ 8.65 – 8.54 
(m, 2H, CHAr), 7.76 – 7.63 (m, 2H, CHAr), 7.34 – 7.17 (m, 20H, CHAr). 
13C NMR (63 MHz, CDCl3) δ 143.1, 140.0, 132.3 (2CAr), 131.4, 130.9 
(4CHAr), 128.3 (2CHAr), 128.2 (4CHAr), 127.4 (2CHAr), 127.2 (4CHAr), 
127.0, 126.7 (2CHAr), 123.4, 120.9 (2CAr), 99.6, 87.8. (2C≡C). IR (ATR, 
cm-1), ṽ = 3054 (m), 3022 (m), 1942 (w), 1874 (w), 1818 (w), 1799 (w), 
1754 (w), 1594 (m), 1579 (w), 1569 (m), 1544 (w). MS (EI, 70 eV), m/z 
(%) = 482 (8), 481 (38), 480 ([M]+, 100), 478 (9), 400 (28), 326 (5), 281 
(7), 230 (10), 201 (7), 73 (10). HR-MS (EI), Calcd for C38H24 (M+), 480.18725, found 
480.18687. 
 
1,4-bis(phenylethynyl)-2,3-di-p-tolylnaphthalene (7b) 
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Following the general procedure, 7b was obtained as a yellow solid 
(85 %), mp = 180 – 181 C. 1H NMR (300 MHz, CDCl3) δ 8.65 – 8.52 
(m, 2H, CHAr), 7.76 – 7.64 (m, 2H, CHAr), 7.45 – 7.27 (m, 10H, 
CHAr), 7.18 -7.6 (m, 8H, CHAr), 2.35 (s, 6H, 2CH3). 13C NMR 
(75 MHz, CDCl3) δ 143.3, 137.1, 136.1, 132.3 (2CAr), 131.4, 130.8, 
128.2 (4CHAr), 128.2 (2CHAr), 127.9 (4CHAr), 127.3, 126.9 (2CHAr), 
123.5, 120.9 (2CAr), 99.4, 88.0 (2C≡C), 21.3 (2CH3). IR (ATR, cm-
1), ṽ = 3077 (w), 2968 (w), 2923 (w), 2867 (w), 1901 (w), 1797 (w), 
1596 (w), 1569 (w), 1544 (w), 1515 (w), 1510 (w). MS (EI, 70 eV), 
m/z (%) = 510 (31), 509 (55), 508 ([M]+,100), 507 (11), 493 (20), 419 (19), 326 (3), 237 (12), 
200 (17), 57 (11), 43 (23). HR-MS (EI), Calcd for C40H28 (M+), 508.21855, found 508.21834. 
 
1,4-bis(phenylethynyl)-2,3-bis(4-(trifluoromethyl)phenyl)naphthalene (7c) 
Following the general procedure, 7c was obtained as a yellow solid 
(82 %), mp = 255 – 256 C. 1H NMR (300 MHz, CDCl3) δ 8.60 (dd, 
3J = 6.3 Hz, 4J = 3.3 Hz, 2H, CHAr), 7.75 (dd, 3J = 6.3 Hz, 4J = 3.3 Hz, 
2H, CHAr), 7.55 (d, 3J = 8.1 Hz, 4H, CHAr), 7.38 (d, 3J = 8.2 Hz, 6H, 
CHAr), 7.30 (dd, 3J = 6.7 Hz, 4J = 3.7 Hz, 4H, CHAr), 7.23 – 7.14 (m, 
4H, CHAr). 19F NMR (282 MHz, CDCl3) δ -62.55. 13C NMR 
(63 MHz, CDCl3) δ 143.6, 141.1 (2CAr), 134.4 (q, 2J = 33.2 Hz, 
2CCF3), 132.5 (2CAr), 131.5, 131.4 (4CHAr), 128.9 (2CHAr), 128.5 
(4CHAr), 128.2, 127.2 (2CHAr), 124.6 (q, 3J = 3.5 Hz, 4CHAr), 124.3 
(q, 1J = 275.8 Hz, 2CF3), 122.9, 121.4 (2CAr), 100.8, 87.1 (2C≡C). IR (ATR, cm-1), ṽ = 3077 
(w), 3049 (w), 3031 (w), 3022 (w), 2935 (w), 2208 (w), 1920 (w), 1616 (m), 1596 (w), 1571 
(w), 1540 (w). MS (EI, 70 eV), m/z (%) = 618 (8), 617 (42), 616 ([M]+,100), 545 (5), 468 (10), 
400 (8), 237 (6), 77 (9). HR-MS (EI), Calcd for C40H22F6 (M+), 616.16202, found 616.16186. 
 
2,3-di([1,1'-biphenyl]-4-yl)-1,4-bis(phenylethynyl)naphthalene (7d) 
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Following the general procedure, 7d was obtained as a white solid 
(92 %), mp = 229 – 230 C. 1H NMR (300 MHz, CDCl3) δ 8.63 
(dd, 3J = 6.4 Hz, 4J = 3.3 Hz, 2H, CHAr), 7.76 – 7.69 (m, 4H, CHAr), 
7.68 – 7.59 (m, 5H, CHAr), 7.52 (d, 3J = 8.3 Hz, 5H, CHAr), 
7.48 – 7.29 (m, 16H, CHAr). 13C NMR (63 MHz, CDCl3) δ 142.7, 
140.9, 139.3, 139.1, 132.3 (2CAr), 131.4, 131.4, 128.7 (4CHAr), 
128.3 (4CHAr), 127.5, 127.2 (2CHAr), 127.0 (4CHAr), 125.9 
(2CHAr), 125.9 (4CHAr),, 123.3, 121.1 (2CAr), 99.8, 87.9 (2C≡C) 
(1 signal of CHAr was overlapped). IR (ATR, cm-1), ṽ = 3056.77 
(m), 3029 (m), 2196 (w), 1594 (m), 1581 (w), 1571 (w), 1538 (w), 1519 (w). MS (EI, 70 eV), 
m/z (%) = 635 (16), 634 (52), 633 (87), 632 ([M]+, 100), 631 (21), 555 (25), 478 (18), 400 (7), 
277 (10), 238 (15), 125 (4), 43 (10). HR-MS (EI), Calcd for C50H32 (M+), 632.24985, found 
632.24807. 
 
2,3-bis(4-methoxyphenyl)-1,4-bis(phenylethynyl)naphthalene (7e) 
Following the general procedure, 7e was obtained as a yellow solid 
(77 %), mp = 235 – 236 C. 1H NMR (300 MHz, CDCl3) δ 
8.61 – 8.55 (m, 2H, 2CHAr), 7.72 – 7.65 (m, 2H, CHAr), 7.36 – 7.27 
(m, 10H, CHAr), 7.23 – 7.14 (m, 4H, CHAr), 6.84 – 6.74 (m, 4H, 
CHAr), 3.81 (s, 6H, 2OCH3). 13C NMR (75 MHz, CDCl3) δ 158.3, 
142.9, 132.5, 132.3 (2CAr), 132.1, 131.5, 128.3 (4CHAr), 128.2 
127.3, 126.9 (2CHAr), 123.5, 121.0 (2CAr), 112.7 (4CHAr), 99.3, 
88.0 (C≡C), 55.2 (2OCH3). IR (ATR, cm-1), ṽ = 3076 (w), 3018 
(w), 2993 (w), 2956 (w), 2931 (w), 2906 (w), 2848 (w), 1889 (w), 
1731 (w), 1606 (m), 1594 (m), 1579 (w), 1569 (w), 1508 (s). MS (EI, 70 eV), m/z (%) = 543 
(9), 542 (29), 541 (43), 540 ([M]+,100), 509 (13), 451 (15), 389 (7), 224 (170, 187 (8), 97 (10), 
43 (24). HR-MS (EI), Calcd for C40H28O2 (M+), 540.20838, found 540.20769. 
 
1,1'-((2,3-diphenylnaphthalene-1,4-diyl)bis(ethyne-2,1-diyl))dinaphthalene (7f) 
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Following the general procedure, 7f was obtained as a yellow solid (59 %), 
mp = 233 – 234 C. 1H NMR (300 MHz, CDCl3) δ 8.82 – 8.76 (m, 2H, 
CHAr), 7.86 – 7.75 (m, 6H, CHAr), 7.68 (dd, 3J = 7.1 Hz, 4J = 1.1 Hz, 2H, 
CHAr), 7.51 – 7.38 (m, 6H, CHAr), 7.37 – 7.27 (m, 12H, CHAr). 13C NMR 
(75 MHz, CDCl3) δ 143.3, 140.4 (2CAr), 133.1 (4CAr), 132.5 (2CAr), 130.6 
(4CHAr), 130.5, 128.7, 128.0 (2CHAr), 127.7 (4CHAr), 127.6, 127.1, 126.8, 
126.7, 126.4, 126.3, 125.2 (2CHAr), 121.1, 121.0 (2CAr), 98.2, 92.4 
(2C≡C). IR (ATR, cm-1), ṽ = 3056 (w), 3047 (w), 1600 (w), 1583 (w), 
1575 (w), 1558 (w), 1542 (w), 1504 (w), 1486 (m). MS (EI, 70 eV), m/z 
(%) = 583 (8), 582 (22), 581 (41), 580 ([M]+,100), 501 (5), 441 (11), 376 (3), 326 (2), 281 (9), 
207 (7), 165 (7), 128 (5), 44 (20). HR-MS (EI), Calcd for C46H28 (M+), 580.21855, found 
580.21733. 
 
2,3-bis(4-methoxyphenyl)-1,4-bis(p-tolylethynyl)naphthalene (7g) 
Following the general procedure, 7g was obtained as a yellow solid 
(66 %), mp = 230 – 231 C. 1H NMR (300 MHz, CDCl3) δ 
8.63 – 8.52 (m, 2H, CHAr), 7.72 – 7.62 (m, 2H, CHAr), 7.24 – 7.08 
(m, 12H, CHAr), 6.85 – 6.73 (m, 4H, CHAr), 3.80 (s, 6H, 2OCH3), 
2.35 (s, 6H, 2CH3). 13C NMR (63 MHz, CDCl3) δ 158.2, 142.7, 
138.4, 132.6, 132.3 (2CAr), 132.1, 131.3, 129.0 (4CHAr), 127.7, 
126.9 (2CHAr), 121.0, 120.5 (2CAr), 112.7 (4CHAr), 99.5, 87.5 
(2C≡C), 55.2 (2OCH3), 21.5 (2CH3). IR (ATR, cm-1), ṽ = 3076 (w), 
3029 (w), 2996 (w), 2954 (w), 2929 (w), 2908 (w), 2833 (w), 2204 
(w), 1905 (w), 1893 (w), 1606 (m), 1575 (w), 1564 (w), 1544 (w), 
1510 (s). MS (EI, 70 eV), m/z (%) = 569 (8), 568 ([M]+, 20), 69 
(11), 44 (22), 43 (100), 42 (26), 41 (40). HR-MS (EI), Calcd for C42H32O2 (M+), 568.23968, 
found 568.23805. 
 
2,3-bis(4-(tert-butyl)phenyl)-1,4-bis(p-tolylethynyl)naphthalene (7h) 
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Following the general procedure, 7h was obtained as a yellow solid 
(58 %), mp = 204 – 205 C. 1H NMR (250 MHz, CDCl3) δ 8.58 (dd, 
3J = 6.4 Hz, 4J = 3.3 Hz, 2H, CHAr), 7.67 (dd, 3J = 6.4 Hz, 4J = 3.3 Hz, 
2H, CHAr), 7.23 – 7.14 (m, 8H, CHAr), 7.10 – 7.05 (m, 8H, CHAr), 
2.33 (s, 6H, 2CH3), 1.32 (s, 18H, 6CH3). 13C NMR (63 MHz, CDCl3) 
δ 149.2, 143.4, 138.3, 137.2, 132.1, (2CAr), 131.5, 130.7, 129.0 
(4CHAr), 127.3, 127.0 (2CHAr), 124.0 (4CHAr), 120.9, 120.7 (2CAr), 
99.7, 87.8 (2C≡C), 34.5 (2C), 31.5 (6CH3), 21.6 (2CH3). IR (ATR, 
cm-1), ṽ = 2956 (m), 2923 (m), 2902 (w), 2861 (w), 2202 (w), 1903 
(w), 1722 (w), 1714 (w), 1681 (w), 1673 (w), 1592 (w), 1573 (w), 
1564 (w), 1485(m), 1471 (m). MS (EI, 70 eV), m/z (%) = 622 (13), 
621 (38), 620 ([M]+, 82), 563 (43), 507 (18), 430 (62), 262 (27), 183 (22), 108 (10), 57 (21), 43 
(100). HR-MS (EI), Calcd for C48H44 (M+), 620.34375, found 620.34350. 
1,4-bis(p-tolylethynyl)-2,3-bis(4-(trifluoromethyl)phenyl)naphthalene (7i) 
Following the general procedure, 7i was obtained as a yellow solid 
(67 %), mp = 238 – 239 C. 1H NMR (300 MHz, CDCl3) δ 
8.62 – 8.54 (m, 2H, 2CHAr), 7.78 – 7.72 (m, 2H, CHAr), 7.59 – 7.46 
(m, 4H, CHAr), 7.35 (d, 3J = 8.0 Hz, 4H, CHAr), 7.12 – 7.03 (m, 8H, 
CHAr), 2.35 (s, 6H, 2CH3). 19F NMR (282 MHz, CDCl3) δ -62.50. 
13C NMR (63 MHz, CDCl3) δ 143.7, 140.8, 139.1, 132.4 (2CAr), 
131.4 (8CHAr), 129.3 (4CHAr), 129.3 (q, 2J = 32.5 Hz, 2CCF3), 128.1, 
127.2 (2CHAr), 124.5 (q, 3J = 3.7 Hz, 4CHAr), 124.3 (q, 1J = 272.0 Hz, 
2CF3), 121.4, 119.9 (2CAr), 101.0, 86.6 (2C≡C), 21.7 (2CH3). IR 
(ATR, cm-1), ṽ = 3060 (w), 3029 (w), 2993 (w), 2925 (w), 2204 (w), 
1920 (w), 1616 (w), 1575 (w), 1542 (w), 1510 (m), 1488 (w), 1454 (w), 1438 (w). MS (EI, 
70 eV), m/z (%) = 647 (5), 645 (40), 644 ([M]+,100), 69 (9), 43 (81), 42 (23), 41 (32). HR-MS 
(EI), Calcd for C42H26F6 (M+), 644.19332, found 644.19143. 
 
 
2,3-di([1,1'-biphenyl]-4-yl)-1,4-bis(p-tolylethynyl)naphthalene (7k)  
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Following the general procedure, 7k was obtained as a yellow 
solid (74 %), mp = 260 – 261 C. 1H NMR (300 MHz, CDCl3) δ 
8.69 – 8.57 (m, 2H, CHAr), 7.78 – 7.68 (m, 2H, CHAr), 7.64 – 7.58 
(m, 4H, CHAr), 7.54 – 7.32 (m, 14H, CHAr), 7.17 (d, 3J = 8.1 Hz, 
4H, CHAr), 7.07 (d, 3J = 8.0 Hz, 4H, CHAr), 2.33 (s, 4H, 2CH3). 
13C NMR (63 MHz, CDCl3) δ 142.5, 141.0 (2CAr), 139.2 (4CAr), 
138.5, 132.3 (2CAr), 131.5, 131.3, 129.1, 128.7 (4CHAr), 127.4, 
127.1, 1270.0 (2CHAr), 127.0 (4CHAr), 125.9 (4CHAr), 121.1, 
120.3 (2CAr), 100.0, 87.3 (2C≡C), 21.5 (2CH3) (one signal of CH 
was overlapped). IR (ATR, cm-1), ṽ = 1911 (w), 1799 (w), 1673 
(w), 1658 (w), 1650 (w), 1598 (w), 1579 (w), 1558 (w), 1538 (w), 
1510 (m), 1484 (m), 1446 (m). MS (EI, 70 eV), m/z (%) = 662 (18), 661 (59), 660 ([M]+,100), 
645 (13), 476 (4), 284 (4). HR-MS (EI), Calcd for C52H36 (M+), 660.28115, found 660.28042. 
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7.4. Supplement for Chapter 3 
 
Scheme S5. The three-step one-pot Synthesis of 10. 
 
Procedure A (one-pot synthesis), 2,3-dibromo-1,4-naphthoquinone 1 (0.3 mmol), the 
appropriate amine (0.3 mmol) and H2O (1 mL) were poured into a pressure tube. The reaction 
was set up at 60 C for 6 h, then, 2-bromophenylboronic acid (0.33 mmol), Pd(PPh3)4 (5 mol%), 
Pd2(dba)3 (5 mol%), RuPhos (10 mol%), K3PO4 (0.9 mmol) and 1,4-dioxane (10 mL) were 
added under argon. The tube was sealed with a Teflon valve and stirred at 90 C. After 24 h, 
the mixture was allowed to reach room temperature, diluted with water and extracted with 
dichloromethane. The combined organic layers were dried over sodium sulfate and 
concentrated under vacuum. The crude material was purified by flash column chromatography 
(silica gel, heptane/ethylacetate). 
 
Scheme S6. The two-step domino synthesis of 10a. 
 
Procedure B (domino synthesis), An argon purged pressure tube was charged with 2,3-
dibromo-1,4-naphthoquinone 1 (0.3 mmol) and the secondary amine (0.36 mmol), Pd(OAc)2 
(5 mol%), PPh3 (10 mol%), tBuONa (1.2 mmol) and toluene (10 mL). The reaction was set up 
at 90 C for 24 h. Afterwards the mixture was allowed to reach room temperature, was diluted 
with water and extracted with ethyl acetate. The combined organic layers were dried over 
sodium sulfate and concentrated under vacuum. The crude material was purified by flash 
column chromatography (silica gel, heptane/ethylacetate). 
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2-bromo-3- (p-tolylamino)naphthalene-1,4-dione (8) 
Starting from p-toluidine with 2,3-dibromonaphthalene-1,4-dione in water 
at 60 C for 12 h, 8 was obtained as a dark red solid, mp = 157 - 158 C. 1H 
NMR (300 MHz, CDCl3) δ = 8.19 (dd, 3J = 7.6 Hz, 4J = 1.3 Hz, 1H, CHAr), 
8.14 – 8.05 (m, 1H, CHAr), 7.81 – 7.60 (m, 3H, CHAr), 7.15 (d, 3J = 8.2 Hz, 
2H, CHAr), 7.00 (d, 3J = 8.3 Hz, 2H, CHAr), 2.36 (s, 3H, CH3). 13C NMR 
(75 MHz, CDCl3) δ= 180.26, 177.44 (C=O), 144.43, 135.98 (CAr), 135.08 
(CHAr), 135.01 (CAr), 132.96 (CHAr), 132.62, 130.01 (CArr), 129.24 (2CHAr), 127.54, 127.18 
(CHAr), 124.98 (2CHAr), 107.00 (CAr), 21.21 (CH3). IR (ATR, cm-1), ṽ = 3302 (m), 3223 (w), 
3095 (w), 3024 (w), 2916 (w), 1672 (s), 1645 (m), 1630 (m), 1591 (m), 1581 (m), 1566 (m), 
1547 (s). MS (EI, 70 eV), m/z (%) = 341 (M+, 73), 326 (4), 262 (100), 247 (12), 219 (9), 178 
(10), 105 (13), 91 (29). HRMS (EI), calcd C17H12BrNO2 (M+) 341.00459, found 341.00382; 
 
2-(2-bromophenyl)-3- (p-tolylamino)naphthalene-1,4-dione (9b) 
Following the general procedure, 9b was obtained as a red solid (17 %), 
mp = 175 – 176 C. 1H NMR (250 MHz, CDCl3) δ = 8.23 – 8.11 (m, 2H, 
CHAr), 7.82 – 7.66 (m, 3H, CHAr), 7.27 – 7.20 (m, 1H, CHAr), 7.04 – 6.81 
(m, 3H, CHAr), 6.78 – 6.62 (m, 4H, CHAr), 2.14 (s, 3H, CH3). 13C NMR 
(63 MHz, CDCl3) δ 182.9, 181.5 (C=O), 142.2, 135.2 (CAr), 135.1 
(CHAr), 134.6, 134.3, 133.6 (CAr), 132.9, 132.4, 132.2 (CHAr), 130.4 
(CAr), 128.7 (CHAr), 128.47 (2CHAr), 127.0, 126.5, 126.5 (CHAr), 125.3 
(CAr), 124.6 (2CHAr), 115.9 (CAr), 20.9 (CH3). IR (ATR, cm-1), ṽ = 3331 (w), 3298 (s), 3064 
(w), 3045 (w), 3010 (w), 2920 (w), 1674 (s), 1633 (m), 1612 (w), 1595 (m), 1569 (s), 1516 (s), 
1505 (s). MS (EI, 70 eV), m/z (%) = 419 (4), 417 (M+, 5), 339 (27), 338 (100), 324 (7), 323 
(26), 295 (3) 294 (5), 190 (6), 176 (7), 165 (6), 161 (9). HRMS (EI), calcd for C23H16BrNO2 
(M+) 417.03589, found 417.03524; calcd for C23H1681BrNO2 (M+) 419.03385, found 
419.03478. 
 
5-phenyl-5H-benzo[b]carbazole-6,11-dione (10a) 
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Following the general procedure, 10a was obtained as a light red solid 
(51 %), and starting from diphenylamine, following the general 
procedure the same compound was isolated in 38 % yield, 
mp = 253 – 255 C. 1H NMR (250 MHz, CDCl3) δ = 8.58 – 8.48 (m, 1H, 
CHAr), 8.25 (dd, 3J = 7.6 Hz, 4J = 1.3 Hz, 1H, CHAr), 8.05 (dd, 3J = 7.5 Hz, 
4J = 1.4 Hz, 1H, CHAr), 7.78 – 7.57 (m, 5H, CHAr), 7.49 - 7.37 (m, 4H, CHAr), 7.21 – 7.14 (m, 
1H, CHAr). 13C NMR (63 MHz, CDCl3) δ = 181.8, 177.7 (C=O), 141.2, 136.9, 135.7, 134.2 
(CAr), 133.9 (CHAr), 133.7 (CAr), 133.1 (CHAr), 129.7 (2CHAr), 129.3, 127.8 (CHAr), 127.8 
(2CHAr), 126.6, 126.5 124.9 (CHAr), 124.0 (CAr), 123.7 (CHAr), 120.0 (CAr), 112.3 (CHAr). IR 
(ATR, cm-1), ṽ = 3070 (m), 3047 (w), 2924 (w), 1649 (s), 1612 (m), 15894 (s), 1570 (m), 
1516 (s), 1499 (m). MS (EI, 70 eV), m/z (%) = 323 (M+, 100), 294 (11), 265 (14), 190 (6), 161 
(7), 132 (9), 1. HR-MS (EI), Calcd for C22H13O2N (M+), 323.09406; found 323.09334. 
 
5-(p-tolyl)-5H-benzo[b]carbazole-6,11-dione (10b) 
Following the general procedure, 10b was obtained as an orange solid 
(49 %), mp = 266 – 268 C. 1H NMR (250 MHz, CDCl3) δ = 8.56 – 8.46 
(m, 1H, CHAr), 8.30 – 8.19 (m, 1H, CHAr), 8.10 – 7.96 (m, 1H, CHAr), 
7.79 – 7.58 (m, 2H, CHAr), 7.46 – 7.29 (m, 6H, CHAr), 7.21 – 7.09 (m, 
1H, CHAr), 2.52 (s, 3H, CH3). 13C NMR (63 MHz, CDCl3) δ = 181.7, 
177.7 (C=O), 141.3, 139.3, 135.7, 134.3, 134.2 (CAr), 133.8 (CHAr), 
133.7 (CAr), 133.1 (CHAr), 130.3 (2CHAr), 127.7 (CHAr), 127.4 (2CHAr), 126.6, 126.4, 124.9 
(CHAr), 124.0 (CAr), 123.8 (CHAr),119.9 (CAr), 112.3 (CHAr), 21.5 (CH3). IR (ATR, cm-1), 
ṽ = 3062 (w), 3050 (w), 2956 (w), 2921 (m), 2851 (m), 1732 (w), 1660 (m), 1641 (m), 1612 
(w), 1588 (m), 1516 (s). MS (EI, 70 eV), m/z (%) = 337 (M+, 100), 322 (38), 308 (9), 278 (12), 
168 (11), 163 (5), 139 (4), 132 (7), 2). HR-MS (EI), Calcd for C23H15NO2 (M+), 337.10973, 
found 337.10925. 
 
5-(4-fluorophenyl)-5H-benzo[b]carbazole-6,11-dione (10c) 
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Following the general procedure, 10c was obtained as an orange solid 
(60 %), mp = 275 - 277 C. 1H NMR (300 MHz, CDCl3) δ = 8.56 – 8.48 
(m, 1H, CHAr), 8.24 (dd, 3J = 7.6 Hz, 4J = 1.2 Hz, 1H, CHAr), 8.04 (dd, 
3J = 7.5 Hz, 4J = 1.2 Hz, 1H, CHAr), 7.77 – 7.63 (m, 2H, CHAr), 
7.47 – 7.40 (m, 4H, CHAr), 7.34 - 7.27 (m, 2H, CHAr), 7.18 – 7.11 (m, 
1H, CHAr). 19F NMR (282 MHz, CDCl3) δ = -111.41;13C NMR 
(126 MHz, CDCl3) δ = 181.7, 177.8 (C=O), 162.9 (d, 1J = 249.7 Hz, CF), 141.2, 135.7, 134.1, 
134.0 (CAr), 133.6 (CHAr), 133.2 (CHAr), 132.9 (d, 4J = 3.5 Hz, CAr), 129.6 (d, 3J = 9.0 Hz, 
2CHAr), 128.0, 126.6, 126.6, 125.0, 124.0, 124.0 (CHAr), 120.2 (CAr), 116.7 (d, 2J = 23.1 Hz, 
2CHAr), 112.0 (CAr), IR (ATR, cm-1), ṽ = 3062 (w), 3047 (w), 3009 (w), 2959 (w), 2921 (m), 
2850 (m), 1658 (s), 1650 (s), 1613 (m), 1590 (m), 1552 (w), 1512 (s). MS (EI, 70 eV), m/z 
(%) = 341 (M+, 100), 312 (16), 296 (7), 283 (15), 257 (4), 170 (9), 141 (6). HR-MS (EI), Calcd 
for C22H12NO2F (M+), 341.08466, found, 341.08426. 
 
5-(4-nitrophenyl)-5H-benzo[b]carbazole-6,11-dione (10d) 
Starting from 4-Nitroaniline, following the general procedure, 10d was 
obtained as an orange solid (37 %), mp = 286 - 288 C. 1H NMR 
(300 MHz, DMSO) δ = 8.52 – 8.45 (m, 2H, CHAr), 8.40 – 8.34 (m, 1H, 
CHAr), 8.13 (dd, 3J = 7.4 Hz, 4J = 1.3 Hz, 1H, CHAr), 8.00 – 7.92 (m, 3H, 
CHAr), 7.90 – 7.78 (m, 2H, CHAr), 7.55 – 7.45 (m, 2H, CHAr), 7.32 – 7.24 
(m, 1H, CHAr). 13C NMR (63 MHz, DMSO) δ = 180.9, 176.7 (C=O), 
147.4, 142.1, 139.8, 135.8 (CAr), 134.2, 133.6 (CHAr), 133.2, 133.0 (CAr), 129.3 (2CHAr), 128.1, 
126.2, 125.9, 125.1 (CHAr), 124.7 (2CHAr), 123.4 (CAr), 122.8 (CHAr), 119.3 (CAr), 112.0 
(CHAr). IR (ATR, cm-1), ṽ = 3116 (w), 3077 (w), 2922 (w), 2851 (w), 1662 (m), 1646 (m), 1607 
(w), 1590 (m), 1556 (w), 1518 (m). MS (EI, 70 eV), m/z (%) = 368 (M+, 100), 339 (4), 322 
(16), 293 (9), 265 (23), 190 (5), 161 (4), 133 (7). HR-MS (EI), calcd for C22H12N2O4 (M+), 
368.07916, found 368.07895. 
 
5-(4-methoxyphenyl)-5H-benzo[b]carbazole-6,11-dione (10e) 
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Following the general procedure, 10e was obtained as a light orange 
solid (47 %), mp = 237 - 239 C. 1H NMR (300 MHz, 
CDCl3) δ = 8.56 – 8.47 (m, 1H, CHAr), 8.25 (dd, 3J = 7.6 Hz, 4J = 1.2 Hz, 
1H, CHAr), 8.11 – 8.01 (m, 1H, CHAr), 7.77 – 7.61 (m, 2H, CHAr), 
7.45 – 7.33 (m, 4H, CHAr), 7.21 – 7.15 (m, 1H, CHAr), 7.13 – 7.07 (m, 
2H, CHAr), 3.93 (s, 3H, OCH3). 13C NMR (126 MHz, CDCl3) δ = 181.6, 
177.7 (C=O), 156.0, 141.4, 135.6, 134.1 (CHAr), 133.7 (CAr), 133.6 (CHAr), 133.0 (CAr), 129.4 
(CHAr), 128.7 (2CHAr), 127.6, 126.5, 126.3, 124.8 (CAr), 123.8 (CHAr), 123.7 (CAr), 119.7 
(CHAr), 114.7 (2CHAr), 112.2 (CAr), 55.6 (OCH3). IR (ATR, cm-1), ṽ = 3296 (m), 3228 (w), 
3091 (m), 3072 (m), 3006 (m), 2957 (m), 2923 (m), 2849 (m), 2835 (m), 1651 (s), 1610 (m), 
1593 (s), 1514 (s), 1486 (s), 1471 (m), 1456 (s), 1441 (s). MS (EI, 70 eV), m/z (%) = 353 (M+, 
100), 338 (9), 322 (11), 310 (8), 265 (6), 254 (9), 176 (8), 163 (4), 126 (6). HR-MS (EI), calcd 
for C23H15NO3 (M+), 353.10464, found 353.10441. 
 
5-(3,5-dimethylphenyl)-5H-benzo[b]carbazole-6,11-dione (10f) 
Following the general procedure, 10f was obtained as a yellow solid 
(47 %), mp = 248 - 250 C. 1H NMR (300 MHz, 
CDCl3) δ = 8.57 – 8.47 (m, 1H, CHAr), 8.25 (dd, 3J = 7.6 Hz, 
4J = 1.2 Hz, 1H, CHAr), 8.06 (dd, 3J = 7.6 Hz, 4J = 1.3 Hz, 1H, CHAr), 
7.77 – 7.61 (m, 2H, CHAr), 7.47 – 7.35 (m, 2H, CHAr), 7.22 – 7.14 
(m, 2H, CHAr), 7.04 (s, 2H, CHAr), 2.43 (s, 6H, 2CH3). 13C NMR 
(75 MHz, CDCl3) δ = 181.8, 177.6 (C=O), 141.3 (CAr), 139.4 (2CAr), 136.7, 135.7, 134.2 (CAr), 
133.8 (CHAr), 133.7 (CAr), 133.1, 131.1, 127.6, 126.6, 126.4 (CHAr), 125.3 (2CHAr), 124.8 
(CHAr), 124.0 (CAr), 123.7 (CHAr), 119.8 (CAr), 112.5 (CHAr), 21.5 (2CH3). IR (ATR, cm-1), 
ṽ = 3055 (w), 3010 (w), 2918 (w), 2861 (w), 1660 (s), 1650 (s), 1614 (m), 1594 (m), 1586 (m), 
1571 (w), 1518 (s), 1491 (m), 1473 (m). MS (EI, 70 eV), m/z (%) = 351 (M+, 100), 336 (88), 
322 (6), 306 (4), 291 (7), 278 (11), 190 (4), 176 (8), 168 (8), 163 (5), 154 (4), 139 (8),). HR-
MS (EI), calcd for C24H17NO2 (M+), 351.12538, found 351.12488. 
 
5-(4- (tert-butyl)phenyl)-5H-benzo[b]carbazole-6,11-dione (10g) 
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Following the general procedure, 10g was obtained as a yellow solid 
(48 %), mp = 294 - 296 C. 1H NMR (300 MHz, CDCl3) δ = 8.56 – 8.48 
(m, 1H, CHAr), 8.25 (dd, 3J = 7.6 Hz, 4J = 1.3 Hz, 1H, CHAr), 8.07 (dd, 
3J = 7.6, 4J = 1.2 Hz, 1H, CHAr), 7.79 – 7.57 (m, 4H, CHAr), 7.49 – 7.32 
(m, 4H, CHAr), 7.24 – 7.13 (m, 1H, CHAr), 1.44 (s, 9H, 3CH3). 13C NMR 
(75 MHz, CDCl3) δ = 181.8, 177.8 (C=O), 152.3, 141.4, 135.7, 134.2, 
134.2 (CAr), 133.9 (CHAr), 133.7 (CAr), 133.1, 127.7 (CHAr), 127.1 (2CHAr), 126.6 (CHAr), 
126.5 (2CHAr), 126.5, 124.9 (CHAr), 124.0 (CAr), 123.8 (CHAr), 120.0 (CAr), 112.5 (CHAr), 35.1 
(C-(CH3)3), 31.6 (3CH3). IR (ATR, cm-1), ṽ = 3309 (w), 3292 (w), 3069 (w), 3041 (w), 2965 
(m), 2868 (m), 1663 (s), 1650 (s), 1613 (m), 1591 (m), 1584 (m), 1556 (m), 1519 (s), 1488 (s). 
MS (EI, 70 eV), m/z (%) = 379 (M+, 60), 364 (100), 336 (5), 322 (10), 265 (4), 168 (9), 154 
(2), 139 (3). HR-MS (EI), Calcd for C26H21NO2 (M+) 379.15668, found 379.15654. 
 
5-butyl-5H-benzo[b]carbazole-6,11-dione (10k) 
Following the general procedure, 10k was obtained as a yellow solid 
(42 %), mp = 109 – 111 C. 1H NMR (300 MHz, CDCl3) δ = 8.50 – 8.46 
(m, 1H, CHAr), 8.25 – 8.11 (m, 2H, CHAr), 7.78 – 7.63 (m, 2H, CHAr), 
7.52 – 7.35 (m, 3H, CHAr), 4.78 – 4.67 (m, 2H, CH2), 1.96 – 1.79 (m, 2H, CH2), 1.54 – 1.41 
(m, 2H, CH2), 0.99 (t, 3J = 7.3 Hz, 3H, CH3). 13C NMR (63 MHz, CDCl3) δ = 181.4, 179.1 
(C=O), 139.6, 135.0, 134.3 (CAr), 133.9 (CHAr), 133.8 (CAr), 132.9, 127.3, 126.6, 126.4, 124.6 
(CHAr), 124.22 (CAr), 124.1 (CHAr), 119.2 (CAr), 111.2 (CHAr), 45.3 (CH2), 32.5 (CH2), 20.3 
(CH2), 14.0 (CH3). IR (ATR, cm-1), ṽ = 3063 (w), 3010 (w), 2997 (w), 2960 (m), 2916 (m), 
2862 (m), 2848 (m), 1657 (s), 1643 (s), 1614 (m), 1593 (s), 1576 (m), 1516 (s). MS (EI, 70 eV), 
m/z (%) = 303 (M+, 80), 274 (17), 260 (100), 247 (31), 232 (7), 219 (9), 203 (8), 190 (17), 176 
(10). HR-MS (EI), Calcd for C20H17NO2 (M+), 303.12538, found, 303.12599 
 
5-pentyl-5H-benzo[b]carbazole-6,11-dione (10l) 
Following the general procedure, 10l was obtained as a yellow solid 
(48 %), mp = 102 - 104 C. 1H NMR (300 MHz, CDCl3) δ = 8.46 (d, 
3J = 7.9 Hz, 1H, CHAr), 8.26 – 8.09 (m, 2H, CHAr), 7.78 – 7.60 (m, 2H, 
CHAr), 7.49 – 7.32 (m, 3H, CHAr), 4.79 – 4.59 (m, 2H, CHAr), 1.99 – 1.79 
(m, 2H, CH2), 1.46 – 1.34 (m, 4H, 2CH2), 0.91 (t, 3J = 6.9 Hz, 3H, CH3). 13C NMR (75 MHz, 
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CDCl3) δ = 181.3, 179.0 (C=O), 139.5, 134.9, 134.3 (CAr), 133.8 (CHAr), 133.8 (CAr), 132.9, 
127.3, 126.6, 126.4, 124.5 (CHAr), 124.2 (CAr), 124.1 (CHAr), 119.1 (CAr), 111.2 (CHAr), 45.5 
(CH2), 30.1 (CH2), 29.1 (CH2), 22.6 (CH2), 14.1 (CH3) IR (ATR, cm-1), ṽ = 3061 (w), 3030 
(w), 3012 (w), 2957 (m), 2947 (m), 2926 (m), 2866 (m), 2727 (w), 1660 (s), 1643 (s), 1614 
(m), 1591 (s), 1518 (s), 1495 (m), 1475 (s), 1456 (m). MS (EI, 70 eV), m/z (%) = 317 (M+, 86), 
288 (11), 274 (16), 260 (100), 247 (32), 219 (11), 204 (10), 190 (20), 176 (12), 163 (7), HRMS 
(ESI-TOF), calcd for C21H19NO2 (M+H+), 318.14886, found, 318.14889 
 
5-hexyl-5H-benzo[b]carbazole-6,11-dione (10m) 
Following general procedur, 10m was obtained as a yellow solid (57 %), 
mp = 115 - 117 C. 1H NMR (250 MHz, CDCl3) δ = 8.46 (d, 3J = 7.8 Hz, 
1H, CHAr), 8.26 – 8.09 (m, 2H, CHAr), 7.77 – 7.60 (m, 2H, CHAr), 
7.51 – 7.33 (m, 3H, CHAr), 4.74 – 4.63 (m, 2H, CH2), 1.95 – 1.78 (m, 2H, 
CH2), 1.53 – 1.28 (m, 6H. 3CH2), 0.88 (t, 3J = 6.7 Hz, 3H, CH3). 13C NMR (63 MHz, 
CDCl3) δ = 181.3, 179.0 (C=O), 139.5, 134.9, 134.3, 133.8 (CAr), 133.8, 132.9, 127.3, 126.6, 
126.4, 124.6 (CHAr), 124.2 (CAr), 124.1 (CHAr), 119.1 (CAr), 111.2 (CHAr), 45.5 (CH2), 31.6 
(CH2), 30.3 (CH2), 26.7 (CH2), 22.7 (CH2), 14.1 (CH3). IR (ATR, cm-1), ṽ = 2968 (w), 2953 
(m), 2922 (m), 2870 (w), 2854 (m), 1657 (s), 1643 (s), 1612 (m), 1591 (s), 1516 (s). MS (EI, 
70 eV), m/z (%) = 331 (M+, 96), 302 (8), 260 (100), 247 (30), 232 (11), 190 (18), 176 (13). HR-
MS (EI), calcd for C22H21NO2 (M+), 331.15668, found, 331.15677. 
 
5-heptyl-5H-benzo[b]carbazole-6,11-dione (10n) 
Following the general procedure, 10n was obtained as a yellow solid 
(44 %), mp = 106 - 108 C. 1H NMR (300 MHz, CDCl3) δ = 8.05 – 8.43 
(m, 1H, CHAr), 8.26 – 8.12 (m, 2H, CHAr), 7.78 – 7.62 (m, 2H, CHAr), 
7.51 – 7.34 (m, 3H, CHAr), 4.70 (m, 2H, CH2), 1.98 – 1.77 (m, 2H, 
CH2), 1.47 – 1.26 (m, 8H, 4CH2), 0.87 (t, 3J = 6.8 Hz, 3H, CH3). 13C NMR (63 MHz, 
CDCl3) δ = 181.3, 179.0 (C=O), 139.5, 134.9, 134.3 (CAr), 133.8 (CHAr), 133.8 (CAr), 132.9, 
127.3, 126.6, 126.4, 124.6 (CHAr), 124.2 (CAr), 124.1 (CHAr), 119.1 (CAr), 111.2 (CHAr), 45.5 
(CH2), 31.8 (CH2), 30.4 (CH2), 29.1 (CH2), 27.0 (CH2), 22.7 (CH2), 14.2 (CH3). IR (ATR, cm-
1), ṽ = 2953 (m), 2918 (s), 2870 (m), 2854 (m), 1657 (vs), 1640 (s), 1614 (m), 1593 (s), 1514 
(s), 1495 (s), 1475 (s). MS (EI, 70 eV), m/z (%) = 345 (M+, 100), 302 (6), 260 (83), 247 (28), 
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232 (13), 190 (14), 105 (5), 88 (1), 77 (4), 55 (2), 41 (10). HRMS (ESI-TOF), calcd for 
C23H23NO2 (M+H+), m/z= 346.18016, found 346.18013; calcd for C23H23NaNO2 (M+ 
Na+), 368.1621, found 368.16218. 
 
5-octyl-5H-benzo[b]carbazole-6,11-dione (10o) 
Following the general procedure, 10o was obtained as a yellow solid 
(33 %), mp = 77 - 78 C. 1H NMR (250 MHz, CDCl3) δ = 8.52 – 8.39 
(m, 1H, CHAr), 8.26 – 8.08 (m, 2H, CHAr), 7.79 – 7.61 (m, 2H, CHAr), 
7.50 – 7.31 (m, 3H, CHAr), 4.81 – 4.60 (m, 2H, CH2), 1.96 – 1.77 (m, 
2H, CH2), 1.47 – 1.24 (m, 10H, 5 CH2), 0.93 – 0.81 (m, 3H, CH3). 13C NMR (63 MHz, 
CDCl3) δ = 181.3, 179.0 (C=O), 139.5, 134.9, 134.3 (CAr), 133.8 (CHAr), 133.8 (CAr), 132.9, 
127.3, 126.6, 126.4, 124.6 (CHAr), 124.2 (CAr), 124.1 (CHAr), 119.1 (CAr), 111.2 (CHAr), 45.5 
(CH2), 31.9 (CH2), 30.4 (CH2), 29.4 (CH2), 29.3 (CH2), 27.1 (CH2), 22.7 (CH2), 14.2 (CH3). IR 
(ATR, cm-1), ṽ = 2955 (w), 2920 (m), 2854 (m), 1657 (s), 1641 (s), 1612 (w), 1595 (s), 1512 
(s), 1493 (m), 1477 (s), 1454 (m), 1433 (w), 1421 (m). MS (EI, 70 eV), m/z (%) = 359 (M+, 
100), 330 (3), 274 (13), 260 (80), 247 (21), 232 (8), 190 (12), 77 (2), 41 (9). HR-MS (EI), calcd 
for C24H25NO2 (M+), 359.18798, found, 359.18793. 
5-benzyl-5H-benzo[b]carbazole-6,11-dione (10p) 
Following the general procedure, 10p was obtained as a yellow solid 
(52 %), mp = 175 – 177 C. 1H NMR (300 MHz, CDCl3) δ = 8.55 – 8.46 
(m, 1H, CHAr), 8.28 – 8.19 (m, 1H, CHAr), 8.17 – 8.12 (m, 1H, CHAr), 
7.78 – 7.62 (m, 2H, CHAr), 7.49 – 7.38 (m, 3H, CHAr), 7.32 – 7.26 (m, 2H, 
CHAr), 7.25 – 7.17 (m, 3H, CHAr), 6.01 (s, 2H, CH2); 13C NMR (63 MHz, 
CDCl3) δ = 181.5, 179.2 (C=O), 140.0, 136.7, 135.0, 134.3 (CAr), 134.0 
(CHAr), 133.8 (CAr), 133.1 (CHAr), 129.1 (2CHAr), 128.0, 127.8 (CHAr), 126.9 (2CHAr), 126.8, 
126.5, 124.9 (CHAr), 124.4 (CAr), 124.2 (CHAr), 119.7 (CAr), 111.7 (CHAr), 48.6 (CH2). IR 
(ATR, cm-1), ṽ = 3305 (w), 3282 (w), 3086 (w), 3056 (w), 3029 (m), 3007 (w), 2922 (w), 2850 
(w), 1658 (s), 1645 (vs), 1594 (m), 1585 (s), 1520 (s), 1493 (s), 1466 (s). MS (EI, 70 eV), m/z 
(%) = 337 (M+, 100), 320 (5), 292 (3), 278 (3), 260 (6), 231 (3), 204 (3), 190 (6), 163 (4), 139 
(3), 114 (2), 91 (98). HR-MS (EI), calcd for C23H15NO2 (M+) 337.10973, found 337.10948. 
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5-phenethyl-5H-benzo[b]carbazole-6,11-dione (10q) 
Following the general procedure, 10q was obtained as a yellow solid 
(55 %), mp = 171 – 172 C. 1H NMR (250 MHz, CDCl3) δ = 8.52 – 8.41 
(m, 1H, CHAr), 8.26 – 8.12 (m, 2H, CHAr), 7.80 – 7.59 (m, 2H, CHAr), 
7.48 – 7.32 (m, 3H, CHAr), 7.29 – 7.16 (m, 5H, CHAr), 4.97 – 4.84 (m, 
2H, CH2), 3.23 – 3.11 (m, 2H, CH2). 13C NMR (63 MHz, 
CDCl3) δ = 181.4, 179.0 (C=O), 139.4, 137.9, 134.8, 134.3 (CAr), 133.9 
(CHAr), 133.7 (CAr), 133.0 (CHAr), 129.1, 128.8 (2CHAr), 127.4, 127.0, 126.6, 126.4, 124.6 
(CHAr), 124.1 (CAr), 124.1 (CHAr), 119.3 (CAr), 111.0 (CHAr), 47.0 (CH2), 36.7 (CH2). IR (ATR, 
cm-1), ṽ = 3074 (m), 3055 (m), 3022 (m), 2958 (m), 2920 (m), 1655 (s), 1643 (s), 1587 (s), 1514 
(s), 1491 (s), 1468 (s), 1450 (s), 1419 (s), 1398 (s), 1369 (m). MS (EI, 70 eV), m/z (%) = 351 
(M+, 33), 260 (100), 247 (14), 232 (4), 203 (6), 176 (9), 151 (3), 128 (2). HR-MS (EI), calcd 
for C24H17NO2 (M+), 351.12538, found 351.12567 
 
5-(3-phenylpropyl)-5H-benzo[b]carbazole-6,11-dione (10r) 
Following the general procedure, 10r was obtained as a yellow solid 
(48 %), mp = 155 – 156 C. 1H NMR (250 MHz, CDCl3) δ = 8.49 – 8.42 
(m, 1H, CHAr), 8.25 – 8.13 (m, 2H, CHAr), 7.77 – 7.64 (m, 2H, CHAr), 
7.41 – 7.27 (m, 5H, CHAr), 7.24 – 7.16 (m, 3H, CHAr), 4.91 – 4.59 (m, 
2H, CH2), 2.92 – 2.64 (m, 2H, CH2), 2.35 – 2.06 (m, 2H, CH2). 13C NMR 
(63 MHz, CDCl3) δ = 181.3, 179.1 (C=O), 140.9, 139.4, 134.9, 134.3 
(CAr), 133.9 (CHAr), 133.7 (CAr), 132.9 (CHAr), 128.6, 128.4 (2CHAr), 
127.4, 126.6, 126.4, 126.3, 124.6 (CHAr), 124.2 (CAr), 124.1 (CHAr), 119.2 (CAr), 111.1 (CHAr), 
45.0, 33.2, 31.5 (CH2). IR (ATR, cm-1), ṽ = 3024 (w), 2960 (w), 2947 (w), 2931 (w), 2914 (w), 
1576 (w), 1516 (s), 1421 (m), 1398 (m), 1356 (m), 1344 (m), 1275 (w), 1242 (s), 1221 (m), 
1207 (s), 1167 (m). MS (EI, 70 eV), m/z (%) = 365 (M+, 72), 336 (2), 274 (23), 261 (100), 247 
(6), 232 (9), 204 (10), 190 (9), 176 (8), 91 (12).HR-MS (EI), calcd for C25H19O2N (M+) 
365.14103, found 365.14055. 
 
5-(4-fluorobenzyl)-5H-benzo[b]carbazole-6,11-dione (10s) 
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Starting from (4-fluorophenyl)methanamine, following the general 
procedure, 10s was obtained as a yellow solid (52 %), mp = 200 – 201 C. 
1H NMR (250 MHz, CDCl3) δ = 8.53 – 8.44 (m, 1H, CHAr), 8.25 – 8.18 
(m, 1H, CHAr), 8.16 – 8.09 (m, 1H, CHAr), 7.78 – 7.62 (m, 2H, CHAr), 
7.48 – 7.35 (m, 3H, CHAr), 7.23 – 7.14 (m, 2H, CHAr), 7.03 – 6.90 (m, 
2H, CHAr), 5.94 (s, 2H, CH2). 19F NMR (235 MHz, CDCl3) δ = -114.39. 
13C NMR (63 MHz, CDCl3) δ = 181.4, 179.1 (C=O), 162.4 (d, 1J = 246.5 Hz, CF), 139.7, 134.7, 
134.2 (CAr), 134.0 (CHAr), 133.6 (CAr), 133.0 (CHAr), 132.4 (d, 4J = 3.2 Hz, CAr), 128.7 (d, 
3J = 8.2 Hz, 2CHAr), 127.8, 126.7, 126.8, 124.8 (CHAr), 124.2 (CAr), 124.2 (CHAr), 119.6 (CAr), 
115.9 (d, 2J = 21.7 Hz, 2CHAr), 111.4 (CHAr), 47.7 (CH2). IR (ATR, cm-1), ṽ = 3284 (w), 3066 
(w), 3055 (w), 3003 (w), 1645 (s), 1595 (s), 1508 (s), 1464 (s), 1194 (s), 1165 (s), 1155 (m), 
1146 (m), 1126 (m), 1099 (m). MS (EI, 70 eV), m/z (%) = 355 (M+, 73), 296 (1), 296 (1), 260 
(2), 222 (3), 190 (6), 130 (2), 109 (100), 83 (10). HRMS (ESI-TOF), calcd for C23H14NFO2 
(M+H+), 356.10813. 
 
5-(4-methoxybenzyl)-5H-benzo[b]carbazole-6,11-dione (10t) 
Following the general procedure, 10t was obtained as a yellow solid 
(58 %), mp = 182 – 183 C. 1H NMR (300 MHz, CDCl3), δ = 8.50 – 8.44 
(m, 1H, CHAr), 8.20 (dd, 3J = 7.5 Hz, 4J = 1.3 Hz, 1H, CHAr), 8.14 (dd, 
3J = 7.4 Hz, 4J = 1.4 Hz, 1H, CHAr), 7.61 – 7.75 (m, 2H, CHAr), 
7.51 – 7.34 (m, 3H, CHAr), 7.10 (d, 3J = 5.8 Hz, 2H, CHAr) 6.84 – 6.77 
(m, 2H, CHAr), 5.90 (s, 2H, CH2), 3.73 (s, 3H, OCH3). 13C NMR 
(75 MHz, CDCl3) δ = 181.4, 179.0 (C=O), 159.3, 139.8, 134.8, 134.2 (CAr), 133.9 (CHAr), 133.7 
(CAr), 132.9 (CHAr), 128.8 (CAr), 128.3 (2CHAr), 127.6, 126.7, 126.4, 124.7 (CHAr), 124.3 (CAr), 
124.1 (CHAr), 119.5 (CAr), 114.3 (2CHAr), 111.6 (CHAr), 55.4 (OCH3), 48.0 (CH2). IR (ATR, 
cm-1), ṽ = 3289 (w), 3052 (m), 2933 (m), 1612 (m), 1591 (s), 1584 (s), 1515 (vs), 1493 (s), 
1466 (s), 1439 (s), 1420 (m), 1396 (s), 1316 (m), 1252 (s), 1239 (vs), 1189 (s), 1166 (s). MS 
(EI, 70 eV), m/z (%) = 367 (M+, 37), 203 (2), 190 (7), 139 (2), 121 (100), 91 (6), 78 (8), 77 (9) 
. HR-MS (EI), calcd for C24H17O3N (M+H+) 368.12812, found 368.12771. 
 
5-(3-(trifluoromethyl)benzyl)-5H-benzo[b]carbazole-6,11-dione (10u) 
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Following the general procedure, 10u was obtained as a yellow solid 
(59 %), mp = 198 – 199 C. 1H NMR (300 MHz, CDCl3) δ = 8.56 – 8.47 
(m, 1H, CHAr), 8.28 – 8.19 (m, 1H, CHAr), 8.18 – 8.10 (m, 1H, CHAr), 
7.80 – 7.64 (m, 2H, CHAr), 7.60 – 7.34 (m, 6H, CHAr), 7.30 – 7.27 (m, 
1H, CHAr overlap with solvent signal), 6.04 (s, 2H, CH2). 19F NMR 
(282 MHz, CDCl3) δ= -62.62. 13C NMR (75 MHz, CDCl3) δ = 181.4, 
179.1 (C=O), 139.7, 137.7, 134.76, 134.2 (CAr), 134.1 (CHAr), 133.6 (CAr), 133.1 (CHAr), 131.4 
(q, 2J= 32.5 Hz, C-CF3), 130.01 (q, 4J = 1.1 Hz, CHAr), 129.6, 128.0, 126.7, 126.5, 125.0 (CHAr), 
124.9 (q, 3J = 3.7 Hz, CHAr), 124.3 (q, 1J = 273 Hz, CF3), 124.3 (CHAr), 124.3 (CAr), 123.8 (q, 
3J = 3.9 Hz, CHAr), 119.8 (CAr), 111.2 (CHAr), 48.2 (CH2). IR (ATR, cm-1), ṽ = 3290 (w), 3078 
(w), 2989 (w), 1612 (w), 1597 (m), 1585 (m), 1419 (m), 1396 (m), 1362 (w), 1352 (w), 1329 
(s), 1282 (m), 1219 (m), 1198 (s). MS (EI, 70 eV), m/z (%) = 405 (M+, 100), 376 (6), 260 (16), 
190 7), 159 (49), 139 (4), 109 (12).HRMS (ESI-TOF), calcd for C24H14NF3O2 (M+H+), 
406.10494, found 406.10512; calcd for C24H14NaNF3O2 (M+Na+), 428.08688, found 
428.08715. 
 
 
5-(3,4-dimethoxyphenethyl)-5H-benzo[b]carbazole-6,11-dione (10v) 
Starting from 2- (3,4-dimethoxyphenyl)ethanamine, following the 
general procedure, 10v was obtained as a yellow solid (66 %), 
mp = 153 – 154 C. 1H NMR (250 MHz, CDCl3) δ = 8.51 – 8.24 (m, 1H, 
CHAr), 8.20 – 7.86 (m, 2H, CHAr), 7.73 – 7.45 (m, 2H, CHAr), 7.41 – 7.06 
(m, 3H, CHAr), 6.74 – 6.43 (m, 3H, CHAr), 5.05 – 4.48 (m, 2H, CH2), 3.69 
(s, 3H, CH3), 3.67 (s, 3H, CH3), 3.09 – 2.85 (m, 2H, CH2). 13C NMR 
(63 MHz, CDCl3) δ = 181.20, 178.81 (C=O), 149.1, 148.0, 139.4, 134.8, 
134.1 (CAr), 133.8 (CHAr), 133.6 (CAr), 132.9 (CHAr), 130.4 (CAr), 127.3, 126.5, 126.3, 124.5 
(CHAr), 124.0 (CAr), 123.9, 121.1 (CHAr), 119.1 (CAr), 112.3, 111.4, 111.0 (CHAr), 56.0, 55.9 
(OCH3), 46.9 (CH2), 36.2 (CH2). IR (ATR, cm-1), ṽ = 3063 (w), 2997 (w), 2918 (m), 2848 (m), 
1655 (s), 1643 (m), 1616 (w), 1605 (w), 1539 (w), 1512 (s), 1437 (m), 1375 (m), 1281 (m), 
1257 (s). MS (EI, 70 eV), m/z (%) = 411 (M+, 54), 260 (49), 247 (13), 203 (8), 176 (11), 164 
(29), 151 (100), 107 (10). HR-MS (EI), calcd for C26H21O4N (M+) 411.14651, found 411.14639. 
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2-methyl-5-phenyl-5H-benzo[b]carbazole-6,11-dione (11a) 
Starting from 4-methyl-N-phenylaniline, following the general 
procedure, the mixture 11a and 10b was obtained as a yellow solid 
(41.7 mg, 41 %). The pure of 11a was isolated by recrystallizing from 
heptane and ethyl acetate (5:1), and washing the precipitate with cold 
ethyl acetate, (25 %) mp = 301 - 302 C. 1H NMR (300 MHz, 
CDCl3) δ = 8.34 – 8.22 (m, 2H, CHAr), 8.07 – 8.01 (m, 1H, CHAr), 
7.77 – 7.56 (m, 5H, CHAr), 7.47 – 7.41 (m, 2H, CHAr), 7.25 – 7.18 (m, 1H, CHAr), 7.06 (d, 
3J = 8.6 Hz, 1H, CHAr), 2.53 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ = 181.8, 177.7 (C=O), 
139.8, 137.1, 135.0, 134.3 (CAr), 133.8 (CHAr), 133.8 (CAr), 133.1, 129.8 (CHAr), 129.6 (2CHAr), 
129.3 (CHAr), 127.7 (2CHAr), 126.6 (CHAr), 126.5, 124.9 (CAr), 124.3 (CHAr), 123.1 (CHAr), 
119.6 (CAr), 111.9 (CHAr), 21.7(CH3). IR (ATR, cm-1), ṽ = 3061 (w), 2910 (w), 1651 (s), 1590 
(m), 1518 (s), 1219 (s), 1176 (m), 1157 (m), 1093 (m), 1047 (m), 1030 (m). MS (EI, 70 eV), 
m/z (%) = 337 (M+, 100), 308 (7), 278 (9), 233 (1), 203 (3), 168 (12), 153 (3), 139 (4), 77 (4). 
HR-MS (EI), calcd for C23H15NO2 (M +) 337.10973, found 337.10948. 
 
2-methyl-5-(p-tolyl)-5H-benzo[b]carbazole-6,11-dione (11b) 
Starting from di-p-tolylamine, following the general procedure, 11b 
was obtained as a yellow solid (42 %), mp = 301 – 302 C. 1H NMR 
(300 MHz, CDCl3) δ = 8.33 – 8.28 (m, 1H, CHAr), 8.26 - 8.21 (m, 1H, 
CHAr), 8.09 – 8.02 (m, 1H, CHAr), 7.68 (m, 2H, CHAr), 7.40 (d, 
3J = 8.1 Hz, 2H, CHAr), 7.34 – 7.29 (m, 2H, CHAr), 7.21 (dd, 
3J = 8.6 Hz, 4J = 1.4 Hz, 1H, CHAr), 7.06 (d, 3J = 8.6 Hz, 1H, CHAr), 
2.52, 2.51 (CH3). 13C NMR (63 MHz, CDCl3) δ = 181.9, 177.8 (C=O), 
139.9, 139.4, 135.7, 135.0, 134.5, 134.4 (CAr), 133.9, 133.1 (CHAr), 130.4 (2CHAr), 130.0 
(CHAr), 129.8 (CAr), 127.5 (2CHAr), 126.7, 126.5 (CHAr), 124.4 (CAr), 123.2 (CHAr), 119.6 
(CAr), 112.1 (CHAr), 21.8, 21.6 (CH3). IR (ATR, cm-1), ṽ = 3063 (w), 2997 (w), 2933 (w), 2922 
(m), 1643 (s), 1591 (s), 1512 (s), 1462 (s), 1452 (s), 1419 (s), 1398 (s), 1257 (s), 1234 (s), 1182 
(s), 1088 (m), 1063 (s), 1047 (m). MS (EI, 70 eV), m/z (%) = 351 (M+, 100), 336 (29), 322 (6), 
294 (6), 278 (6), 168 (9), 151 (3), 132 (4). HRMS (ESI-TOF), calcd for C24H17NO2 (M+H+), 
m/z= 352.13321, found 352.13327; calcd for C24H17NaNO2 (M+Na+), m/z= 374.11515, found 
374.11509. 
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4-methyl-5-(o-tolyl)-5H-benzo[b]carbazole-6,11-dione (11c) 
Following the general procedure, 11c was obtained as an orange solid 
(47 %), mp = 189 – 190 C. 1H NMR (300 MHz, CDCl3) δ = 8.46 (d, 
3J = 8.1 Hz, 1H, CHAr), 8.25 (dd, 3J = 7.6 Hz, 4J = 1.4 Hz, 1H, CHAr), 
8.01 (dd, 3J = 7.6 Hz, 4J = 1.3 Hz, 1H, CHAr), 7.71 – 7.66 (m, 2H, 
CHAr), 7.55 – 7.28 (m, 4H, CHAr), 7.14 (d, 3J = 7.1 Hz, 2H, CHAr), 
2.02 (s, 3H, CH3), 1.85 (s, 3H, CH3).13C NMR (63 MHz, CDCl3) δ = 181.8, 177.7 (C=O), 138.5, 
138.5, 136.9, 135.6, 134.3, 133.8 (CAr), 133.6, 133.0, 130.7, 130.4, 129.8, 128.7 (CHAr), 126.7 
(CAr), 126.6, 126.4, 126.3, 124.9 (CHAr), 123.8 (CAr), 121.9 (CHAr), 119.7 (CAr), 18.3, 17.5 
(CH3). IR (ATR, cm-1), ṽ = 3054 (w), 2917 (m), 1646 (s), 1515 (s), 1471 (m), 1454 (s), 1394 
(s), 1290 (s), 1214 (s), 1176 (m), 1147 (s), 1106 (m). MS (EI, 70 eV), m/z (%) = 353 (3), 352 
(26), 351 (100), 350 (18), 337 (14), 336 (48), 334 (24), 322 (17), 278 (11), 218 (15), 176 (7), 
139 (6). HRMS (EI), calcd for C24H17NO2 (M+), m/z= 351.12538, found 351.12555. 
 
2-methoxy-5-(4-methoxyphenyl)-5H-benzo[b]carbazole-6,11-dione (11d) 
Following the general procedure, 11d was obtained as an orange solid 
(38 %), mp = 239 – 240 C. 1H NMR (300 MHz, CDCl3) δ 8.19 (dd, 
3J = 7.5 Hz, 4J = 1.2 Hz, 1H, CHAr), 8.02 (dd, 3J = 7.5 Hz, 4J = 1.2 Hz, 
1H, CHAr), 7.85 (d, 4J = 1.9 Hz, 1H, CHAr), 7.69 – 7.58 (m, 2H, CHAr), 
7.40 – 7.31 (m, 2H, CHAr), 7.15 – 6.95 (m, 4H, CHAr), 3.93 (s, 3H, 
OCH3), 3.92 (s, 3H, OCH3). 13C NMR (75 MHz, CDCl3) δ 181.7, 
177.4 (C=O), 160.0, 158.1, 136.7, 135.4, 134.2, 133.8 (CAr), 133.7, 133.0 (CHAr), 129.5 (CAr), 
128.7 (2CHAr), 126.6, 126.3 (CHAr), 124.7 (CAr),119.7 (CHAr), 119.2 (CAr), 114.7 (2CHAr), 
113.4, 102.8(CHAr), 55.9, 55.7 (OCH3). IR (ATR, cm-1), ṽ = 1648 (s), 1612 (m), 1587 (m), 1513 
(s), 1490 (s), 1475 (s), 1463 (s), 1438 (m), 1423 (m). MS (EI, 70 eV), m/z (%) = 385 (4), 384 
(25), 383 (100), 368 (19), 340 (3), 297 (3), 277 (2). HRMS (EI), calcd for C24H17NO4 (M+), 
m/z= 383.11576, found 383.39608 
 
1-methoxy-5-(2-methoxyphenyl)-5H-benzo[b]carbazole-6,11-dione (11e) 
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Following the general procedure, 11e was obtained as an orange 
solid (35 %), mp = 239 – 240 C. 1H NMR (300 MHz, 
CDCl3) δ = 8.22 (d, 3J = 7.5 Hz, 1H, CHAr), 8.04 (dd, 3J = 7.5 Hz, 
4J = 1.2 Hz, 1H, CHAr), 7.88 (d, 3J = 1.8 Hz, 1H, CHAr), 7.75 – 7.59 
(m, 2H, CHAr), 7.39 – 7.32 (m, 2H, CHAr), 7.15 – 6.99 (m, 4H, 
CHAr), 3.95 (s, 3H, OCH3), 3.93 (s, 3H, OCH3). 13C NMR (75 MHz, CDCl3) δ = 181.8, 177.5 
(C=O), 160.1, 158.1, 136.8, 135.5, 134.3, 133.9 (CAr), 133.7, 133.0 (CHAr), 129.5 (CAr), 128.7 
(2CHAr), 126.6, 126.3 (CHAr), 124.8 (CAr), 119.7 (CHAr), 119.3 (CAr), 114.8 (2CHAr), 113.4, 
102.9 (CHAr), 56.0, 55.7 (OCH3). IR (ATR, cm-1), ṽ = 3061 (w), 2997 (w), 2550 (w), 2355 (w), 
1649 (s), 1612 (m), 1514 (s), 1491 (s), 1439 (m), 1423 (m), 1398 (m), 1344 (m), 1317 (m), 
1286 (m), 1128 (m), 1109 (m), 1092 (m). MS (EI, 70 eV), m/z (%) = 383 (M+, 100), 368 (30), 
340 (7), 297 (6), 269 (3), 240 (5), 192 (5). HRMS (EI), calcd for C24H17NO4 (M+), 
m/z= 383.11521, found 383.11509. 
 
5-mesityl-2-methyl-5H-benzo[b]carbazole-6,11-dione (11f)  
Following the general procedure, 11f w as obtained as an orange solid 
(44 %), mp = 239 – 240 C. 1H NMR (250 MHz, CDCl3) δ 8.38 - 8.29 
(m, 1H, CHAr), 8.27 (dd, 3J = 7.6 Hz, 3J = 1.4 Hz, 1H, CHAr), 8.04 (dd, 
3J = 7.6 Hz, 4J = 1.3 Hz, 1H, CHAr), 7.77 – 7.60 (m, 2H, CHAr), 7.23 
(dd, 3J = 8.6 Hz, 4J = 1.6 Hz, 1H, CHAr), 7.08 (s, 2H, CHAr), 6.86 (d, 
3J = 8.6 Hz, 1H, CHAr), 2.54 (s, 3H, CH3), 2.42 (s, 3H, CH3), 1.86 (s, 
6H, 2CH3). 13C NMR (63 MHz, CDCl3) δ 181.6, 177.6 (C=O), 138.9, 138.1 (CAr), 135.5 
(2CAr135.3, 134.8, 134.3 (CAr), 133.6 (CHAr), 133.4 (CAr), 132.8 (CHAr), 132.6 (CAr), 129.7 
(CAr), 129.3 (2CHAr), 126.4 (CHAr), 126.4 (CHAr), 124.2 (CAr), 123.0 (CHAr), 119.0 (CAr), 111.4 
(CHAr), 21.6 (CH3), 21.2 (CH3), 17.3 (2CH3). IR (ATR, cm-1), ṽ = 2946 (w), 1654 (s), 1619 
(m), 1592 (s), 1521 (s), 1483 (s), 1461 (s), 1442 (m), 1415 (s), 1380 (s), 1373 (m), 1330 (m), 
1047 (s). MS (EI, 70 eV), m/z (%) = 381 (4), 380 (28), 379 (100), 378 (15), 364 (28), 362 (12), 
351 (11), 350 (22), 246 (25), 182 (7), 146 94), . HRMS (EI), calcd for C26H21NO3 (M+), 
m/z= 379.15668, found 379.15633 
 
5-mesityl-2-methoxy-5H-benzo[b]carbazole-6,11-dione (11g) 
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Following the general procedure, 11g was obtained as an orange solid 
(51 %), mp = 239 – 240 C. 1H NMR (250 MHz, CDCl3) δ 8.25 (dt, 
3J = 6.2 Hz, 4J = 3.2 Hz, 1H, CHAr), 8.04 (dd, 3J = 7.5 Hz, 4J = 1.3 Hz, 
1H, CHAr), 7.93 (d, 4J = 2.4 Hz, 1H, CHAr), 7.79 – 7.58 (m, 2H, CHAr), 
7.11 – 6.98 (m, 3H, CHAr), 6.86 (d, 3J = 9.1 Hz, 1H, CHAr), 3.97 (s, 
3H, OCH3), 2.42 (s, 3H, CH3), 1.86 (s, 6H, 2CH3). 13C NMR (63 MHz, 
CDCl3) δ 181.8, 177.5 (C=O), 158.3, 139.1, 135.6, 135.3, 135.0, 134.5 (CAr), 133.8 (CHAr), 
133.7 (2CAr), 133.0 (CAr), 132.7 (CHAr), 129.5 (2CHAr), 126.8 (CAr), 126.6, 126.4 (CHAr), 125.0 
(CAr), 120.0 (CHAr), 119.1 (CAr), 113.0, 103.1 (CHAr), 56.0 (OCH3), 21.4 (CH3), 17.5 (2CH3). 
IR (ATR, cm-1), ṽ = 2917 (m), 2850 (w), 2833 (w), 1652 (s), 1591 (s), 1511 (s), 1483 (s), 1459 
(s), 1452 (s), 1434 (s), 1288 (s), 1259 (s), 1216 (s), 1178 (s), 1153 (s), 1122 (m), 1089 (m). MS 
(EI, 70 eV), m/z (%) = 397 (4), 396 (28), 395 (100), 380 (16), 366 (17), 336 (11), 262 (14), 119 
(12). HRMS (EI), calcd for C26H21NO3 (M+), m/z= 395.44984, found 395.44984 
5-cyclohexyl-5H-benzo[b]carbazole-6,11-dione (11h) 
Following the general procedure, 11h was obtained as an orange solid 
(19 %), mp = 159 – 160 C.1H NMR (300 MHz, CDCl3) δ 8.55 – 8.51 
(m, 1H, CHAr, 8.27 – 8.05 (m, 2H, CHAr), 7.80 – 7.59 (m, 3H, CHAr), 
7.45 – 7.29 (m, 2H, CHAr), 5.74 (br-s, 1H, NCH), 2.53 – 1.33 (m, 10H). 
13C NMR (75 MHz, CDCl3) δ 181.5, 179.3, 138.8, 134.9, 134.7, 133.9 
(CAr), 133.7, 132.9, 126.8, 126.7, 126.1 (CHAr), 125.1 (CAr), 124.3, 124.2 (CHAr), 119.5 (CAr), 
114.3 (CHAr), 57.1 (CH), 31.1 (br, 2 CH2), 26.4 (2CH2), 25.5 (CH2). IR (ATR, cm-1), ṽ = 3070 
(w), 2920 (m), 2856 (w), 1722 (m), 1645 (s), 1588 (s), 1552 (w), 1510 (s), 1494 (s), 1451 (s). 
MS (EI, 70 eV), m/z (%) = 329 (M+, 57), 300 (2), 286 (5), 247 (100), 219 (19), 190 (21), 163 
(7), 105 (4), 77 (6), 55 (5). HRMS (EI), calcd for C22H19NO2 (M+), m/z= 329.14103, found 
329.14101 
Benzo[b]indolo[3,2,1-jk]carbazole-9,14-dione (12a) 
 
Starting from carbazole, following the general procedure, 13a was 
obtained as a light red solid (28 %), mp = 251 – 253 C. 1H NMR 
(300 MHz, CDCl3) δ = 8.64 (d, 3J = 8.1 Hz, 1H, CHAr), 8.27 – 8.15 
(m, 3H, CHAr), 7.99 – 7.87 (m, 2H, CHAr), 7.81 – 7.70 (m, 2H, CHAr), 
7.64 – 7.59 (m, 2H, CHAr), 7.44 – 7.35 (m, 1H, CHAr). 13C NMR (75 MHz, CDCl3) δ = 181.7, 
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177.9 (C=O), 142.2, 139.4, 136.5 (CAr), 134.1 (CHAr), 133.8 (CAr), 133.3 (CHAr), 132.9, 131.6 
(CAr), 128.4, 127.5, 126.9, 126.8 (CHAr), 126.3 (CAr), 125.3, 124.0, 123.3, 122.0 (CHAr), 120.9, 
117.3 (CAr), 117.0 (CHAr). IR (ATR, cm-1), ṽ = 3304 (w), 3286 (w), 3049 (w), 2920 (m), 2850 
(m), 2679 (w), 1655 (s), 1593 (s), 1479 (s), 1263 (m), 1238 (s), 1223 (s), 1093 (m), 1063 (m), 
1041 (m), 1012 (m). MS (EI, 70 eV), m/z (%) = 321 (M+, 100), 292 (18), 264 (17), 238 (3), 188 
(3), 161 (3), 132 (11). HRMS (ESI-TOF), calcd for C22H11NO2 (M+H+), m/z= 322.08626, 
found 322.08623; calcd for C22H11NaNO2 (M+Na +), m/z= 344.0682, found 344.06811. 
 
2,3-di (9H-carbazol-9-yl)naphthalene-1,4-dione (12b) 
Starting from carbazole, following the general procedure, 13b was 
obtained as a black-violet solid (32 %), mp = 103 – 105 C.1H NMR 
(300 MHz, CDCl3) δ = 8.40 – 8.33 (m, 2H, CHAr), 7.92 – 7.85 (m, 
2H, CHAr), 7.75 – 7.67 (m, 4H, CHAr), 7.11 – 6.96 (m, 12H, CHAr). 
13C NMR (75 MHz, CDCl3) δ 180.0 (2C=O), 138.8 (4CAr), 136.7 
(2CAr), 134.7 (2CHAr), 131.9 (2CAr), 127.6 (2CHAr), 125.7 (4CHAr), 
124.8 (4CAr), 121.3 (4CHAr), 120.0 (4CHAr), 111.7 (4CHAr). IR 
(ATR, cm-1), ṽ = 3045 (w), 3024 (w), 2924 (w), 1666 (m), 1624 (w), 1591 (m), 1489 (w), 1448 
(m), 1441 (m), 1371 (m), 1331 (m), 1311 (m), 1263 (s), 1223 (s), 1180 (m), 1113 (m), 1101 
(m), 1053 (w). MS (EI, 70 eV), m/z (%) = 490 (100), 489 ([M+H]+, 488 (15), 322 (9), 245 (8), 
167 (18), 91 (7), 69 (13), 43 (19). HRMS (ESI-TOF), calcd for C34H20N2O2 (M+H+), 
m/z= 489.15975, found 489.16001. 
2-bromo-3-(2-methyl-1H-indol-3-yl)naphthalene-1,4-dione (12c) 
 Starting from 2-methylindole, following the general procedure, 13c was 
obtained as a black-violet solid (67 %), mp = 117 – 118 C. 1H NMR 
(250 MHz, CDCl3) δ8.40 (s, NH), 8.28 – 8.11 (m, 2H, CHAr), 7.86 – 7.70 
(m, 2H, ), 7.32 – 7.25 (m, 2H, ), 7.25 – 7.00 (m, 2H, ), 2.33 (s, 3H, CH3). 
13C NMR (75 MHz, CDCl3) δ181.5, 178.5 (C=O), 145.7, 139.2, 135.8, 
135.4 (CAr), 134.1, 134.0 (CHAr), 132.0, 131.4 (CAr), 127.5 (2CHAr), 127.0 (CAr), 121.8, 120.5, 
119.9, 110.9 (CHAr), 108.1 (CAr), 13.9 (CH3). IR (ATR, cm-1), ṽ = 3312 (m), 1643 (m), 1599 
(s), 1548 (s), 1310 (m), 1239 (m), 1257 (m), 1194 (m), 1093 (s). MS (EI, 70 eV), m/z (%) = 369 
(17), 368 (25), 367 (94), 366 (17), 365 (85), 286 (100), 269 (12), 258 (17), 230 (24), 143 (29). 
HRMS (ESI-TOF), calcd for C19H12BrNO2 (M+H+), m/z= 366.01242, found 366.01256.  
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7.5. Supplement for Chapter 4 
 
Scheme S7. Synthesis of 2,3,5,6-Tetrabromopyridine 17  
 
Procedure for starting compound 17: Bromine was dropped slowly into 200 ml glacial acetic 
acid solution of pyridine-2,6-diamine (10,9 g, 100 mmol). Then the reaction was stirred for 5 h 
at room temperature. The mixture worked up with Na2SO3 to remove all residual bromine, then 
was neutralized by NaOH to pH = 8-9. The brown solid was filtered, and washed with water. 
The obtained brown solid was dissolved in solution of HBr 48%. The solution was dropped into 
a saturated aqueous solution of NaNO2 in -3 oC. The mixture was stirred for 3 h -3 oC and at 
room temperature for 2h. After neutralizing with NaOH, the mixture was extracted with ethyl 
acetate. The organic layers were dried over sodium sulfate and concentrated under vacuum. The 
crude material was purified by flash column chromatography (silica gel, heptane/ethylacetate). 
 
 
Scheme S8. 2,3-Dibromobenzofuran synthesis 
 
Procedure for the starting compound 21: A solution of benzofuran (125 mmol) and AcOK 
(55.1 g, 562.5 mmol) in dichloromethane was dropped slowly into the solution of Br2 in 
dichloromethane at 20 oC, then the mixture was reflux for 18 h. After removing the residual 
bromine by Na2SO3, the mixture was extracted with dichloromethane. The organic layers were 
dried over sodium sulfate and concentrated under vacuum. The crude material was purified by 
flash column chromatography (silica gel, heptane). 
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Scheme S9. 2,3,4,5-Tetrabromofuran synthesis 
Procedure for the starting compound 25: Br2 was dropped into the solution of furan-2-
carboxylic acid (336 mg, 3 mmol) and KOH (168 mg, 3 mmol) under nitrogen atmosphere. The 
mixture was reflux for 6 h, then worked up with Na2SO3 and was extracted with 
dichloromethane. The organic layers were collected and dried by Na2SO4. The obtained solid 
was refluxed in MeOH in the presence of KOH for 12h. The solution was diluted with water, 
then extracted with ethyl acetate. The organic layer was collected, dried, then purified by flash 
column chromatography (silica gel, heptane). 
 
Scheme S10. Synthesis of indolo[2,3-b]quinoxalines 15e. 
 
Scheme S11. Synthesis of 5,7-disubstituted 5,7-dihydropyrido[3,2-b,5,6-b']diindoles 19. 
 
Scheme 25. Synthesis of benzo[4,5]-furo[3,2-b]indoles 23. 
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Scheme S12. Synthesis of furo[3,2-b,4,5-b']diindole 27. 
 
General procedure for Suzuki-Miyaura reaction. Brominated starting materials, 2-
bromophenylboronic acid, Pd(PPh3)4 (5 mol%) and base were added to a 500 mL Schlenk flask 
under Argon atmosphere. To the mixture 70 mL of 1,4-dioxane and 10 mL of distilled water 
were added. The reaction was heated at desired temperature until the reaction was completed. 
The mixture was allowed to reach room temperature, was diluted with water and extracted with 
dichloromethane. The combined organic layers were dried over Na2SO4, filtered and the solvent 
was evaporated in vacuo. The brown residue was purified by column chromatography (silica 
gel, heptane/ethylacetate) to yield 14, 18, 22, and 26, respectively. 
 
General procedure for double C-N cross-coupling  
The corresponding amount of amine was added to a pressure tube charged with 14, 18, 22 or 
26 and Pd2(dba)3 (5 mol%), ligand (10 mol%) and base under Argon. The mixture was dissolved 
in anhydrous toluene (10 mL). The tube was sealed with a Teflon valve and stirred at the 
designated temperature. After the reaction was completed, the mixture was allowed to reach 
room temperature, worked up with water and extracted with dichloromethane. The combined 
organic layers were dried over sodium sulfate and concentrated under vacuum. The crude 
material was purified by flash column chromatography (silica gel, heptane/ethylacetate) gel to 
yield compounds 15, 19, 23, and 27, respectively. 
 
 
6-propyl-6H-indolo[2,3-b]quinoxaline (15a) 
Following the general procedure to yield 15a (80 %) as a yellow solid; 
m.p. 99 - 100 ºC; 1H NMR (300 MHz, CDCl3) δ 8.50 (d, 3J = 7.7 Hz, 1H, 
CHAr), 8.31 (dd, 3J = 8.3 Hz, 4J = 1.3 Hz, 1H, CHAr), 8.14 (dd, 
3J = 8.3 Hz, 4J = 1.1 Hz, 1H, CHAr), 7.82 – 7.60 (m, 3H, CHAr), 7.48 (d, 
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3J = 8.2 Hz, 1H, CHAr), 7.44 – 7.33 (m, 1H, CHAr), 4.58 – 4.37 (m, 2H, CH2), 2.13 – 1.90 (m, 
2H, CH2), 1.03 (t, 3J = 7.4 Hz, 3H, CH3); 13C NMR (63 MHz, CDCl3) δ 145.8, 144.7, 140.8, 
140.0, 139.2 (CAr), 131.0, 129.4, 128.8, 127.9, 126.0, 122.9, 120.9 (CHAr), 119.5 (CAr), 109.6 
(CHAr), 43.2, 21.9 (CH2), 11.7 (CH3). IR (ATR, cm-1), ṽ =2970 (m), 2951 (m), 2929 (w), 2870 
(m), 1610 (m), 1581 (m), 1574 (m), 1487 (s), 1464 (s), 1435 (m), 1406 (s), 1394 (m), 1369 (m). 
MS (EI, 70 eV), m/z (%) = 261 (M+, 46), 232 (73), 219 (100), 102 (11), 90 (10), 77 (7); HRMS 
(ESI), calcd. for C17H16N3 ([M+H]+), 262.13387; found, 262.13391. 
6-Pentyl-6H-indolo[2,3-b]quinoxaline (15b) 
Following the general procedure to yield 15b (93 %) as a yellow solid; 
m.p. 90 - 91 ºC; 1H NMR (300 MHz, CDCl3) δ 8.40 (d, 3J = 7.6 Hz, 1H, 
CHAr), 8.22 (dd, 3J = 8.3 Hz,4J = 1.3 Hz, 1H, CHAr), 8.06 (dd, 
3J = 8.3 Hz, 4J = 1.2 Hz, 1H, CHAr), 7.73 – 7.53 (m, 3H, CHAr), 7.39 (d, 
3J = 8.2 Hz, 1H, CHAr), 7.35 – 7.25 (m, 1H, CHAr), 4.45 – 4.34 (m, 2H, CH2), 1.94 – 1.77 (m, 
2H, CH2), 1.33 (m, 4H, 2CH2), 0.81 (t, 3J = 7.1 Hz, 3H, CH3); 13C NMR (63 MHz, CDCl3) 
δ 145.6, 144.4, 140.6, 140.0, 139.2 (CAr), 130.8, 129.3, 128.6, 127.8, 125.8, 122.7, 120.6 
(CHAr), 119.4 (CAr), 109.4 (CHAr), 41.4, 29.1, 28.1, 22.3 (CH2), 13.9 (CH3); IR (ATR, cm-1), 
ṽ = 2964 (w), 2953 (w), 2931 (w), 2870 (w), 1608 (m), 1579 (m), 1491 (m), 1466 (s), 1441 (w), 
1406 (s), 1379 (m), 1358 (m). MS (EI, 70 eV), m/z (%) = 289 (M+, 52), 260 (6), 246 (11), 2332 
(80), 219 (100), 129 (11), 90 (10), 77 (9); HRMS (EI), calcd. for C19H19N3 ([M]+), 289.15735; 
found, 289.15720. 
 
6-Heptyl-6H-indolo[2,3-b]quinoxaline (15c) 
Following the general procedure to yield 15c (85 %) as a yellow solid; 
m.p. 66 - 68 ºC; 1H NMR (300 MHz, CDCl3) δ 8.50 (d, 3J = 7.7 Hz, 1H, 
CHAr), 8.32 (dd, 3J = 8.3 Hz, 4J = 1.3 Hz, 1H, CHAr), 8.15 (dd, 3J = 8.3 Hz, 
4J = 1.2 Hz, 1H, CHAr), 7.81 – 7.64 (m, 3H, CHAr), 7.47 (d, 3J = 8.2 Hz, 1H, CHAr), 7.42 – 7.32 
(m, 1H, CHAr), 4.58 – 4.40 (m, 2H, CH2), 2.03 – 1.85 (m, 2H, CH2), 1.51 – 1.16 (m, 8H, 4CH2), 
0.86 (3J = 6.8 Hz, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 145.8, 144.6, 140.7, 139.8, 139.0 
(CAr), 131.1, 129.2, 128.8, 127.9, 126.1, 123.0, 120.9 (CHAr), 119.4 (CAr), 109.6 (CHAr), 41.6, 
31.8, 29.1, 28.6, 27.1, 22.7 (CH2), 14.1 (CH3). IR (ATR, cm-1), ṽ = 2951 (m), 2922 (m), 2870 
(m), 2850 (m), 1606 (m), 1581 (m), 1487 (s), 1464 (s), 1435 (m), 1408 (s), 1394 (m), 1369 (s), 
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1358 (s). MS (EI, 70 eV), m/z (%) = 317 (M+, 41), 233 (100), 219 (96), 102 (6); HRMS (ESI), 
calcd. for C21H24N3 ([M+H]+), 318.19647; found, 318.19666. 
 
6-(Prop-1-en-1-yl)-6H-indolo[2,3-b]quinoxaline (15d) 
Following the general procedure to yield 15d (73 %) as a yellow solid; 
m.p. 142 - 143 ºC; 1H NMR (300 MHz, CDCl3) δ 8.50 (d, 3J = 7.6 Hz, 
1H, CHAr), 8.32 (dd, 3J = 8.2 Hz, 4J = 1.4 Hz, 1H, CHAr), 8.21 – 8.15 (m, 
1H, CHAr), 7.83 – 7.63 (m, 3H, CHAr), 7.47 - 7.38 (m, 2H, CHAr), 
6.92 – 6.79 (m, 1H, CH=CH), 6.27 – 6.07 (m, 1H, CH=CH), 1.76 (dd, 3J = 7.0 Hz, 4J = 1.8 Hz, 
3H, CH3);13C NMR (63MHz, CDCl3) δ 144.2, 140.6, 140.2, 139.4 (CAr), 131.0, 129.2, 128.9, 
128.2, 128.1, 126.4, 122.6, 121.6, 121.1 (CHAr), 119.8 (C), 110.8 (CHAr), 14.1 (CH3) (one signal 
of C was missing). IR (ATR, cm-1), ṽ = 3055 (m), 3045 (m), 2978 (m), 2931 (m), 2912 (m), 
2852 (m), 1662 (m), 1628 (m), 1606 (m), 1581 (m), 1574 (m), 1485 (s), 1462 (s), 1435 (m). 
MS (EI, 70 eV), m/z (%) = 259 (M+, 100), 244 (29), 232 (22), 219 (42); HRMS (ESI), calcd. 
for C17H14N3 ([M+H]+), 260.11822; found, 260.11817. 
6-Benzyl-6H-indolo[2,3-b]quinoxaline (15e) 
Following the general procedure to yield 15e (94 %) as a yellow solid; 
m.p. 181 – 182 ºC; 1H NMR (300 MHz, CDCl3) δ 8.42 (d, 3J = 7.5 Hz, 
1H, CHAr), 8.25 (dd, 3J = 8.2 Hz,4J = 1.3 Hz, 1H, CHAr), 8.06 (dd, 
3J = 8.3 Hz,4J = 1.2 Hz, 1H, CHAr), 7.71 – 7.61 (m, 2H, CHAr), 
7.57 – 7.47 (m, 1H, CHAr), 7.36 – 7.08 (m, 7H, CHAr), 5.63 (s, 2H, CH2);13C NMR (75 MHz, 
CDCl3) δ145.9, 144.4, 140.8, 140.0, 139.5, 136.6 (CAr), 131.2, 129.3, 129.0 (CHAr), 128.9 
(2CHAr), 128.0, 127.8, 127.3 (2CHAr), 126.3, 122.9(CHAr), 121.3, 119.7 (CAr), 110.2 (CHAr), 
45.1 (CH2). IR (ATR, cm-1), ṽ = 3059 (m), 3026 (w), 1610 (m), 1581 (m), 1574 (m), 1485 (s), 
1466 (s), 1452 (m), 1433 (m), 1406 (s). GC-MS (EI, 70 eV), m/z (%) = 309 (M+, 100), 266 (7), 
251 (7), 232 (14), 207 (7), 91 (43), 84 (17), 66 (15), 49 (8); HRMS (ESI), calcd. for C21H16N3 
([M+H]+), 310.13387; found, 310.13398; calcd. for C21H16N3Na ([M+Na]+), 332.11582; found, 
332.11606. 
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6-(4-Methoxybenzyl)-6H-indolo[2,3-b]quinoxaline (15f) 
Following the general procedure to yield 15f (92 %) as a yellow 
solid; m.p.129 – 130 ºC;1H NMR (300 MHz, CDCl3) δ 8.41 (d, 
3J = 7.7 Hz, 1H, CHAr), 8.25 (dd, 3J = 8.3 Hz, 4J = 1.3 Hz, 1H, 
CHAr), 8.08 (dd, 3J = 8.3 Hz, 4J = 1.2 Hz, 1H, CHAr), 7.77 – 7.49 
(m, 3H, CHAr), 7.36 – 7.19 (m, 4H, CHAr), 6.78 – 6.71 (m, 2H, CHAr), 5.58 (s, 2H, CH2), 3.67 
(s, 3H, CH3); 13C NMR (63 MHz, CDCl3) δ 159.1, 145.7, 144.2, 140.6, 140.0, 139.4 (CAr), 
130.9, 129.3, 128.7 (CHAr), 128.6 (2CHAr), 128.5 (CAr), 127.8, 126.0, 122.6, 121.0 (CHAr), 
119.66 (CAr), 114.1 (2CHAr), 110.1 (CHAr), 55.2 (OCH3), 44.4 (CH2).IR (ATR, cm-1), ṽ = 2929 
(w), 1612 (w), 1583 (m), 1489 (m), 1470 (m), 1443 (w), 1410 (m), 1369 (m), 1360 (m). GC-
MS (EI, 70 eV), m/z (%) = 339 (M+, 37), 121 (100), 90 (12); HRMS (ESI), calcd. for 
C22H18N3O1([M+H]+), 340.14444; found, 340.14427. 
 
5,7-diheptyl-5,7-dihydropyrido[3,2-b,5,6-b']diindole (19a) 
Following the general procedure to yield 19a (80 %) as a white solid; 
m.p. 162 - 164 ºC; 1H NMR (300 MHz, CDCl3) δ 8.58 (d, 3J = 7.6 Hz, 
2H, CHAr), 7.55 - 7.48 (m, 2H, CHAr), 7.42 – 7.30 (m, 5H, CHAr), 
4.16 (t, 3J = 7.1 Hz, 4H, 2CH2), 1.91-1.76 (m, 4H, 2CH2), 1.50-1.15 (m, 16H, 8CH2), 0.86 (t, 
3J = 6.9 Hz, 6H, 2CH3); 13C NMR (63 MHz, CDCl3) δ 141.5, 136.7, 133.7 (2CAr). 126.4 
(2CHAr), 122.3 (2CAr), 120.8. 119.4, 108.6 (2CHAr), 94.2 (CHHetar), 43.1, 31.8, 29.2, 28.9, 27.4, 
22.7 (2CH2), 14.2 (2CH3).IR (ATR, cm-1), ṽ = 3061(w), 3020(w), 2953(w), 2933(w), 2877(w), 
2852(w), 1595(s), 1466(s), 1454(m), 1441(m), 1410(m). MS (EI, 70 eV), m/z (%) = 453 (M+, 
100), 368 (40), 282 (12), 269 (25); HRMS (EI), calcd. for C31H39N3 ([M]+), 453.31385; found, 
453.31353. 
 
5,7-Dipropyl-5,7-dihydropyrido[3,2-b,5,6-b']diindole (19b) 
Following the general procedure to yield 19b (86 %) as a white solid; 
m.p. 168 - 170 ºC; 1H NMR (300 MHz, CDCl3) δ 8.48 (d, 3J = 7.7 Hz, 
2H, CHAr), 7.46 – 7.40 (m, 2H, CHAr), 7.32 – 7.20 (m, 5H, CHAr), 
4.09 (t, 3J = 7.1 Hz, 4H, 2CH2), 1.90 – 1.73 (m, 4H, 2CH2), 0.88 (t, 
3J = 7.4 Hz, 6H, 2CH3); 13C NMR (63 MHz, CDCl3) δ 141.5, 136.73, 
133.7 (2CAr), 126.2, 122.3 (2CHAr), 120.6 (2CAr), 119.3, 108.5 (2CHAr), 94.1 (CHHetar), 44.5, 
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22.1 (2CH2), 11.9 (2CH3). IR (ATR, cm-1), (= 2958(m), 2929(m), 2872(m), 1593(m), 1574(m), 
1520(w), 1464(s), 1408(m), 1385(m), 1365(m), 1358(m). MS (EI, 70 eV), m/z (%) = 341 (M+, 
100), 312 (89), 269 (39), 171 (6), 141 (20); HRMS (EI), calcd. for C23H23N3 ([M]+), 341.18865; 
found, 341.18864. 
 
5,7-Didodecyl-5,7-dihydropyrido[3,2-b,5,6-b']diindole(19c) 
Following the general procedure to yield 19c (71 %) as a white solid; 
m.p. 91 - 93 ºC; 1H NMR (300 MHz, CDCl3) δ 8.57 (d, 3J = 7.5 Hz, 
2H, CHAr), 7.55 – 7.49 (m, 2H, CHAr), 7.42 – 7.29 (m, 5H, CHAr), 
4.43 – 4.15 (m, 4H, 2CH2), 2.05 – 1.75 (m, 4H, 2CH2), 1.56 – 1.07 (m, 36H, 18CH2), 0.87 (t, 
3J = 6.7 Hz, 6H, 2CH3); 13C NMR (63 MHz, CDCl3) δ 141.4, 136.8, 133.7 (2CAr), 126.3 
(2CHAr), 122.3 (2CAr), 120.6, 119.3, 108.4 (2CHAr), 94.1 (CHHetar), 43.1, 31.9, 29.6 (2CH2), 
29.6 (4CH2), 29.5, 29.4, 29.3, 28.7, 27.3, 22.6 (2CH2), 14.0 (2CH3). IR (ATR, cm-1), ṽ = 2918 
(s), 2848 (s), 1597 (m), 1466 (s), 1412 (m), 1350 (m), 1321 (s), 1257 (m), 1246 (m), 1209 (m), 
1190 (m), 1117 (m). MS (EI, 70 eV), m/z (%) = 593 (M+, 100), 438 (45), 270 (16), 44 (21); 
HRMS (EI), calcd. for C41H59N3 ([M]+), 593.47035; found, 593.47119. 
 
5,7-Diallyl-5,7-dihydropyrido[3,2-b,5,6-b']diindole(19d) 
Following the general procedureto yield 19d (84 %) as a white solid; 
m.p. 156 – 158 ºC; 1H NMR (300 MHz, CDCl3) δ 8.49 (d, 3J = 7.2 Hz, 
2H, CHAr), 7.44 (m, 2H, CHAr), 7.28 (m, 5H, CHAr), 6.02 – 5.86 (m, 
2H, 2CH=CH2), 5.04 (dd, 2J = 18.2 Hz,3J = 13.7 Hz, 4H, 2CH=CH2), 
4.88 – 4.75 (m, 4H, 2CH2); 13C NMR (63 MHz, CDCl3) δ 141.4, 133.6, 133.6 (2CAr), 
131.9(2CH=CH2), 126.5, 120.6, 119.6 (2CHAr), 117.0 (2CH=CH2), 108.6 (2CHAr), 94.7 
(CHetar), 45.3 (2CH2) (one C signal was missing). IR (ATR, cm-1), ṽ = 3057 (w), 2999 (w), 1616 
(w), 1597 (m), 1514 (w), 1464 (s), 1435 (m), 1408 (m), 1385 (m), 1358 (m), 1336 (m), 1317 
(s), 1284 (m), 1254 (s). GC-MS (EI, 70 eV), m/z (%) = 337 (M+, 100), 296 (70), 255 (28), 127 
(16), 43 (37); HRMS (EI), calcd. for C23H19N3 ([M]+), 337.15735; found, 337.15705. 
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5,7-Dibenzyl-5,7-dihydropyrido[3,2-b,5,6-b']diindole (19e) 
Following the general procedure to yield 19e (70 %) as a white 
solid; m.p. 278 - 280 ºC; 1H NMR (300 MHz, CDCl3) δ 8.51 (d, 
3J = 7.6 Hz, 2H, CHAr), 7.42 – 6.94 (m, 17H, CHAr), 5.28 (s, 4H, 
2CH2); 13C NMR (75 MHz, CDCl3) δ 141.9 (4CAr), 136.5, 133.9 
(2CAr), 129.0 (2CHAr), 129.0, 127.8, 126.6 (4CHAr), 126.6 
(2CHAr), 120.1 (CHHetar), 108.9 (2CHAr), 46.2 (2CH2) (one signal of C is missing). IR (ATR, 
cm-1), ṽ = 3028 (w), 2922 (w), 2852 (w), 1616 (w), 1597 (m), 1510 (w), 1495 (m), 1483 (w), 
1464 (s), 1450 (m), 1441 (m), 1408 (m). MS (EI, 70 eV), m/z (%) = 437 (M+, 100), 346 (61), 
255 (12), 91 (60), 65 (8); HRMS (EI), calcd. for C31H23N3 ([M]+), 437.18865; found, 
437.18850. 
 
5,7-Bis(4-methoxybenzyl)-5,7-dihydropyrido[3,2-b,5,6-b']diindole(19f) 
Following the general procedure to yield 19f (60 %) as a white solid; m.p. 217 - 219 ºC; 1H 
NMR (250 MHz, CDCl3) δ 8.53 (d, 3J = 7.7 Hz, 
2H, CHAr), 7.44 – 7.36 (m, 2H, CHAr), 7.31 – 7.21 
(m, 5H, CHAr), 7.01 – 6.88 (m, 4H, CHAr), 
6.76 – 6.59 (m, 4H, CHAr), 5.23 (s, 4H, 2CH2), 3.64 
(s, 6H, 2CH3); 13C NMR (63 MHz, CDCl3) δ 159.0 
(2CAr), 141.7 (4CAr), 133.7, 128.5 (2CAr), 127.8 (2CHAr),127.8 (4CHAr), 119.7 (2CAr), 114.2 
(2CHAr), 114.2, 108.7 (4CHAr), 55.2 (2OCH3), 46.1 (2CH2) (one CH is missing); IR (ATR, cm-
1), ṽ = 2955 (w), 2939 (w), 2839 (w), 1608 (m), 1595 (m), 1510 (s), 1464 (s), 1443 (m), 1408 
(m), 1389 (m), 1352 (m). MS (EI, 70 eV), m/z (%) = 497 (M+, 81), 207 (8), 121 (100), 77 (11); 
HRMS (EI), calcd. for C33H27O2N3 ([M]+), 497.20978; found, 497.20946. 
 
3-Bromo-2-(2-bromophenyl)benzofuran (22) 
White solid, 84 %. 1H NMR (250 MHz, CDCl3) δ= 7.75 (d, 3J = 7.9 Hz, 
1H, CHAr), 7.65 – 7.50 (m, 3H, CHAr), 7.49 – 7.31 (m, 4H, CHAr). 13C 
NMR (63 MHz, CDCl3) δ= 154.0, 151.4 (CAr), 133.6, 132.8, 131.5 
(CHAr), 130.7, 128.5 (CAr), 127.3, 125.9 (CHAr), 124.0 (CAr), 123.7, 120.2, 111.8 (CHAr), 97.4 
(CAr). IR (ATR, cm-1), ṽ = 3055 (w), 2953 (w), 1610 (w), 1591 (w), 1574 (w), 1562 (w), 1477 
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(w), 1460 (w), 1444 (s), 1344 (w). MS (EI, 70 eV), m/z (%) = 353 (M+, 100), 243 (32), 192 
(12), 163 (57), 137 (9), 122 (8), 82 (11). HRMS (EI, 70 eV),[C14H8OBr2], 349.89364, found 
349.89317, [C14H8OBr81Br], 351.89160, found 351.89126, [C14H8O81Br2], 353.88955, found 
353.88937. 
10-Phenyl-10H-benzofuro[3,2-b]indole (23a) 
White solid, 63 %. M.p. 137 – 139 °C. 1H NMR (250 MHz, CDCl3) 
δ 7.95 – 7.87 (m, 1H, CHAr), 7.75 – 7.58 (m, 6H, CHAr), 7.55 – 7.42 (m, 
2H, CHAr), 7.38 – 7.28 (m, 3H, CHAr), 7.25 – 7.20 (m, 1H, CHAr). 
13C NMR (63 MHz, CDCl3) δ 159.3, 143.7, 139.6, 138.4 (CAr), 129.8 
(2CHPh), 126.8 (CHAr), 126.5 (CAr), 125.08 (2CHPh), 124.0, 123.2, 122.5, 120.7 (CHAr), 
118.6(CAr), 118.4, 117.4 (CHAr), 114.6 (CAr), 112.7, 111.3 (CHAr). IR (ATR, cm-1), ṽ = 3063 
(w), 3045 (w), 2922 (w), 2850 (w), 1595 (w), 1547 (w), 1508 (m), 1498 (m), 1487 (m), 1450 
(s), 1435 (m), 1417 (w). MS (EI, 70 eV), m/z (%) = 283 (M+, 100), 254 (44), 226 (4), 206 (5), 
177 (7), 151 (8), 126 (3). HRMS (EI, 70 eV), m/z (%) [C20H13ON], 283.09917, found 
283.09843. 
10-(p-tolyl)-10H-benzofuro[3,2-b]indole (23b) 
White solid, 75 %.M.p., 134-135 °C. 1H NMR (300 MHz, CDCl3) δ 
7.93 – 7.86 (m, 1H, CHAr), 7.68 – 7.49 (m, 5H, CHAr), 7.45 – 7.40 (m, 
2H, CHAr), 7.37 – 7.26 (m, 3H, CHAr), 7.25 – 7.20 (m, 1H, CHAr), 2.51 (s, 
3H, CH3). 13C NMR (63 MHz, CDCl3) δ 159.5, 143.6, 139.8, 136.8, 135.9 
(CAr), 130.5 (2CHAr), 126.8 (CAr), 125.1 (2CHAr), 124.0, 123.2, 122.6, 
120.7 (CHAr), 118.8(CAr), 118.6, 117.5 (CHAr), 114.6 (CAr), 112.8, 111.4 (CHAr), 21.3 (CH3). 
IR (ATR, cm-1), ṽ = 3051 (w), 3034 (w), 2918 (w), 1614 (w), 1549 (w), 1520 (s), 1485 (w), 
1454 (s), 1441 (m). MS (EI, 70 eV), m/z (%) =, 297 (M+, 100), 282 (31), 268 (12), 254 (22), 
226 (2), 206 (4), 190 (2), 177 (5), 165 (4), 149 (7). HRMS (EI, 70 eV) [C21H15ON], 297.11482, 
found 297.11421. 
10-(4-Fluorophenyl)-10H-benzofuro[3,2-b]indole (23c) 
White solid, 79 %.M.p., 167 – 168 °C. 1H NMR (300 MHz, CDCl3) 
δ 7.94 – 7.84 (m, 1H, CHAr), 7.68 – 7.60 (m, 3H, CHAr), 7.59 – 7.52 (m, 
1H, CHAr), 7.47 – 7.40 (m, 1H, CHAr), 7.37 – 7.27 (m, 5H, CHAr), 
7.26 – 7.20 (m, 1H, CHAr). 19F NMR (282 MHz, CDCl3) δ -114.58. 13C 
NMR (63 MHz, CDCl3) δ 163.2 (d, 1J = 248.3 Hz, CF), 159.3, 143.6, 
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139.8 (CAr), 134.4 (d, 4J = 3.0 Hz, CAr), 126.9 (d, 3J = 8.5 Hz, 2CHAr), 126.6 (CAr),124.1, 123.3, 
122.6, 120.8 (CHAr), 118.5 (CAr), 118.1, 117.5 (CHAr), 116.7 (d, 2J = 22.7 Hz, 2CHAr), 114.5 
(CAr), 112.8, 111.0 (CHAr). IR (ATR, cm-1), ṽ = 3063 (m), 1911 (w), 1874 (w), 1837 (w), 1549 
(w), 1513 (s), 1498 (s), 1453 (s), 1441 (m), 1413 (w). MS (EI, 70 eV), m/z (%) =, 301 (M+, 
100), 272 (45), 251 (7), 224 (2), 196 (3), 177 (4), 150 (11). HRMS (EI, 70 eV)[C20H12ONF], 
301.08974, found 301.08924. 
10-(3-(Trifluoromethyl)phenyl)-10H-benzofuro[3,2-b]indole (23d) 
White solid, 81 %. M.p. 178 - 179 °C. 1H NMR (300 MHz, CDCl3) δ 7.96 
(s, 1H, CHAr), 7.92 – 7.84 (m, 2H, CHAr), 7.79 – 7.57 (m, 4H, CHAr), 
7.47 – 7.40 (m, 1H, CHAr), 7.35 – 7.27 (m, 3H, CHAr), 7.25 – 7.20 (m, 
1H, CHAr). 19F NMR (282 MHz, CDCl3) δ -62.67. 13C NMR (75 MHz, 
CDCl3) δ 159.3, 144.2, 139.4, 139.1 (CAr), 132.5 (q, 2J = 32.9 Hz, CCF3), 
130.5 (CHAr), 128.0 (q, 4J = 1.0 Hz, CHAr), 126.1 (CAr), 124.3, 124.0 (CHAr), 123.7 (q, 
1J = 274.4 Hz, CF3), 123.3 (q, 3J = 3.8 Hz, CHAr), 122.8 (CHAr), 121.8 (q, 3J = 3.8 Hz, CHAr), 
121.4 (CHAr), 118.4 (CAr), 118.1, 117.7(CHAr), 115.1 (CAr), 112.9, 110.9 (CHAr). IR (ATR, cm-
1), ṽ = 3061 (w), 1612 (w), 1593 (w), 1576 (w), 1512 (m), 1495 (m), 1483 (w), 1456 (S), 1439 
(m), 1417 (w). MS (EI, 70 eV), m/z (%) = 351 (M+, 100), 332 (4), 322 (18), 302 (3), 282 (13), 
254 (27), 226 (3), 206 (3), 175 (9), 151 (6). HRMS (EI, 70 eV)[C21H12ONF3], 351.08655, found 
351.08586. 
10-(4-Methoxyphenyl)-10H-benzofuro[3,2-b]indole (23e) 
White solid, 65 %. M.p., 139 - 141 °C. 1H NMR (300 MHz, CDCl3) 
δ 7.91 – 7.82 (m, 1H, CHAr), 7.61 (d, 3J = 8.2 Hz, 1H, CHAr), 7.58 – 7.49 
(m, 3H, CHAr), 7.46 – 7.40 (m, 1H, CHAr), 7.33 – 7.27 (m, 1H, CHAr), 
7.26 – 7.16 (m, 3H, CHAr), 7.13 – 7.06 (m, 2H, CHAr), 3.89 (s, 3H, OCH3). 
13C NMR (75 MHz, CDCl3) δ 159.42, 158.62, 143.37, 140.12, 131.30, 
127.03 (CAr), 126.7 (2CHAr), 124.0, 123.1, 122.6, 120.6 (CHAr), 118.8 (CAr), 118.4, 117.4 
(CHAr), 115.1 (2CHAr), 114.4 (CAr), 112.8, 111.3 (CHAr), 55.7 (CH3). IR (ATR, cm-1), ṽ = 3005 
(m), 2951 (m), 2924 (m), 2872 (m), 2850 (m), 2831 (m), 1514 (s), 1504 (s), 1452 (s), 1435 (m). 
MS (EI, 70 eV), m/z (%) = 313 (M+, 100), 298 (13), 282 (8), 270 (21), 254 (10), 241 (14), 157 
(7), 121 (7). HRMS (EI, 70 eV)[C21H15O2N], 313.10973, found 313.10934. 
10-(3,4-Dimethoxyphenyl)-10H-benzofuro[3,2-b]indole (23f) 
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White solid, 51 %. M.p., 175 - 176 °C. 1H NMR (300 MHz, CDCl3) 
δ 7.85 – 7.77 (m, 1H, CHAr), 7.61 – 7.48 (m, 2H, CHAr), 7.45 – 7.39 (m, 
1H, CHAr), 7.28 – 7.18 (m, 3H, CHAr), 7.17 – 7.12 (m, 2H, CHAr), 7.09 
(d, J = 2.4 Hz, 1H, CHAr), 7.00 (d, 3J = 8.5 Hz, 1H, CHAr), 3.93 (s, 3H, 
OCH3), 3.85 (s, 3H, OCH3). 13C NMR (75 MHz, CDCl3) δ 159.5, 149.9, 
148.2, 143.4, 140.1, 131.5, 127.01 (CAr), 124.1, 123.2, 122.7, 120.6 (CHAr), 118.8 (CAr), 118.3, 
117.7, 117.5 (CHAr), 114.4 (CAr), 112.9, 111.8, 111.4, 109.4 (CHAr), 56.4, 56.3 (OCH3). IR 
(ATR, cm-1), ṽ = 3063 (w), 3003 (w), 2951 (w), 2928 (w), 2850 (w), 2833 (w), 1595 (m), 1574 
(w), 1547 (w), 1514 (s), 1450 (s), 1439 (s), 1417 (m). MS (EI, 70 eV), m/z (%) = 343 (M+, 
100), 328 (14), 312 (10), 256 (14), 228 (8), 206 (9), 177 (6), 151 (6), 120 (4). HRMS (EI, 
70 eV),[C22H17O3N], 343.12029, found 343.12067. 
10-(4-(Tert-butyl)phenyl)-10H-benzofuro[3,2-b]indole (23g) 
White solid, 84 %. M.p., 195 - 197 °C. 1H NMR (300 MHz, CDCl3) 
δ 7.94 – 7.86 (m, 1H, CHAr), 7.72 – 7.59 (m, 6H, CHAr), 7.58 – 7.53 (m, 
1H, CHAr), 7.37 – 7.26 (m, 3H, CHAr), 7.26 – 7.21 (m, 1H, CHAr), 1.45 (s, 
9H, 3CH3). 13C NMR (63 MHz, CDCl3) δ 159.5, 150.0, 143.7, 139.8, 
135.8 (CAr), 126.7, 124.7 (2CHAr), 124.0, 123.2, 122.6, 120.7 (CHAr), 
118.9 (CAr), 118.7, 117.5 (CHAr), 114.6 (CAr), 112.8, 111.6 (CHAr), 34.9 (C(CH3)3), 31.6 (3CH3) 
(one signal of C could not be detected). IR (ATR, cm-1), ṽ = 3059 (w), 2958 (m), 2901 (w), 
2864 (w), 1605 (w), 1547 (w), 1520 (m), 1504 (m), 1479 (w), 1454 (s), 1439 (m). MS (EI, 70 
eV), m/z (%) = 339 (M+, 100), 324 (36), 309 (8), 282 (20), 254 (10), 206 (8), 177 (3), 162 (4), 
148 (14). HRMS (EI, 70 eV)[C24H21ON], 339.16177, found 339.16142. 
10-Benzyl-10H-benzofuro[3,2-b]indole (23h) 
White solid, 67 %. M.p., 136 – 137 °C.1H NMR (250 MHz, CDCl3) 
δ 7.89 – 7.81 (m, 1H, CHAr), 7.62 – 7.54 (m, 1H, CHAr), 7.44 – 7.32 (m, 
2H, CHAr), 7.30 – 7.26 (m, 1H, CHAr), 7.25 – 7.13 (m, 8H, CHAr), 5.56 
(s, 2H, CH2). 13C NMR (63 MHz, CDCl3) δ 159.3, 142.7, 140.2, 137.5 
(CAr), 129.1 (2CHAr), 127.9 (CHAr), 127.3 (CAr), 126.8 (2CHAr), 123.9, 122.7, 122.7, 119.9 
(CHAr), 118.9 (CAr), 117.9, 117.5 (CHAr), 114.0 (CAr), 112.8, 110.5 (CHAr), 49.0 (CH2). IR 
(ATR, cm-1), ṽ = 3057 (w), 1516 (w), 1495 (w), 1456 (s), 1441 (m), 1417 (w), 1394 (m), 1354 
(m). MS (EI, 70 eV), m/z (%) = 297 (M+, 100), 268 (4), 220 (8), 206 (81), 190 (1), 177 (19), 
151 (21). HRMS (EI, 70 eV),[C21H15ON], 297.11482, found 297.11421. 
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10-Heptyl-10H-benzofuro[3,2-b]indole (23i) 
 White solid, 53 %. M.p., 54 - 55 °C. 1H NMR (300 MHz, CDCl3) δ 7.85 
(d, 3J = 7.8 Hz, 1H, CHAr), 7.78 – 7.71 (m, 1H, CHAr), 7.68 – 7.60 (m, 
1H, CHAr), 7.46 (d, 3J = 8.3 Hz, 1H, CHAr), 7.38 – 7.27 (m, 3H, CHAr), 
7.25 – 7.18 (m, 1H, CHAr), 4.43 (t, 3J = 7.1 Hz, 2H, CH2), 2.08 – 1.85 (m, 2H, CH2), 1.47 – 1.14 
(m, 8H, 4CH2), 0.85 (t, 3J = 6.8 Hz, 3H, CH3). 13C NMR (63 MHz, CDCl3) δ 159.4, 142.4, 
139.7, 127.0 (CAr), 123.8, 122.7, 122.3, 119.4 (CHAr), 119.0 (CAr), 117.8, 117.4 (CHAr), 113.6 
(CAr), 112.9, 110.3 (CHAr), 45.6, 31.8, 30.7, 29.2, 27.2, 22.7 (CH2), 14.2 (CH3). IR (ATR, cm-
1), ṽ = 3064 (w), 3053 (w), 2949 (m), 2937 (m), 2918 (m), 2868 (w), 2850 (m), 1543 (w), 1514 
(w), 1456 (s), 1441 (m). MS (EI, 70 eV), m/z (%) = 305 (M+, 100), 276 (2), 220 (86), 206 (10), 
190 (5), 165 (12), 151 (7). HRMS (EI, 70 eV), [C21H23ON], 305.17741, found 305.17746. 
10-Cyclohexyl-10H-benzofuro[3,2-b]indole (23j) 
White solid, 57 % .M.p., 163 - 164 °C. 1H NMR (300 MHz, CDCl3) δ 
7.90 – 7.75 (m, 2H, CHAr), 7.63 – 7.55 (m, 1H, CHAr), 7.49 (d, 3J = 8.5 Hz, 
1H, CHAr), 7.34 – 7.27 (m, 2H, CHAr), 7.24 – 7.10 (m, 2H, CHAr), 
4.56 – 4.37 (m, 1H, C6H11), 2.21 – 1.82 (m, 7H, C6H11), 1.65 – 1.40 (m, 
3H, C6H11). 13C NMR (63 MHz, CDCl3) δ 159.4, 143.3, 139.2, 125.3 (CAr), 123.7, 122.6, 122.4, 
119.7 (CHAr), 119.3 (CAr), 119.2, 117.4, 112.9, 110.5 (CHAr), 54.8 (CH), 33.0, 26.2 (2CH2), 
25.7 (CH2) (one CAr-signal could not be detected). IR (ATR, cm-1), ṽ = 3064 (w), 3053 (w), 
2949 (m), 2937 (m), 2918 (m), 2868 (w), 2850 (m), 1543 (w), 1514 (w), 1456 (s), 1441 (m). 
3064 (w), 2935 (m), 2920 (m), 2852 (m), 1504 (w), 1454 (s), 1417 (w), MS (EI, 70 eV), m/z 
(%) = 289 (M+, 92), 207 (100), 177 (13), 151 (15). HRMS (EI, 70 eV)[C20H19ON], 289.14612, 
found 289.14568. 
3,4-Dibromo-2,5-bis(2-bromophenyl)furan (26) 
White solid, 78 %. M.p., 64 – 65 °C. 1H NMR (300 MHz, CDCl3) 
δ 7.70 (dd, 3J = 8.0 Hz, 4J = 1.2 Hz, 2H, CHAr), 7.56 (dd, 3J = 7.7 Hz, 
4J = 1.7 Hz, 2H, CHAr), 7.47 – 7.38 (m, 2H, CHAr), 7.36 – 7.28 (m, 2H, 
CHAr).13C NMR (63 MHz, CDCl3) δ 149.8(2CAr), 133.6, 132.7, 
131.4(2CHAr), 130.3(2CAr), 127.3(2CHAr), 123.8, 104.3(2CAr).IR (ATR, cm-1), ṽ = 3064 (w), 
3053 (w), 2949 (m), 2937 (m), 2918 (m), 2868 (w), 2850 (m), 1543 (w), 1514 (w), 1456 (s), 
1441 (m). 2953 (w), 2920 (m), 2850 (m), 1574 (w), 1558 (w),1464 (m), 1456 (m), 1423 (m). 
MS (EI, 70 eV), m/z (%) = 536(100), 531 (M+, 75), 
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429(12),376(7),351(10),297(7),267(21),185(40),155(27),112(8).HRMS (EI, 
70 eV)[C16H8OBr4], 531.73032,found531.73071. 
5,6-Diphenyl-5,6-dihydrofuro[3,2-b,4,5-b']diindole (27a) 
Green solid, 51 %. M.p., 220 – 222 °C. 1H NMR (500 MHz, C6D6) δ 
8.01 – 7.95 (m, 2H, CHAr), 7.39 (m,2H, CHAr), 7.24 – 7.18 (m, 2H, 
CHAr), 7.13 – 7.08 (m, 2H, CHAr), 6.90 – 6.84 (m, 4H, CHAr), 
6.78 – 6.66 (m, 6H, CHAr). 13C NMR (126 MHz, C6D6) δ 146.5, 139.5, 
139.1(2CAr), 128.9 (4CHAr), 126.4 (2CHAr), 125.8 (4CHAr), 122.6 (2CHAr), 121.8 (2CAr), 121.4, 
116.8 (2CHAr), 116.4 (2CAr), 111.4 (2CHAr). IR (ATR, cm-1), ṽ = 3064 (w), 3053 (w), 2949 
(m), 2937 (m), 2918 (m), 2868 (w), 2850 (m), 1543 (w), 1514 (w), 1456 (s), 1441 (m). 3053 
(w), 3036 (w), 2953 (w), 2918 (w), 2848 (w), 1595 (m), 1576 (m), 1564 (w), 1558 (w), 1506 
(w), 1495 (s), 1462 (m), 1456 (s), 1446 (m), 1423 (s), 1404 (m). MS (EI, 70 eV), m/z (%) = 399 
(29), 398 (M+, 100), 397 (38), 369 (11), 292 (6), 264 (3), 199 (9). HRMS (EI, 70 eV) 
[C28H18ON2], 398.14136, found 398.14080. 
5,6-Di-p-tolyl-5,6-dihydrofuro[3,2-b,4,5-b']diindole (27b) 
Green solid, 65 %. M.p., 221 - 223 °C.1H NMR (300 MHz, CDCl3) δ 
7.87 (d, J = 7.6 Hz, 2H, CHAr), 7.43 (d, 3J = 8.5 Hz, 2H, CHAr), 
7.29 – 7.15 (m, 4H, CHAr), 7.13 – 7.07 (m, 4H, CHAr), 6.88 (d, 
3J = 8.1 Hz, 4H, CHAr), 2.35 (s, 6H, 2CH3). 13C NMR (75 MHz, 
CDCl3) δ 145.7, 138.9, 136.4, 136.1 (2CAr), 129.5, 125.6 (4CHAr), 
122.0 (2CHAr), 121.6 (2CAr), 120.7, 116.4 (2CHAr), 115.5, 111.2 (2CHAr), 21.2 (2CH3).IR 
(ATR, cm-1), ṽ = 2949 (m), 2937 (m), 2918 (m), 2850 (m), 1456 (s), 1441 (m). 2920 (m), 1606 
(m), 1581 (m), 1514 (s), 1462 (s), 1446 (m), 1429 (s), 1410 (m).MS (EI, 70 eV), m/z (%) = 426 
(M+, 100), 411 (13), 305 (3), 213 (10), 190 (3), 152 (1). HRMS (EI, 70 eV) [C30H22ON2], 
426.17266, found 426.17206 
 
5,6-Bis(4-fluorophenyl)-5,6-dihydrofuro[3,2-b,4,5-b']diindole (27c) 
145 
 
Green solid,59 %. M.p., 224 - 225 °C. 1H NMR (300 MHz, C6D6) 
δ 8.17 – 7.97 (m, 2H, CHAr), 7.37 – 7.30 (m, 4H, CHAr), 7.27 – 7.21 
(m, 2H, CHAr), 6.75 – 6.59 (m, 4H, CHAr), 6.59 – 6.30 (m, 4H, 
CHAr).19F NMR (282 MHz, C6D6) δ -115.22. 13C NMR (63 MHz, 
C6D6) δ 161.5 (d, 1J= 246.7 Hz, 2CF), 146.2, 139.5(2CAr), 134.8 (d, 
4J = 2.9 Hz, 2CAr), 127.6 (d, 3J = 8.5 Hz, 4CHAr), 122.7 (2CHAr), 121.7 (2CAr), 121.5, 116.8 
(2CHAr), 116.2, (2CAr), 115.7 (d, 2J = 22.9 Hz, 4CHAr), 111.1 (2CHAr). IR (ATR, cm-1), ṽ = 3053 
(w), 2916 (w), 2874 (w), 1608 (m), 1581 (m), 1568 (m), 1504 (s), 1485 (s), 1462 (s), 1429 (s), 
1410 (m).MS (EI, 70 eV), m/z (%) = 434 (M+, 100), 405 (11), 385 (3), 338 (2), 310 (3), 283 
(2), 217 (8). HRMS (EI, 70 eV) [C28H16ON2F2], 434.12252, found 434.12178. 
5,6-Bis(3-(trifluoromethyl)phenyl)-5,6-dihydrofuro[3,2-b,4,5-b']diindole (27d) 
Green solid, 66 %.M.p., 205 – 207 °C. 1H NMR (300 MHz, CDCl3) 
δ 7.87 (d, 3J = 7.7 Hz, 2H, CHAr), 7.53 (s, 2H, CHAr), 7.44 (m, 4H, 
CHAr), 7.37 – 7.27 (m, 4H, CHAr), 7.26 – 7.15 (m, 4H, CHAr).19F 
NMR (282 MHz, CDCl3) δ -62.63.13C NMR (75 MHz, CDCl3) 
δ 146.5, 139.3, 139.0 (2CAr), 131.9 (q, 2J = 33.1 Hz, 2CCF3), 129.7 
(2CHAr), 128.6 (q, 3J = 3.8 Hz, 2CHAr), 123.4 (q, 4J = 1.5 Hz, 2CHAr), 123.3 (q, 1J = 272.5 Hz, 
2CF3), 122.9 (2CHAr), 122.2(q, 3J = 3.8 Hz, 2CHAr), 121.6 (2CHAr), 120.6 (2CAr), 116.8 
(2CHAr), 116.0 (2CAr), 110.7 (2CHAr).IR (ATR, cm-1), ṽ = 3078 (w), 1614 (w), 1595 (m), 1579 
(w), 1568 (w), 1495 (m), 1464 (s), 1456 (s), 1443 (m), 1427 (m), 1404 (w). MS (EI, 70 eV) m/z 
(%) = 534 (M+, 100), 505 (7), 437 (3), 388 (2), 290 (3), 267 (12), 232 (2), 145 (8). HRMS (EI, 
70 eV) [C30H16ON2F6], 534.11613, found 534.11547 
 
5,6-Bis(4-methoxyphenyl)-5,6-dihydrofuro[3,2-b,4,5-b']diindole (27e) 
Green solid, 53 % .M.p., 250-252 °C. 1H NMR (500 MHz, C6D6) 
δ 8.03 – 7.97 (m, 2H, CHAr), 7.41 – 7.36 (m, 2H, CHAr), 7.25 – 7.21 
(m, 2H, CHAr), 7.15 – 7.12 (m, 2H, CHAr), 6.81 – 6.75 (m, 4H, CHAr), 
6.35 – 6.26 (m, 4H, CHAr), 3.31 (s, 6H, OCH3). 13C NMR (126 MHz, 
C6D6) δ 158.4, 146.1, 139.8, 131.8 (2CAr), 127.4 (4CHAr), 122.4 
(2CAr), 122.4, 121.1, 116.8 (2CHAr), 116.1 (2CAr), 114.3 (4CHAr), 111.3 (2CHAr), 54.8 
(2OCH3).IR (ATR, cm-1), ṽ = 3063 (w), 2955 (m), 2922 (m), 2850 (m), 2837 (m), 1581 (m), 
1568 (m), 1504 (S), 1470 (m), 1454 (s), 1427 (s). MS (EI, 70 eV), m/z (%) = 458 (M+, 100), 
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443 (5), 371 (5), 229 (13), 207 (1), 151 (3). HRMS (EI, 70 eV) [C30H22O3N2], 458.16249, found 
458.16239 
5,6-Bis(4-(tert-butyl)phenyl)-5,6-dihydrofuro[3,2-b,4,5-b']diindole (27f) 
Green solid, 86 %. M.p., 230 - 232 °C. 1H NMR (300 MHz, CDCl3) 
δ 7.85 (d, 3J = 7.7 Hz, 2H, CHAr), 7.40 (d, 3J = 8.2 Hz, 2H, CHAr), 
7.25 – 7.10 (m, 12H, CHAr), 1.29 (s, 18H, 6CH3). 13C NMR (75 MHz, 
CDCl3) δ 149.6, 146.0, 140.0, 136.2 (2CAr), 125.8, 125.3 (4CHAr), 
122.1 (2CHAr), 121.5 (2CAr), 120.9, 116.3 (2CHAr), 115.7 (2CAr), 
111.7 (2CHAr), 34.6 (2CẢ), 31.6(6CH3). IR (ATR, cm-1), ṽ = 3057 (w), 3041 (w), 2962 (m), 
1608 (w), 1576 (w), 1514 (m), 1487 (w), 1462 (s), 1446 (m), 1427 (m), 1404 (m), MS (EI, 
70 eV), m/z (%) = 510 (M+, 100), 437 (7), 409 (2), 320 (4), 292 (1), 248 (4), 213 (5). HRMS 
(EI, 70 eV) [C36H34ON2], 510.26657, found 510.26635. 
5,6-Dibenzyl-5,6-dihydrofuro[3,2-b,4,5-b']diindole (27g) 
Green solid, 53 %. M.p., 230 – 232 °C. 1H NMR (250 MHz, CDCl3) 
δ 7.82 – 7.74 (m, 2H, CHAr), 7.24 – 7.05 (m, 12H, CHAr), 6.92 – 6.82 
(m, 4H, CHAr), 5.21 (s, 4H, CH2).13C NMR (63 MHz, CDCl3) 
δ 144.79, 138.8, 137.2 (2CAr), 128.9 (4CHAr), 127.52 (2CHAr), 125.6 
(4CHAr), 121.6 (2CHAr), 121.4 (2CAr), 119.9, 116.3 (2CHAr), 114.9 
(2CAr), 110.0 (2CHAr), 48.8 (2CH2).IR (ATR, cm-1), ṽ = 2920 (w), 1732 (w), 1699 (w), 1576 
(m), 1556 (w), 1495 (m), 1464 (m), 1452 (s), 1427 (s), 1408 (m). MS (EI, 70 eV), m/z (%) = 426 
(M+, 100), 335 (39), 306 (12), 91 (24), 73 (5), 60 (7), 43 (8). HRMS (EI, 
70 eV)[C30H22ON2], 426.17266, found 426.17337. 
5,6-Diheptyl-5,6-dihydrofuro[3,2-b,4,5-b']diindole (27h) 
 Green solid, 46 %. M.p., 109 – 111 °C. 1H NMR (300 MHz, Acetone) 
δ 7.85 – 7.68 (m, 2H, CHAr), 7.65 – 7.52 (m, 2H, CHAr), 7.30 – 7.10 
(m,4H, CHAr), 4.69 – 4.39 (m, 4H, 2CH2), 2.02 – 1.88 (m, 4H, 2CH2), 
1.50 – 1.25 (m, 16H, 8CH2), 0.84 (t, 3J = 6.8 Hz, 6H, 2CH3). 13C NMR (75 MHz, Acetone) δ 
145.0, 139.4 (2CAr), 122.2 (2CHAr), 122.1 (2CAr), 120.4, 116.6 (2CHAr), 115.5 (2CAr), 111.5 
(2CHAr), 47.2, 32.5, 31.5, 29.9, 27.8, 23.2 (2CH2), 14.3 (2CH3).IR (ATR, cm-1), ṽ = 2951 (m), 
2924 (m), 2854 (m), 1645 (w), 1620 (w), 1578 (m), 1485(w), 1464(s), 1429 (s), 1408 (w). MS 
(EI, 70 eV), m/z (%) = 442 (M+, 100), 357 (3), 314 (1), 259 (8), 137 (3), 96 (1), 76 (1), 43 (4). 
HRMS (EI, 70 eV) [C30H38ON2], 442.29787, found 442.29764. 
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